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Summary 
 
Chronic obstructive pulmonary disease (COPD) is characterised by shortness of breath, 
cough and excess sputum production. The most common conditions included in COPD 
are chronic bronchitis (inflammation in the airway) and emphysema (destruction of lung 
tissue) resulting in irreversible airflow restriction. COPD is a major cause of morbidity 
and mortality and predicted to be the third leading cause of death by 2030. COPD is 
more prevalent in the older population. In those over 40 years of age in western 
countries, it is estimated that >10% of the population is affected by COPD. COPD is 
associated with substantial loss of productivity and significant direct and indirect costs. 
 
The causes of COPD are the long-term exposure to toxic substances and gases such as 
cigarette smoke, which induce an amplified inflammatory response in the lung, 
particularly in the small airway. The resultant tissue destruction is irreversible and 
without cure.  
 
Due to the irreversible nature of the condition, available treatments only provide 
symptomatic relief and management of exacerbations. The commonly used treatments 
are bronchodilators, corticosteroids (for severe cases), and antibiotics (for 
exacerbations). These treatments are limited in their effectiveness and are associated 
with a range of adverse events. 
 
Patients with COPD have increasingly used complementary and alternative medicines 
(CAM), particularly herbal medicines. In Australia, 17.3% or nearly one in five COPD 
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sufferers have used some form of CAM therapy. There have been randomised 
controlled trials (RCT) evaluating the benefits of herbal medicines for COPD. Panax 
ginseng is one herb, which shows promise for a number of health conditions including 
COPD. However, existing Panax ginseng studies have produced inconsistent evidence 
on efficacy due to a range of methodological issues including inadequate reporting of 
participant allocation methods, small sample sizes, inappropriate outcome measures and 
inadequate information of the herbal preparation. Under the framework of evidence-
based healthcare, all interventions need to be evaluated systematically to provide high-
level clinical evidence to support the rational use of such interventions. In the case of 
Chinese herbal medicine, both modern and classical literature on relevant herbs needs to 
be reviewed to investigate efficacy and clinical relevance.  
 
Study objectives: 
1) Search and analyse the classical literature on Chinese herbal medicine for symptoms 
associated with COPD. 
2) Review the extant systematic reviews of Panax ginseng for any health condition. 
3) Systematically review the English and Chinese literature of Panax ginseng in RCTs 
for any health condition.  
4) Review the potential mechanisms of Panax ginseng on reducing inflammation and 
oxidative stress. 
5) Design and implement an RCT that addresses the identified methodological short 
falls identified in the literature and evaluate the efficacy and safety of Panax ginseng for 
patients with moderate COPD. 
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A comprehensive search and analysis of the Zhong Yi Fang Ji Da Ci Dian (ZYFJDCD) 
fulfilled the first objective. The ZYFJDCD is the largest compendium of Chinese herbal 
formulae with over 96,592 entries. The search resulted in 1,147 citations relevant to 
COPD. The results confirmed the use of Chinese herbal formulae and herbs similar to 
what is used in the modern setting for COPD.  
 
To achieve the second objective, a review of systematic reviews on Ginseng for any 
health condition was completed. The methods of the overview are in line with the 
Cochrane Collaboration. Thirteen systematic reviews were included. These evaluated 11 
broad health areas and showed promise of efficacy for lung diseases, disorders of 
glucose metabolism, angina pectoris, and erectile dysfunction. 
 
To achieve the third objective, a systematic review guided by the ‘Cochrane Handbook 
for Systematic Reviews of Interventions’ was completed. The review identified 65 
English and two Chinese RCTs. The most promising findings from this review 
supported the value of Panax ginseng for use in moderating the immune response, 
particularly cell-mediated immunity with implications for chronic respiratory diseases. 
However, the review also identified methodological issues that need to be addressed in 
future studies such as information on quality control of the Panax ginseng products, 
allocation concealment, sample size calculation and the use of intention-to-treat 
approach. 
 
To address the fourth objective, a review was conducted to identify the potential 
mechanisms of Panax ginseng for reducing inflammation and oxidative stress relevant 
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to COPD. Findings revealed Panax ginseng and its active components, the 
ginsenosides, exert multiple actions. Panax ginseng possesses actions including 
regulation of immune cell activity and numbers, modulation of cytokine and mediator 
production, reduction in oxidative stress, and regulation of their related pathways. 
 
To achieve the fifth objective, a randomised, double blind, placebo controlled clinical 
trial was designed and implemented. The study evaluates the efficacy and safety of 
Panax ginseng for moderate COPD, that is, FEV1/FVC < 0.70, FEV1 ≥ 50% and < 80% 
predicted. Outcome measures include quality of life, lung function, use of relief 
medication, exacerbations and adverse events. The study integrates contemporary 
clinical research methodology guided by Chinese medicine principles and theory for 
clinical practice (ANZCTR: ACTRN12610000768099). 
 
A stepwise approach was developed to identify candidate herbal medicines for COPD 
through systematic reviews on classical and modern literature, and then prioritise the 
key herb for further investigation with respect to its efficacy, potential mechanisms of 
action and evaluation of its efficacy and safety through an RCT. Although there is 
extensive literature, methodological flaws often limit the acceptance and applicability of 
results. This highlights the importance of improving standards and reporting in future 
research. Rigorous clinical trials focusing on specific health conditions and indications 
would improve the body of evidence. The clinical trial presented here will provide 
critical clinical data and build on previous RCTs and systematic reviews. Although the 
results of the clinical trial are not yet available the rigorous trial design and the use of a 
well-characterised high quality Ginseng product will ensure reliable results. Given the 
5 
 
increasing prevalence and burden associated with COPD, particularly in the elderly, this 
research is timely to explore alternatives that may help patients to improve their quality 
of life and lung function.  
 
This thesis applies a systematic “whole evidence” approach in investigating a Chinese 
herb for the management of a major health condition that is triggered by smoking. There 
is no cure in modern medicine for COPD, and thus an investigation such as this is of 
significant value. This thesis revealed promising benefits of Panax ginseng for the 
treatment of COPD. Our multi-centre RCT will provide a conclusive answer to this 
well-characterised Ginseng product for the management of moderate level COPD 
patients.  
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Chapter 1: General introduction 
 
1.1 Background 
Chronic obstructive pulmonary disease (COPD) is a common, incurable and disabling 
respiratory condition (1). William Briscoe is believed to be the first person to use the 
term “COPD” in his discussions on airflow obstruction and the slow spaces in the 
lung in 1965 (2). Well-known as the "smoker's cough”, COPD symptoms include 
breathlessness, persistent cough and excess sputum production. COPD is characterised 
by the pulmonary diseases emphysema and chronic bronchitis. These two diseases 
produce similar symptoms and are both causes of COPD. After onset symptoms are 
persistent over a lifetime.   
 
COPD is ranked as the fourth leading cause of death worldwide and is predicted to rank 
third by 2030 (3). COPD has a high prevalence in Australia, reported to be one in five 
aged over 40 years (4). This disease often affects adults in the prime of their life and 
results in high social and economic costs. 
 
The pathophysiology of COPD is due to a complex cascade of chronic inflammation 
leading to airway narrowing and alveolar wall destruction. The inflammation seen in 
COPD is often a response to cigarette smoke coupled with genetic susceptibility (5).  
 
COPD is an incurable progressive disease. Current treatments are unsatisfactory and 
only nominally effective. Treatments include bronchodilators and corticosteroids and 
they are associated with a number of limitations. Treatments are based on drugs 
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effective for asthma however in COPD there is limited evidence of benefit particularly 
at the early stage of the disease. These medications, particularly inhaled steroids also 
pose a risk of long-term side-effects such as cataracts and osteoporosis (1). 
Subsequently there is an unmet need to provide effective relief of symptoms, slow the 
progression and improve quality of life (QoL). 
 
Complementary and alternative medicines (CAM) including Chinese medicine are 
gaining popularity in western countries including Australia (6). Patients with COPD are 
increasingly using CAM. A recent study in Australia, reported that 17.3% of COPD 
patients had used CAM (7). Chinese medicine (CM) including herbal medicine are 
particularly popular (7).  
 
Chinese medicine (CM) is a unique medical system developed over millennia in China. 
The basic theories of yin, yang, five elements and Qi guide the diagnosis, prevention 
and treatment of disease. Long periods of clinical practice and knowledge support the 
use of CM for chronic lung diseases like COPD. This knowledge is useful in the 
modern setting for understanding the application of herbal medicines. 
 
Herbal medicines are important sources for drug discovery. However, the traditional 
drug discovery pathway has been associated with a number of concerns such as low 
success rate from investigative new drug candidates to new therapeutics, it is time 
consuming, and costly. Hence, there has been an increasing emphasis of a more targeted 
approach in drug discovery involving the use of classical literature such as those of CM. 
This trend is coupled with the increasing use of CAM including Chinese herbal 
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medicine (CHM). Objectively and scientifically evaluating its use under controlled 
environments and using scientific methods enriches the application of CM. The 
knowledge generated can improve understanding and potentially expand its application 
for diseases like COPD. 
 
Recently, research has provided data for the safety and efficacy of herbal medicines for 
COPD (8, 9). Specific CHM may be effective for COPD however, quality data is 
limited.  
 
In CM, Panax ginseng has been used for thousands of years to treat breathlessness, 
fatigue as well as debilitation and reduced mental and physical capacities due to chronic 
illness. Panax ginseng shows a promising effect on COPD and immune function. 
Recent laboratory studies have indicated that Panax ginseng possesses a broad range of 
pharmacological actions (10). 
 
A recent review concluded that Panax ginseng improves the immune response, 
particularly cell-mediated immunity with implications for chronic respiratory diseases 
(11). Additionally, a recent RCT evaluated Panax ginseng for COPD, results indicated 
improved lung function and a good safety profile with no adverse events (12).  
 
Although studies have evaluated Panax ginseng, they often lack rigour and consistency 
(11). Results from systematic reviews and individual RCTs are often promising but 
inconclusive and methodological flaws compromise their validity.  
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To date, despite frequent use, the role of CHM including Panax ginseng in treating 
COPD is not clear. The research presented in this thesis reviews Panax ginseng in 
modern and classical literature. It also evaluates the efficacy and safety of Panax 
ginseng for COPD with a focus on QoL improvements in a rigorous RCT.   
 
1.2 Objectives  
The objectives are: 
 Conduct systematic reviews of the existing literature on Panax ginseng for any 
health condition. 
 Search the classical CM literature to establish formulae and herbs often used to 
treat conditions consistent with COPD.  
 Evaluate the potential of Panax ginseng to reduce inflammation and oxidative 
stress. 
 Design and implement an RCT evaluating the safety and efficacy of Panax 
ginseng for moderate COPD.   
 
1.3 Significance of the research 
This research concerns the systematic gathering, evaluation and further investigation of 
efficacy and safety of Panax ginseng for COPD involving systematic reviews and an 
RCT. It explores theories and knowledge from CM and conventional medicine. The 
research summarises the existing literature and develops a novel clinical trial. The 
results aim to determine if CHM, specifically Panax ginseng is safe and effective for the 
treatment of COPD.   
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Systematic reviews identify, evaluate and summarise data from individual studies and 
provide information to guide health care decision makers (13). RCTs are the gold 
standard of clinical trials and they evaluate the efficacy and safety of interventions in a 
population of patients. To inform the design of the RCT presented in this thesis, 
comprehensive systematic reviews of Panax ginseng were undertaken. The reviews 
were guided by the Cochrane Handbook (13).  
 
This research evaluated the classical CM literature to identify CHM for COPD. 
Classical CM literature provides a source of information for herbal medicine use over 
millennia. The information identifies particular herbal formulae and herbs used for 
specific conditions.  
 
Exploring the plausible mechanisms of herbal medicines can aid in understanding 
suitable indications. Panax ginseng has multiple actions and exerts a wide range of 
effects on reducing inflammation and oxidative stress (10). To this end, a review was 
conducted to evaluate the potential mechanisms of Panax ginseng. 
 
To inform the design of the RCT the preceding research listed above was undertaken. 
The RCT entitled ‘Ginseng Extract and Respiratory Symptoms (GEARS)’ is rigorous 
and aims to evaluate the effect of a standardised Panax ginseng extract for patients with 
moderate COPD.  
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The specific research questions of the trial are:        
1. Does Panax ginseng produce beneficial effects/symptomatic relief in subjects 
with moderate COPD, in terms of improved QoL and/or improved respiratory function? 
2. Does Panax ginseng reduce the use of conventional symptom-relief medication 
in subjects with moderate COPD? 
3. With six months treatment and six months follow-up, what are the time courses 
of onset and persistence of any beneficial effects of Panax ginseng in subjects with 
moderate COPD? 
4. What adverse effects does Panax ginseng produce in subjects with moderate 
COPD? 
 
1.4 Organisation of the thesis 
This thesis consists of seven chapters, as follows:  
 
Chapter One introduces the background of the research. The objectives, significance 
and scope of the research are highlighted, and an overview of the thesis structure is 
included.   
 
Chapter Two describes the literature relevant to COPD. The chapter begins with a 
detailed background of the disease including definitions, prevalence, pathophysiology, 
risk factors, diagnosis, assessment, treatment and management. The latter part of the 
chapter introduces CM concepts relevant to COPD with detailed information on CM 
diagnosis, existing research, and introduces the herbal medicine Panax ginseng. 
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Chapter Three provides details of Panax ginseng, including its species identification, 
historical use, constituents, pharmacology, safety, efficacy, and clinical research in this 
area. 
  
Chapter Four presents an original search and analysis of the classical Chinese 
literature for COPD. The first two sections discuss the rationale and method of 
searching and establish the novelty of this type of review. The second section presents 
detailed results of the herbal formulae and herbs identified including frequencies and 
citation ranking.  The final section provides a general discussion integrating results and 
opinion and elaborating on citations consistent with COPD.   
 
Chapter Five presents three systematic reviews. Firstly, a review of systematic reviews 
summarising the existing published reviews of Panax ginseng for any health condition. 
Secondly, a systematic review of published Panax ginseng RCTs and finally, the 
mechanism of Panax ginseng relevant to reducing inflammation and oxidative stress in 
experimental and clinical research, is presented.     
 
Chapter Six presents the protocol development and implementation of the ‘Ginseng 
Extract for Respiratory Symptoms’ (GEARS) clinical trial. The design of the clinical 
trial is to the highest scientific rigour and is the first of its kind in Australia. 
 
Chapter Seven discusses and summarises the research findings and conclusions. It also 
discusses strengths and limitations of the project and includes recommendations for 
future research.   
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Chapter 2: Literature review of COPD 
 
2.1 Introduction  
Chronic obstructive pulmonary disease (COPD) is a common, incurable and disabling 
respiratory condition encompassing two main pathologies, emphysema and chronic 
bronchitis. Symptoms include breathlessness, persistent cough and excess sputum 
production. Throughout the course of disease acute infective exacerbations are common 
and can exponentially deteriorate lung function and lead to considerable morbidity and 
reduced quality of life (QoL) (1). COPD is preventable, however, exposure to risk 
factors (chiefly cigarette smoking) contribute significantly to the disease. 
 
COPD is highly prevalent and is the fourth leading cause of death worldwide (3). The 
onset of COPD is often in the prime of one’s working life, has a significant impact on 
productivity, and imposes an economic burden on individuals, communities and 
governments (4).  
 
2.2 Definition of COPD 
COPD is a disease of the lungs. It is an umbrella term used to describe the overlapping 
conditions, chronic bronchitis and emphysema. COPD is characterised by airflow 
obstruction that is not fully reversible. Symptoms include dyspnea, cough and sputum 
production. 
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The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as 
‘a common preventable and treatable disease that is characterised by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles and gases. 
Exacerbations and comorbidities contribute to the overall severity in individual 
patients’ (1). 
 
2.3 Prevalence of COPD  
The World Health Organisation (WHO) estimates that COPD affects 127 million people 
worldwide (14). COPD increases an individuals’ risk of death 3.2 times compared with 
the general population (4).  COPD deaths occur primarily in low and middle income 
countries and it is predicted to rank as the third leading cause of death by 2030 (3). The 
worldwide prevalence of COPD in adults is approximately 9–10% (15).  Estimates of 
prevalence from around the world are summarised in Table 1. 
 
Table 1: Prevalence of COPD among adults aged over 40 years  
County % of 
population 
over 40 
years with 
COPD 
Reference County % of population 
over 40 years 
with COPD 
Reference 
Australia  18.6% (4) Japan  10.9% (16) 
China  8.2% (17) South Korea 17.2% (18) 
Finland 9.4%* (19) UK  
4.7%* 
 
(20) 
Greece 8.4% (21) USA 
5.1%* 
 
(22) 
* In these countries prevalence of COPD is among adults aged over 18 years. 
Note: Estimates were calculated from survey self-reports and conservative approximation of 
undiagnosed cases. 
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2.3.1 Prevalence of COPD in Australia 
In Australia, COPD affects over 2 million people (4). Of these, it is estimated almost 1 
million are undiagnosed and untreated (4). Individuals aged over 40 years are most 
commonly affected, estimated at 18.6% or approximately one in five (4). The majority 
are women aged over 60 years (56.5%). Despite reduced rates of smoking, it is 
predicted that COPD will affect 4.5 million Australians by 2050 (4).  
 
2.3.2 Economic impact of COPD 
The socio-economic impact of COPD is substantial. COPD has significant direct and 
indirect costs to individuals, society and the government. In Australia, it is estimated to 
cost $8.8 billion per annum, with individuals bearing costs of up to $7,446 annually (4). 
Figure 1 presents the bearers of financial costs.  
 
 
Figure 1: Financial costs of COPD 
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2.4 Mechanisms of COPD  
Exchanging oxygen and carbon dioxide maintains life. In a normal lung, air travels 
down the trachea into the bronchi entering progressively smaller tubes until it 
terminates in the bronchioles and alveoli. The alveoli facilitate delivery of oxygen to the 
blood and removal of carbon dioxide.  
 
The pathogenesis of COPD involves a complex process associated with an abnormal 
and amplified immune response and lung tissue repair and remodelling (23). Long-term 
inflammation in the lung leads to airway narrowing, fibrosis, mucous plugging and 
airway closure. The characteristic airflow limitation is caused by a combination of 
emphysema and chronic bronchitis (24).  
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2.4.1 Emphysema  
The pathogenesis of emphysema involves alveolar destruction. Chronic inflammation in 
the lungs causes permanent dilation of the peripheral air spaces accompanied by 
destruction of the walls of the bronchioles, alveolar ducts, and alveoli. There is loss of 
elastic recoil and gas exchange surfaces as well as airway wall collapse, leading to 
hyperinflation and air trapping (24). Figure 2 presents the pathogenesis of emphysema.  
 
 
Figure 2: Pathogenesis of emphysema 
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2.4.2 Chronic bronchitis  
Chronic bronchitis is caused by inflammation of the bronchial tubes and excess mucus 
production.  The tiny cilia in the lungs are unable to clear the build-up of mucus leading 
to narrowing and/or blockage of the airway lumen and thickening due to fibrosis. 
Clinically, chronic bronchitis is defined as a productive cough for over three months 
and for more than two successive years. Figure 3 presents the pathogenesis of chronic 
bronchitis. 
 
 
Figure 3: Pathogenesis of chronic bronchitis 
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2.4.3 Comorbidities of COPD 
Comorbidities of COPD may include cardiovascular disease, cachexia, osteoporosis, 
anaemia, gastrointestinal disease, metabolic disease and depression (1). These 
conditions often contribute to diminished QoL and need to be monitored with the 
primary pulmonary component of COPD.    
 
2.5 Risk factors for the development of COPD  
Lifestyle choices, environmental factors and genetic predisposition contribute to the risk 
of developing COPD. Cigarette smoking is the foremost risk factor, however, other 
factors can cause and contribute to COPD, including environmental pollution, 
occupational irritants as well as genetics and age (1). COPD is a slow progressing 
disease. The incidence increases with age as the cumulative inhalation of noxious 
particles over years results in irreversible lung damage. Table 2 presents an overview of 
the risk factors for the development of COPD.  
 
Table 2: Risk factors for COPD 
Smoking (e.g., cigarettes, pipe, cigar, marijuana and hashish) 
Environmental air pollution (indoor  and outdoor) 
Occupational irritants 
Genes (e.g., alpha–1 antitrypsin deficiency) 
Age  
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Cigarette smoking accounts for an estimated 80–90% of all COPD cases (5). In 
Australia, 23%, or approximately one in four adults smoke (25). Smoking prevalence is 
similar in other countries. In the United Kingdom (UK) it is estimated at 21% (26), in 
the United States of America (USA) 19.3% (27) and in China 28.1% (28).  
 
Environmental air pollution, both indoor and outdoor has been identified as a risk factor 
and contributing factors for developing COPD (29). Indoor air pollution includes 
passive smoking, and heating or cooking with biomass fuels in unventilated dwellings. 
Living in urban cities contributes to outdoor air pollution.  
 
Occupational exposure to irritants including chemical fumes, dusts and gases may 
increase the risk of developing COPD. For example, COPD has been identified in coal 
workers as an occupational disease causing significant loss of lung function and 
disability (30). 
 
Genetic variations may contribute to an individual’s susceptibility in the development of 
COPD. About 10–15% of cigarette smokers develop clinically significant COPD that is 
symptomatic enough to require therapeutic intervention (31). One specific genetic risk 
factor for COPD is alpha–1 antitrypsin deficiency. About 1–4% of COPD suffers have 
alpha–1 antitrypsin deficiency (32). This protein is a serine protease inhibitor (e.g., 
neutrophil elastase). When alpha–1 antitrypsin is deficient, proteolytic activity goes 
unchecked and the extracellular matrix and elastin are destroyed leading to alveolar wall 
apoptosis and collapse (emphysema).   
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2.6 Pathology of COPD 
Inhaled irritants activate chronic inflammation in COPD and cause an influx of 
inflammatory cells into the central and peripheral airways and lung parenchyma (23). 
Inflammation normally subsides however, in COPD a cyclical cascade of inflammatory 
cells migrate to the lungs and cause chronic inflammation. The inflammatory cells 
include neutrophils, macrophages and CD8-positive T lymphocytes. The migrated cells 
release chemotactic factors, interleukin (IL) 8, pro-inflammatory cytokines, tumour 
necrosis factor (TNF) α, reactive oxygen species (ROS) and protease enzymes. These 
mediators facilitate the recurrent inflammatory response as well as tissue repair and 
remodelling. 
Figure 4 presents the basic pathophysiology of COPD. 
 
Neutrophils are the first inflammatory cells to enter the lungs. Activated epithelial cells 
produce chemotactic factors such as IL-8 that recruit neutrophils. The neutrophils then 
release pro-inflammatory mediators including serine proteases and neutrophil elastase. 
Anti-protease becomes imbalanced resulting in significant levels of protease that cannot 
be counteracted (33). These enzymes destroy the extra-cellular matrix components 
(elastin) cause mucus hyper secretion and emphysematous change. 
 
Oxidative stress amplifies inflammation and plays a key role in COPD. Markers such as 
hydrogen peroxide and 8-isoprostane are increased in the exhaled breath of patients with 
COPD (34). Oxidative stress can facilitate inflammation by activating nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-B) which in turn stimulates 
transcription of DNA to produce the pro-inflammatory mediators TNF-α and IL-8.  
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Systemic changes are evident in patients with COPD. Oxidative stress factors induce the 
release of ROS and circulating cytokines (e.g., TNF-α and IL-8) leading to systemic 
inflammation causing cachexia, weight loss and wasting of skeletal muscle (33).  
 
 
 
Figure 4: Basic pathophysiology of COPD 
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Basic pathophysiology of COPD: After exposure to cigarette smoke, inflammatory cells including 
macrophages, neutrophils and CD8+ T cells migrate to the airways and lung parenchyma. The inflammatory 
cells secrete chemokines and cytokines. Neutrophils are activated to degranulate and produce ROS. Enzyme 
proteases are also activated. These processes result in damage to epithelial cells, degradation of elastic fibres 
and extracellular matrix and loss of elastic recoil, which induces repair and remodelling. Airways become 
chronically inflamed resulting in loss of lung clearance and mucus hyper secretion. Fibrosis leads to further 
remodelling and narrowing of the airways.    
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2.7 Diagnosis of COPD  
COPD develops over many years and often presents symptomatically in middle to late 
life. Early diagnosis and intervention can slow disease progression improve lung health 
and prevent further damage (1). Clinical assessment of COPD begins with effective 
communication between the patient and the health care provider. Diagnosis of COPD 
requires subjective evaluation of symptoms and overall health, combined with lung 
function tests (spirometry).These include post-bronchodilator forced expiratory volume 
in one second (FEV1), forced vital capacity (FVC), and the ratio, FEV1/FVC (1). Early 
diagnosis of COPD combined with a treatment plan may delay or prevent the 
progression of airflow limitation, improve QoL and long term outcomes (1).  
 
In 2001, scientists from the United States National Heart, Lung and Blood Institute 
(NHLBI) and the World Health Organisation (WHO) formed the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) to standardise the diagnosis and 
management of COPD. They produced a report ‘Global strategy for the diagnosis, 
management and prevention of COPD’ under the guidance of a panel of international 
experts. A full revision was undertaken in 2006 and the report is now revised annually, 
providing an up to date summary of the field (1). Many national respiratory societies 
have followed the GOLD recommendations. In Australia and New Zealand, the 
Thoracic Society and the Australian Lung Foundation provide information for clinical 
practice based on both the GOLD report and systematic reviews and meta-analyses. 
These guidelines are disseminated as ‘The COPD-X Plan’ (35). 
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The GOLD report recommends a diagnosis of COPD should be considered in patients 
with a history of risk factors, most notably tobacco smoking, and presenting with 
dyspnea, chronic cough and/or sputum production. The diagnosis should be confirmed 
by lung function spirometry, that is, post-bronchodilator FEV1/FVC <0.70 [Table 3].  
 
Table 3: Diagnosis of COPD  
History Symptoms Confirmation 
 Aged over 40 years  Dyspnea  Spirometry: post–
bronchodilator 
FEV1/FVC <0.70 
 Expose to risk factors 
(e.g., tobacco smoke) 
 Chronic cough 
 Chronic sputum 
production 
 
2.8 Classification of COPD  
COPD severity is based on the patient’s symptoms, the level of spirometric deficiency, 
and other factors including frequency of exacerbations, overall health status and 
comorbidities. Diagnosis of COPD is confirmed by post-bronchodilator FEV1/FVC 
<0.70 and severity classification is based on FEV1 and divided into four stages; mild, 
moderate, severe and very severe [Table 4]. Mild, stage I COPD often presents as very 
mild cough and sputum production or no symptoms. Patients may be unaware of any 
abnormal lung function at this stage. Moderate, stage II COPD presents with shortness 
of breath particularly on exertion as well as coughing and sputum production. Patients 
often seek medication to treat symptoms and exacerbations. Severe, stage III COPD 
presents with increased airflow limitation, worsening shortness of breath at rest and 
during exercise and fatigue. Patients often experience frequent exacerbations.  Very 
severe, stage IV COPD presents as extreme airflow limitation and often respiratory 
failure. Other complications may include cor pulmonale and exacerbations may 
jeopardise a patient’s life.  
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Table 4: Severity classification of COPD 
Stage Lung function indices 
Stage I: Mild 
 
- FEV1/FVC < 0.70   
- FEV1 ≥ 80% predicted 
Stage II: Moderate - FEV1/FVC < 0.70   
- FEV1 ≥ 50% and < 80% predicted 
Stage III: Severe - FEV1/FVC < 0.70   
- FEV1 ≥ 30% and < 50% predicted 
Stage IV: Very Severe - FEV1/FVC < 0.70   
- FEV1 < 30% predicted or FEV1 < 50% predicted 
plus chronic respiratory failure 
FEV1: forced expiratory volume in one second, FVC: forced vital capacity.  
Note: Severity classification of COPD based on GOLD criteria (1). All values refer to post-bronchodilator spirometry. 
Predicted refers to predicted values that are calculated with reference to the expected range of normal lung capacity of an individual 
with similar characteristics including gender, height, age and ethnicity.   
 
2.9 Exacerbations  
Exacerbations of COPD are ‘an acute event characterised by a worsening of the 
patient’s respiratory symptoms that is beyond normal day-to-day variations and leads 
to a change in medications’ (1). There is acute symptom worsening and increased 
volume and purulence of sputum. Treatments include bronchodilators, systemic 
glucocorticoids, antibiotics, and supplemental oxygen (1). Exacerbations can be caused 
by respiratory infection (viral or bacterial), air pollution or the cause of exacerbation 
may be unknown. Repeated exacerbations can worsen the prognosis by accelerating 
decline in lung function and worsen QoL. Individuals who experience an exacerbation 
are encouraged to participate in pulmonary rehabilitation and develop self-management 
plans to reduce the risk of recurrence (1).   
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2.10 Differential diagnosis of COPD  
COPD should be differentiated from other diseases with similar symptoms. These 
diseases may include; asthma, congestive heart failure, lung carcinoma, bronchiectasis, 
tuberculosis, lung abscess, and pneumonia. Table 5 presents the differential diagnosis of 
COPD.  
 
2.10.1 Differential diagnosis with asthma 
Asthma is a difficult condition to distinguish from COPD and a co-diagnosis may be 
considered. Asthma causes the airways to become narrow and swell, producing a thick 
mucous due to a cascade of events triggered by inhaled irritants or allergens. Unlike 
asthma, COPD does not involve the whole airway but is generally isolated to the 
bronchioles and lung parenchyma (35). In people with asthma, sputum samples and 
bronchoalveolar-lavage fluid contains eosinophils, whereas in COPD sputum samples  
mainly contain macrophages and neutrophils (33). Asthma often presents earlier in life 
with day-to-day fluctuations in symptoms, whereas COPD is commonly seen in older 
individuals with a history of smoking and constant and progressively worsening 
symptoms. Cough and wheeze may be seen in both conditions and cannot be used alone 
to differentiate. The major difference between asthma and COPD is the reversibility in 
airflow obstruction. To test for this spirometry is performed before and after inhalation 
of a bronchodilator medication. Largely reversible obstruction is seen in asthma, but in 
COPD, it is largely irreversible (36).  
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Table 5: Differential diagnosis of COPD  
Condition Symptoms Common symptoms for all conditions 
COPD Onset in mid-life (people aged over 40 years) Fatigue  
Wheezing  
Panting  
Weight loss  
Hoarseness or changing voice 
History of smoking or exposure to other types of smoke 
Chronic constant symptoms, that progressively worsen 
Dyspnea  
Chronic cough (productive or non–productive) 
Sputum production  
Limitation of activity and exercise (often to avoid getting breathless) 
Pursed lip breathing 
Barrel chest 
Irreversible airflow limitation 
Asthma Onset earlier in life (often in childhood) 
Symptoms fluctuate and are variable from day to day 
Predominant night time cough or early morning  
Allergy, rhinitis and eczema also present 
Family history of asthma 
Reversible airflow limitation 
Cardiac (congestive heart 
failure) 
Chest pain and or heaviness sensation in the chest 
Ankle oedema 
Dyspnea while lying flat (sleeping) 
Lung carcinoma Haemoptysis As above plus fever 
Chest pain 
Bronchiectasis Chronic cough with large volumes of thick, tenacious, purulent sputum 
Haemoptysis 
Pulmonary tuberculosis Haemoptysis 
Lung abscess Subacute onset 
Purulent sputum and/or blood–streaked sputum 
Pneumonia Acute to subacute cough 
Chest pain  
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2.11 Assessment of COPD 
2.11.1 Lung function – spirometry 
Spirometry, ‘the measure of breath’, is the GOLD standard for assessing lung function. 
It is useful for screening at risk patients, diagnosing, classifying severity, assessing 
interventions and monitoring COPD (37).  It can provide reproducible and standard 
objective evaluations in confirming airflow limitation that is not fully reversible. 
Spirometry is performed using an instrument called a spirometer. Functionally, it is easy 
to use and there are many devices on the market.  Tests measure the flow-rate and 
volume during forced exhalation after a maximal deep inspiration [Figure 5]. For 
COPD, three spirometry values are commonly measured, these are FEV1, FVC and 
FEV1/FVC ratio. Table 6 presents the values. 
 
 
Figure 5: Spirogram of volume-time curves and flow-volume curves  
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The volume-time curve presents the FEV1 and FVC values. The lung volume is presented in litres expired per second. Normal 
lung volume is much greater than that of a person with COPD and after the administration of a bronchodilator the lung volume 
will often improve slightly. The flow-volume curve represents the expiratory flow rate in litres per second with the curve peaking 
at the maximal expiratory flow. COPD patients will have a deflated curve and limited maximal expiratory flow.   
Note: Volume-time curves and flow-volume curves based on GOLD data (1). 
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Table 6: Spirometry values used to measure lung function  
Values Definition Expected outcome in 
COPD patients 
Forced Vital Capacity 
(FVC)  
 
The total volume of air that 
can be forcibly exhaled after 
a full inspiration. 
Normal or slightly 
reduced 
Forced Expiratory Volume 
in One Second (FEV1) 
The volume of air that is 
exhaled in the first second of 
forced expiration. 
Reduced 
Ratio of FEV1 to FVC 
expressed as a percentage 
(FEV1 /FVC) 
Percentage of the vital 
capacity which is expired in 
the first second of maximal 
expiration 
Reduced (< 70%) 
 
Lung function values should be measured post-bronchodilator, that is, after the 
inhalation of a suitable bronchodilator (e.g., salbutamol) (38). Spirometry values are 
compared to predicted normal values that have been determined through comprehensive 
analysis of healthy populations using variables including age, height, gender, and 
ethnicity (35). This method is used to avoid over-diagnosis of COPD, especially in the 
aged. Spirometry is globally recognised as an essential tool for assessing COPD, yet 
there are limitations. The full impact of COPD cannot be measured by FEV1 alone. It is 
able to classify the severity of disease and predict outcomes. However, it cannot 
accurately predict dyspnea symptoms, the impact on QoL, or mortality. To perform the 
tests and interpret results, a certain level of technical ability is required. Some patients 
find the effort to perform the inhalation and/or expiration problematic and readings may 
be invalid. Furthermore, an over-estimation of diagnosis using spirometry in the older 
population is a concern. Lung function deteriorates with age and normal limits for 
individuals over 70 years are lower, therefore results need to be interpreted with caution 
(36).  
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2.11.2 Radiology 
Imaging technologies such as x-ray, computed tomography (CT) and magnetic 
resonance imaging (MRI) are not diagnostic for COPD. They assist treatment and 
management and are useful in differential diagnosis and identifying comorbidities, such 
as cardiac failure and infection. 
 
2.11.3 Symptom questionnaires 
Symptom questionnaires can often provide useful information on the impact of disease. 
Examples include the Medical Research Council Dyspnea scale (MRC-D) (39) and the 
COPD assessment test (CAT) (40). These tools can supplement history taking and lung 
function tests in the clinical and research setting.  
 
2.11.4 Quality of life 
Assessing QoL particularly health-related QoL (HRQoL) can reflect a treatment’s effect 
on overall health including aspects of physical, psychological and social wellbeing. 
Questionnaires are particularly useful in research trials to highlight the possible clinical 
significance of interventions. A good number of generic and disease specific 
questionnaires have been developed. They often differ in numerous ways such as goals, 
contents, scaling methods and cultural factors.  
 
Generic questionnaires can be used across different diseases, ethnicities, and cultures. 
They measure broad domains of health and wellbeing, such as general, physical and 
mental health. Validated examples include the Short Form Health Survey (SF-36) (41) 
and the World Health Organization Quality of Life Brief (WHOQOL-BREF) (42). 
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When evaluating HRQoL in COPD, two disease specific questionnaires are most 
commonly utilised, the St. George’s Respiratory Questionnaire (SGRQ) (43) and the 
Chronic Respiratory Questionnaire (44). These disease specific questionnaires have an 
advantage over generic varieties as they can measure impact on various COPD domains, 
including symptoms and activities. When evaluating HRQoL in COPD it is often 
appropriate to use a disease specific questionnaire complemented by a generic 
instrument to provide a more complete representation of overall QoL (45). 
 
2.11.5 Exercise capacity  
Rehabilitation programs and some clinical trials evaluate the impact of COPD by using 
bicycle ergometry, treadmill exercise and/or timed walking tests, e.g., the 6-minute walk 
test. These activities can assess changes in functional exercise capacity following 
pulmonary rehabilitation and are useful prognostic tools (1).   
 
2.11.6 Other 
BODE index   
The BODE index is often used for predicting mortality in COPD (46). BODE stands for 
and evaluates 1) Body mass index, 2) degree of airflow Obstruction, FEV1, 3) Dyspnea 
using a modified MRC-D scale, and 4) Exercise capacity measured by the 6-minute 
walk test. This index is a practical tool in the clinical setting where higher scores 
correlate to an increased risk of mortality (46). 
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Blood gas 
Blood gas measurements can assist in monitoring potential lung and heart failure in 
severe COPD. Particularly when oxygen saturation is extremely low, and the acid-base 
balance is compromised. 
 
Blood tests  
Blood tests are undertaken at intervals throughout the treatment of COPD for 
identifying secondary conditions such as infections and neoplasms. Further to this, 
blood tests verify cases of COPD caused by alpha–1 antitrypsin deficiency.   
 
Nitric oxide 
Exhaled nitric oxide is commonly used to evaluate asthma. In COPD the results are 
often inconsistent, therefore it is seldom used.  
 
Biomarkers  
Currently biomarkers have not been established to predict or monitor COPD. Potential 
targets include inflammatory cells and oxidative markers in bronchial fluid, exhaled 
breath and blood. However, heterogeneity within and between sufferers has hindered 
developed and limited clinical relevance (47).     
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2.12 Treatment and management of COPD   
There is no cure for COPD. Therefore a multifaceted approach including pharmacologic 
and non-pharmacologic interventions is required. Smoking cessation is the only 
intervention proven to reduce the decline in lung function (48). However, drug therapies 
are also required as smoking cessation alone is not enough to reduce lung inflammation. 
Current pharmacological treatments include bronchodilators and corticosteroids. They 
are nominally effective, and primarily intended to control and alleviate symptoms and 
prevent complications (1). Management of COPD aims to reduce risk factors, alleviate 
symptoms, prevent progression, improve exercise tolerance, improve QoL, prevent and 
treat exacerbations, and reduce mortality (1). However, there is currently an unmet need 
to optimise the management of COPD. Figure 6 presents the treatments for COPD 
according to severity. 
 
 
Figure 6: Treatments for COPD according to severity 
  
Mild 
(Stage I) 
Moderate 
(Stage II) 
Severe 
(Stage III) 
Very severe 
(Stave IV) 
Short acting bronchodilators (rescue relief, when needed) 
Vaccination 
Long acting bronchodilators (when needed) 
Pulmonary rehabilitation 
Inhaled corticosteroids 
 
02, Surgery 
 
Note: Treatments of COPD according to severity are based on GOLD data (1). 
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2.13 Pharmacologic agents for COPD 
2.13.1 Bronchodilators  
Bronchodilator medications are fundamental in managing symptoms of COPD (1). 
Inhaled bronchodilators provide symptomatic relief by reducing hyperinflation and 
dyspnea. However, they do not slow the progression of COPD (35).  Bronchodilators 
include anticholinergics, 2-agonists and methylxanthines. Table 7 presents the 
pharmacologic interventions for COPD. 
 
Bronchodilators are prepared as short acting or long acting and can improve lung 
function. They are the first line therapy for COPD and prescribed throughout all stages 
(1). Long acting bronchodilators include the previously mentioned drug classes, 
anticholinergics and 2-agonists. They can improve breathlessness, lung function 
(FEV1), QoL, and decrease frequency of exacerbations (33). They are more effective 
and convenient than short acting bronchodilators (35). Although bronchodilators are 
useful for symptom relief they do not improve lung function or reduce inflammation in 
the lungs or systemically.  
 
Methylxanthines including theophylline are smooth muscle relaxants serving as 
bronchodilators. Their full mechanism is not defined however they are considered non-
selective phosphodiesterase inhibitors and are thought to reduce muscle fatigue. 
Unfortunately, adverse effects have limited their therapeutic application in COPD (49).  
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Table 7: Pharmacologic interventions for COPD 
Category Class Generic names Stage of 
COPD 
prescribed 
Short acting 
bronchodilators 
Anticholinergics  Ipratropium bromide I to IV 
2-agonists Salbutamol  
Long acting 
bronchodilators 
Anticholinergics  Tiotropium 
Aclidinium bromide 
II to IV 
2-agonists Salmeterol 
Indacaterol 
Eformoterol 
Oral Bronchodilators  Methylxanthines Theophylline IV 
Anti-inflammatories ICS Budesonide 
Fluticasone 
Prednisolone (Oral) 
III and IV 
Exacerbations 
PDE-4 inhibitors Cilomilast 
Roflumilast 
Combination 
medications 
ICS and 2-agonists Budesonide and 
Eformoterol 
Fluticasone and 
Salmeterol 
II to IV 
ICS: Inhaled corticosteroids 
Note: Stages of COPD; Stage I mild (FEV1/FVC < 0.70, FEV1 ≥ 80% predicted); Stage II moderate (FEV1/FVC < 0.70, FEV1 ≥ 50% 
and < 80% predicted); Stage III severe (FEV1/FVC < 0.70, FEV1 ≥ 30% and < 50% predicted); Stage IV very severe (FEV1/FVC < 
0.70, FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure) 
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2.13.2 Anti-inflammatories  
Inhaled corticosteroids (ICS) reduce inflammation and COPD exacerbations. However 
they do not improve lung function and are not recommended for long term use (35). In 
severe cases of COPD, ICS are combined with bronchodilator treatment (50). Oral 
glucocorticoids are also used for short periods throughout disease progression, 
particularly during exacerbations (51).  
 
Recently, phosphodiesterase 4 (PDE-4) inhibitors have been approved as new drugs for 
severe COPD. They increase cyclic AMP levels and exert a wide range of anti-
inflammatory actions. They can prevent decline in lung function, improve QoL and 
decrease the frequency of exacerbations (52). Unfortunately, adverse effects have 
limited the clinical usefulness of PDE-4 inhibitors (1) and despite approval in Europe 
and the USA they are not approved in Australia.  
 
2.13.3 Other  
During acute exacerbations of COPD, antibiotics are often prescribed due to bacterial 
infections. Additionally, annual vaccinations for influenza may reduce or prevent 
exacerbations (53).  
 
2.14 Non-pharmacologic interventions for COPD  
2.14.1 Pulmonary rehabilitation  
Rehabilitation programs are recommended in the management of COPD. Activities are 
structured to include exercise programs to improve skeletal and respiratory muscles, as 
well as behavioural, psychosocial, and educational support (54). Pulmonary 
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rehabilitation programs encourage sufferers to develop self-care and self-management 
plans, aiding to reduce dyspnea, anxiety, depression and improve exercise capacity and 
QoL.  
 
2.14.2 Oxygen therapy 
Oxygen supplementation is prescribed in advanced disease and aids to improve QoL 
and survival especially for individuals with hypoxemia (55).  
 
2.14.3 Lung volume reduction surgery  
Surgical removal of emphysematous tissue or bullectomy is reported to be beneficial in 
some patients with severe COPD. It reduces hyperinflation and improves breathing 
efficiency (1). Lung volume reduction carries substantial risks and is only suitable for 
individuals with advanced symptoms. 
 
2.14.4 Lung transplantation 
Transplantation may be considered in sufferers in the advanced stages of COPD (56). 
The scarce number of available donor organs and resources limits this method. 
 
2.15 Novel treatment approaches  
Current drug therapies for COPD only provide modest benefit and no single treatment 
sufficiently prevents or treats COPD. Improved understanding of the mechanisms 
involved in COPD has allowed some novel approaches to be investigated. Emerging 
treatments focus on broad inflammatory candidates including anti-TNF and IL-10 
agonists. Anti-TNF drugs have application in other chronic inflammatory diseases, such 
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as rheumatoid arthritis and Crohn’s disease, and may be useful for COPD (57). Other 
potential drug candidates include matrix metalloproteinase inhibitors. Pre-clinical 
studies have indicated that inhibition of these enzymes could prevent extracellular 
matrix degradation and slow lung tissue destruction (58). Mucolytic agents may be 
useful for COPD patients, however, the clinical value has not been determined and 
further research is needed (59). Antioxidant therapies may also be useful to counter 
oxidative stress and subdue inflammation. These novel therapies present opportunities 
for drugs however their development is in the early stages and widespread availability is 
not expected for many years. Furthermore their clinical application is often restricted by 
significant side effects and it is still unclear if inhibiting a single mediator or process 
will have a significant clinical effect (33). 
 
2.16 Complementary therapies for COPD  
Complementary and alternative medicines (CAM), particularly herbal medicines have 
been increasingly used for the management of COPD (7, 60). CAM interventions 
include natural products, dietary supplements and body-based practices including 
acupuncture and massage. A recent survey in Australia suggested that nearly one in five 
individuals with moderate to severe COPD had used some form of CAM therapy and 
one in six used herbal medicine (7). 
 
The effectiveness and safety of CAM for COPD has not been wholly established. 
Evidence suggests that several interventions including herbs and acupuncture may be 
effective for improving symptoms of dyspnea and lung function (9, 12, 61). 
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2.17 Chinese medicine for COPD  
2.17.1 Introduction 
Chinese medicine (CM) has a long history of use for chronic lung diseases like COPD. 
It is a system of health care that conceptualises disease and health uniquely and presents 
a holistic picture of the patient and their illness. Traditionally, CM relies on patient 
reported symptoms and observation of the tongue and pulse in formulating a diagnosis. 
Other factors such as the environment, seasons, emotions, diet, and lifestyle are 
acknowledged as influencing an individual’s health.  
 
The fundamental theories of CM include yin, yang, five elements and Qi. These 
theories were conceptualised through observation of the laws of nature and applied to 
the human body and disease to guide diagnosis and treatment (62). The internal organs, 
Zang (solid) and Fu (hollow) are interconnected and able to generate and control each 
other. They have unique functional activities rather than anatomical and 
pathophysiological paradigms. The dynamic balance between yin and yang is impaired 
during disease causing imbalance in the body. The treatment goals of CM are to 
regulate and harmonise the relationship between yin and yang and the Zang Fu, 
therefore encouraging salubrious balance.  
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2.17.2 Chinese medicine diagnosis of COPD  
Modern CM texts refer to COPD as two characteristic patterns fei zhang (肺胀) (Lung 
distension) and chuan zheng (喘症) (Panting pattern). Man xing zu sai xing fei bing (慢
性阻塞性肺病) is the translation for COPD. COPD in CM is understood using 
different theories to western medicine (WM). It is based on the history and observation 
of the patient and does not require any specialised WM testing. In CM, COPD is related 
to three organs, these are the Lung, Spleen and Kidney [Figure 7]. The Lungs dominate 
Qi and respiration and governs diffusion and depurative down bearing, as well as 
regulating the waterways. The Spleen maintains the transportation and transformation 
of food, upbearing and raising the Qi and supporting the flow of blood in the vessels. 
The Kidneys store the vital essence promoting growth and development and supporting 
the respiratory system (63). These concepts do not equate to WM functions of the 
organs. 
 
 
Figure 7: Lung, Spleen and Kidney interconnectivity in Chinese medicine 
Sends to the Kidney 
Purifies air  
Produces essence  
Kidney Spleen 
Lung 
Sends to the Lung to 
diffuse and disperse 
The Lung, Spleen and Kidney are interconnected thought the five element theory. The Lungs purify the inhaled air and send it to 
the Kidneys. The Kidney then supports the Spleen function to produce essence and Qi to send to the Lung to support its ability to 
diffuse and disperse.   
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The Lung dominates the Qi of the body. Pollutants in the air inhibit the Lung’s ability 
to separate the clean and turbid air and impede diffusing and dispersion. The Lung Qi 
becomes deficient causing cough and dyspnea. When the Lungs are dysfunctional, they 
fail to support the Spleen and Kidneys. The Kidneys then become deficient and they are 
unable to receive Qi. In turn the Kidneys are then unable to support the Lung and 
Spleen function and lead to further Lung and Spleen Qi deficiency [Figure 7]. 
 
The diagnosis of COPD in CM often involves phlegm. This is due to the inhibited 
regulation of waterways by the Lungs and Kidneys and failure of the Spleen to 
transport and transform, leading to phlegm accumulation in the Lung. The phlegm can 
narrow and block the airways leading to dyspnea and mucous hyper-secretion.  Figure 8 
presents the pathomechanisms of COPD in CM. 
 
 
Figure 8: Pathomechanisms of COPD in Chinese medicine 
  
Environmental pollutants 
(smoking) 
Lung Qi deficiency 
Spleen Qi deficiency 
Mild to moderate COPD 
Kidney Qi deficiency 
Severe COPD 
Exacerbation 
Wind Cold or Wind 
Heat impair the Lung 
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2.17.3 Chinese medicine differentiation of COPD 
According to CM theory, COPD can be differentiated into three syndromes, Lung Qi 
deficiency, Lung and Spleen Qi deficiency or Lung, Spleen and Kidney Qi deficiency 
(64). Table 8 summarises the CM differential diagnosis of COPD. Lung Qi deficiency 
symptoms include coughing, wheezing excessive sputum production and a propensity 
to catch a cold. The tongue is pale and possibly depressed in the anterior third and the 
pulse is thready. The Spleen controls digestion and nourishes the Lung. When there is 
Spleen Qi deficiency symptoms include tiredness, heavy limbs, poor appetite, swollen 
tongue and a therapy pulse.  Kidneys function to support and warm the body, they 
receive Qi from the Lungs and support the respiratory function. Kidney Qi deficiency 
includes cold limbs, weakness and pain in the back and knees, nocturnal enuresis, 
shortness of breath after slight exertion, a pale dry tongue and a deep and weak pulse. 
During acute exacerbations of COPD wind-cold or wind-heat may be diagnosed. In 
CM, these pathogenic factors invade the susceptible Lungs and cause increased sputum 
purulence, chills and/or fever, sweating, a yellow tongue coating and a superficial and 
rapid pulse.  
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Table 8: Chinese medicine differential diagnosis of COPD 
Syndrome Key symptoms Tongue Pulse 
Lung Qi deficiency 1. Sweating easily  
2. Catch a cold easily 
3. Difficulty to recover from 
a cold 
4. Dyspnea, wheezing and 
cough 
Pale and swollen 
tongue body with 
a depressed 
anterior third 
Thready 
Spleen Qi 
deficiency 
1. Tiredness or exhaustion 
2. Heavy limbs  
3. Poor appetite and fullness 
in the stomach without 
eating  
4. Loose bowel motions 
5. Headache or heavy head 
Pale and swollen 
tongue body with 
a white tongue 
coating 
 
Thready 
Kidney Qi 
deficiency 
1. Aversion to cold 
2. Cold limbs 
3. Weakness or pain in the 
lower back or knee  
4. Nocturnal  enuresis (> 2 
times per night) 
5. Shortness of breath after 
slight exertion 
Pale and dry 
tongue body 
Deep 
Weak 
Wind-cold or wind-
heat 
 
1. Increased sputum 
purulence 
2. Chills and/or fever 
3. Sweating 
Thin and yellow 
tongue coating 
Superficial  
Rapid 
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2.17.4 Chinese medicine treatments for COPD  
Chinese medicine (CM) theories of health and healing differ from WM. Therapies are 
individualised based on CM differentiation and the imbalance that disease creates. 
Treatment principles in CM set out to recreate balance by strengthening deficiencies and 
reducing excesses. In CM, unlike WM, the stages of COPD are not clearly defined and 
the diagnosis requires consideration of the signs and symptoms, including severity of 
dyspnea and cough, the amount and colour of the phlegm and other systemic symptoms. 
COPD can be treated with herbal medicines, acupuncture, diet therapy, massage (Tui 
na), and exercise (Tai chi). Principles of treatment in CM include tonification of the 
Lung, Spleen and Kidney as well as clearing phlegm and eliminating wind-cold or 
wind-heat when applicable. These concepts do not equate to WM functions of the 
organs. 
 
2.17.5 Chinese herbal medicine for COPD  
In the clinical setting CHM is selected based on the differentiation of disease and herbal 
formulae are prescribed and modified to account for individual patient differences. 
Table 9 highlights common CM treatments for COPD. Chinese herbal medicine (CHM) 
has been used for over 2,000 years to treat respiratory conditions and may offer new 
approaches to more effectively treat COPD. Panax ginseng is one of the commonly used 
herbs for treating respiratory conditions due to Qi deficiency, which includes COPD.  
Recent preclinical and clinical research has shown beneficial effects of herbal medicine 
for treating COPD, with the most promising being Panax ginseng (9, 11, 65). 
 
.   
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2.17.6 Acupuncture for COPD 
Acupuncture is used to treat COPD. It involves the insertion of needles into specific 
points on the body according to CM theory. Table 9 highlights common CM treatments 
for COPD. 
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Table 9: Chinese medicine treatments for COPD 
Syndrome Herbal formulas Acupuncture points 
Lung Qi deficiency Name: Bu Fei Tang 
Herbal ingredients: Ren Shen, Huang Qi, 
Shu Di, Wu Wei Zi, Zi Wan, Sang Bai Pi 
Name: Yu Ping Feng San 
Herbal ingredients: Huang Qi, Bai Zhu, 
Fang Feng 
Tai yuan (LU 9) 
Fei shu (BL 13) 
Lie que (LU 7) 
Spleen Qi deficiency  Name: Bu Zhong Yi Qi Tang  
Herbal ingredients: Ren Shen, Huang Qi, 
Bai Zhu, Gan Cao, Dang Gui, Chen Pi, 
Sheng Ma, Chai Hu 
Name: Liu Jun Zi Tang  
Herbal ingredients: Ren Shen, Zhi Gan 
Cao, Fu Ling, Bai Zhu, Chen Pi, Ban Xia 
Zu san li (ST 36) 
Pi shu (BL 20) 
Kidney Qi deficiency Name: Shen Qi Wan 
Herbal ingredients: Shu Di, Shan Zhu Yu, 
Shan Yao, Fu Ling, Mu Dan Pi, Fu Zi, 
Rou Gui 
Name: Sheng Mai San  
Herbal ingredients: Ren Shen, Wu Wei Zi, 
Mai Dong 
Tai xi (KI 3) 
Shen shu (BL 23) 
Wind-Cold or Wind-Heat Name: Ma Huang Tan 
Herbal ingredients: Ma Huang, Gui Zhi, 
Xing Ren, Gan Cao 
Name: Gui Zhi Tang 
Herbal ingredients: Gui Zhi, Bai Shao, 
Sheng Jiang, Da Zao, Gao Cao 
Feng chi (GB 20) 
Lie que (LU 7) 
Chi ze (LU 5) 
Da zhui (GV 14) 
Phlegm accumulation Name: Er Chen Tang  
Herbal ingredients: Ban Xia, Chen Pi, Fu 
Ling, Gan Cao 
Name: Ping Wei San  
Herbal ingredients: Cang Zhu, Hou Po, 
Chen Pi, Gan Cao, Sheng Jiang, Da Zao 
Feng long (ST 40) 
 
2.17.7 Chinese medicine research for COPD  
Chinese herbal medicine and acupuncture are commonly used by COPD suffers (7). 
However, an evidence-based approach for selecting treatments has not been established. 
 
The effectiveness of CHM for COPD has been evaluated in several systematic reviews 
(8, 9, 66). A number of herbal medicines were investigated and results indicated that 
Panax ginseng, Salvia miltiorrhiza and Hedera helix had a good effect on pulmonary 
function, including FEV1 (9). CHM formulae were investigated for their effect on 
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HRQoL in patients with COPD (8). The included studies used the SGRQ or Cai’s QoL 
questionnaire. The results showed improvement in overall HRQoL scores. The efficacy 
and safety of CHM formulae containing Ginseng for COPD has been reviewed (66). 
Results indicate that Ginseng formulae can improve lung function FEV1 and QoL. 
Ginseng formulae were considered safe overall and no serious adverse events were 
reported in the included studies (66). Results from these reviews were limited by small 
sample sizes and poor methodological quality. Additionally, there were no replicated 
RCTs and results could not be pooled.  
 
Other CM treatments for COPD includ acupuncture and Tai chi.They have been 
evaluated in randomised controlled trials (RCTs). Acupuncture reduced pulmonary 
medications in a recent review and was effective in reducing dyspnea on exertion in 
patients with COPD (61, 67). Tai chi ‘Qigong’ was found to be effective in improving 
respiratory function and activity tolerance in COPD sufferers (68).  
 
The current evidence of CM for COPD reveals promising results despite some 
methodological weaknesses in study design. Further investigation of CM treatments 
may provide novel therapies for COPD. 
 
2.17.8 Panax ginseng as a treatment for COPD 
Panax ginseng has demonstrated benefit on a number of health conditions (11). The 
systematic review presented in Chapter 5 reveals that Panax ginseng had the most 
promising evidence for moderating the immune response, particularly cell-mediated 
immunity and clinical applicability for chronic respiratory diseases. 
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It is plausible that Panax ginseng can benefit COPD given its multiple activities on 
reducing inflammation and oxidative stress. These actions include the regulation of 
TNF-α and IL-8 and suppression of the NF-B pathway. The mechanisms of action are 
described in Chapter 5. Ginseng also has antioxidant capacity and can increase nitric 
oxide and decrease reactive oxygen species (ROS). Furthermore, Ginseng also 
possesses anti-protease properties (69, 70). 
 
Similar to the newly developed PDE-4 drugs, Ginseng has been shown to elevate 
intracellular cAMP levels (71). Side effects of the PDE-4 drugs are common and 
Ginseng may be a safer alternative. 
 
One study evaluated Panax ginseng for COPD (12). Panax ginseng extract, G115 at 100 
mg twice a day or placebo was administered for three months. Lung function and 
exercise capacity improved in the G115 group but not placebo.  The study had several 
methodological shortcomings, including inadequate sample size (n=92), short follow-up 
period and lack of assessment of QoL.  
 
Ginseng may be most beneficial for COPD sufferers in the mild to moderate stages. 
These individuals are often prescribed inhaled steroids without any evidence of benefit, 
but are at risk of long-term side-effects (1). The therapeutic potential of Panax ginseng 
in the management of COPD remains inconclusive. While the results from pre-clinical 
and clinical trials are encouraging, rigorous trials with high quality methodological 
design will provide further information about the potential usefulness of Panax ginseng 
as a treatment for COPD. 
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Chapter 3: Literature review of Panax ginseng 
 
3.1 Introduction 
Panax species from the Araliaceae family are the most researched herbal medicines (72, 
73). Many Panax species have been recognised with morphometric and constituent 
diversity [Table 10] (74). Of these, Panax ginseng is the most researched for medicinal 
purposes (75). Panax is a composite Greek word, pan meaning ‘all’ and axos ‘cure’, 
denoting a ‘cure-all’. Panax ginseng is commonly used in Chinese medicine (CM) and 
the name Ginseng originates from the Chinese ‘Ren shen’ or man-root due to its fork 
shape, which resembles a human body and legs. The Russian scientist Carl Anton 
Meyer identified and named Panax ginseng C.A. Meyer in 1843 (74). For the purposes 
herewith Panax ginseng C.A Meyer will be referred to as Ginseng.  
 
Table 10: Botanical classification of Araliaceae, Panax and the main species 
Family Genus Main Species 
Araliaceae Panax  
 
Panax ginseng C.A. Mey. 
 
  Panax japonicas C.A.Mey. 
 
Panax notoginseng (Burkill) C.Y.Wu & Feng 
 
Panax pseudoginseng Wall. 
 
Panax quinquefolius L. 
 
Panax stipuleanatus Tsai  & Feng 
 
Panax trifolius L. 
 
Panax wangianus S.C.Sun 
 
Panax zingiberenseis C.Y.Wu & Feng 
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3.2 Prevalence of Ginseng use 
For millennia, CM practitioners have used Ginseng. In the West it has become one of 
the most commonly used herbs (76). Ginseng accounts for 24.1% of herbal use in 
America, only behind Echinacea (40.3%) (72). In Australia, Ginseng accounts for 5.9% 
of herbal use (73). Although Ginseng is one of the most expensive herbs it remains a top 
seller. Korean Ginseng is often purported to be the most potent and therefore fetches the 
highest prices. Products on the market include wild roots, cultivated roots, granulated 
powders, standardised extracts, tablets, teas, and lollies.  
 
3.3 Identification of Ginseng  
Ginseng is naturally found in a cool climate of the temperate zone in Northern Korea, 
Northeast China and Far East Russia. Due to diminished wild sources, Ginseng is 
cultivated for commercial use in Korea, China and North America. It is a perennial plant 
with branched roots 2.5–20 cm in length and 0.5–3.0 cm wide, verticillate leaves and a 
central umbel with small green flowers and clusters of red berries. The roots are ‘human 
like’ in appearance with small roots and rootlets branched off the centre. The roots are 
the main part of the plant used for medicinal purposes and they are harvested after 4–6 
years of growth. Figure 9 presents an image of a mature Ginseng plant. Figure 10 
provides samples of different forms of Ginseng, including slices, rootlets, whole root 
and capsules. 
 
Ginseng is a very valuable herb and wild roots can be sold for thousands of dollars. 
Over time several Panax species have been sold as Panax ginseng often due to 
similarities in appearance but at times for profitability. Other species, although similar 
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in appearance have different constituent contentand their therapeutic effect and function 
differ (77). Similar species include Panax quinquefolius (American Ginseng), Panax 
notoginseng and Eleutherococcus senticosus (Siberian Ginseng). Panax quinquefolius 
(Pin yin: Xi yang shen) is not a native species of China. It was imported in the 1700’s 
from America and is now part of the Chinese materia medica having similar functions 
as Panax ginseng. In Chinese medicine theory, Panax notoginseng (Pin yin: San qi) 
functions to stop bleeding, reduce swelling and alleviate pain, for conditions such as 
angina or traumatic pain. Its constituent profile is similar to Panax ginseng but the root 
does not have the typical ‘man-root’ appearance. Siberian Ginseng, Eleutherococcus 
senticosus (Pin yin: Ci wu jia) from the Araliaceae family is often substituted for Panax 
ginseng. It is similar in appearance however, it does not contain the active constituents, 
ginsenosides.   
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Figure 9: Mature Ginseng plant 
Source, Court W.E. Ginseng, the Genus Panax: CRC Press; 2000 
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Figure 10: Ginseng samples  
 
3.4 Ginseng use in Chinese medicine  
In CM, Ginseng, is highly valued and has been used for thousands of years as a tonic for 
improving stamina and vitality. It has supposed adaptogenic properties making it useful 
for many conditions (78). The earliest recorded account of Ginseng is in the Shen Nong 
Ben Cao Jing (Farmer God's Materia Medica), compiled between 206 B.C. – A.D. 220. 
The reference describes Ginseng as a multipurpose medicinal with the ability to 
strengthen the body (79). The most famous traditional reference to Ginseng is from the 
Ben Cao Tu Jing (Atlas of Materia Medica) c. A.D. 1061, Song Dynasty (80).  
 
 
Selection of Ginseng samples. From left; steamed (Red Ginseng) cut into slices, steamed (Red Ginseng) rootlets, air dried 
whole root, and Ginseng capsules.  
Source: iStock Photo. 
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It says: 
‘It was said that in order to evaluate the effect of genuine Shangdang ginseng, two 
persons were asked to run together. One was given the ginseng while the other ran 
without. After running for approximately three to five Li [equivalent to 1,500 to 2,500 
meters], the one without the ginseng developed severe shortness of breath, while the one 
who took the ginseng breathed evenly and smoothly’.  
 
This reference highlights the early historical use of Ginseng and places it as an 
important medicinal plant used over centuries.  Figure 11 presents two images of 
Ginseng from traditional CM texts.  
 
 
Figure 11: Traditional images of Ginseng 
A B 
A: Ren shen plant, [wood block print]. Image source: Jing Shi Zheng Lei Bei Ji Ben Cao (c. 1082), in 
the Complete Collection of Traditional Texts in Chinese Material Medica, Volume 7, pg. 361. B: Ren 
shen plant, [drawing]. Image source: Yu Zhi Ben Cao Pin Hui Jing Yao (c. 1505), in the Complete 
Collection of Traditional Texts in Chinese Material Medica, Volume 29, Pg. 877. 
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3.4.1 Chinese medicine properties of Ginseng 
Chinese medicine classifies Ginseng as a tonifying herb, it is sweet, slightly bitter, 
slightly warm and enters the Heart, Lung and Spleen channels (81). The nature of 
Ginseng is slightly warm therefore it relates to yang and it is able to warm the yang and 
disperse cold. It is also sweet in nature and can repair and supplement. Ginseng is 
indicated for use in Qi deficiency conditions, specifically for Lung and/or Spleen Qi 
deficiency. Other functions include the generation of body fluids and calming the spirit. 
It is often prescribed alone or in combination with other herbs for shortness of breath, 
wheezing, general weakness, lack of appetite, forgetfulness, thirst and impotence.  
 
3.5 Constituents of Ginseng  
The therapeutic activity of Ginseng relies on a unique mix of triterpenoid saponins 
called ginsenosides. Ginsenosides consist of a steroid nucleus with carbon atoms 
arranged in a four-ring structure with various sugar attachments. Figure 12 shows the 
chemical structure of the ginsenosides Rg1 and Rb1. Over 150 ginsenosides have been 
identified from two main groups, dammarane and oleanane. Dammerane includes 
protopanaxadiols, for example, Rb1, Rb2, Rc, Rd, and protopanaxatriols, for example, 
Rg1, Rg2, Re, and Rf. Oleanane includes oleanolic acid for example Ro (82). 
Ginsenosides are named as Rx based on their structure, where R refers to the root and x 
denotes chromatographic polarities in alphabetical order. That is, Rb is more polar than 
Rc which is even more polar than Rd.  
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Figure 12: Chemical structure of ginsenoside Rg1 and Rb1 
 
Ginsenosides are measured using spectrophotometry and high performance liquid 
chromatography (HPLC). Rg1 is commonly used as the marker ginsenoside calculated 
as no less than 1.5% (83). Ginsenoside content will chiefly rely on the species of 
Ginseng. There are some ginsenosides unique to individual species, for example Rf is 
present in Panax ginseng but not in Panax quinquefolius. Within species variability can 
also exist due to factors such as geographic source, climate, time of harvest and 
processing techniques (84).  
 
Ginsenosides are concentrated in the roots of Ginseng and different theories exist 
regarding the best part of the root to use, for example the main root, lateral sections or 
the rootlets. Most often the main root is desirable for medicinal purposes. Ginseng also 
contains polysaccharides, peptides, polyacetylenic alcohols, fatty acids, sugars, and 
Ginsenoside Rg1 Ginsenoside Rb1 
Source: National Centre for Biotechnology Information. PubChem Compound Database; CID=441923 and 73148, 
http://pubchem.ncbi.nlm.nih.gov/ (accessed Sept. 27, 2012). 
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trace elements (10, 78). The pharmacokinetics of Ginseng and ginsenosides have not 
been fully established. Ginsenosides are large compounds and have poor membrane 
permeability. The absorption and bioavailability of ginsenosides and their metabolites 
are extremely low, particularly after oral administration (85). Some studies have 
detected serum ginsenosides (Rb1) as low as 0.64% (86). Ginsenosides are quickly 
absorbed from the digestive tract and their peak time is between 1–2 hours and total 
elimination varies between 24 and 72 hours (87). Several ginsenosides are hydrolysed 
after ingestion and undergo bio-transformation to form new compounds, for example 
compound K is a metabolite of Rb1. Evidence suggests that ginsenosides may be pro-
drugs requiring bio-activation though deglycosylation and fatty acid esterification in the 
intestines (88).  
 
3.6 Standardisation and quality control  
Chinse herbal medicines (CHM) are often processed after harvest to produce an 
enhanced therapeutic effect, reduce toxicity and/or change their properties. Methods 
may include frying with honey or vinegar or stir baking or steaming. After harvest, 
Ginseng roots are traditionally air-dried and peeled (White Ginseng) or steamed which 
turns the root a deep red colour (Red Ginseng). The steaming process changes 
Ginseng’s properties from slightly warm to hot and supposedly increases its therapeutic 
effect. The recommended daily dose of Ginseng is 0.5–2 g of dried root per day or 200–
600 mg for extracts. 
 
Standardised Ginseng extracts are preferred among researchers as they ensure 
consistency between batches and therapeutic advantage. The most commonly referenced 
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standardised extract is G115, manufactured by Ginsana SA. This product has been 
evaluated in over 46 studies over 35 years (89, 90). The manufacturers of G115 select 
raw plant material aged 5 to 7 years from Korea and Northern China. The processing 
method involves a 20 step standardisation procedure yielding a total ginsenoside content 
of 4% (4mg) (Rg1, Rb1, Re, Rf, Rg2, Rc, Rb2, Rd). Quality control and standardisation 
methods are essential when using Ginseng for therapeutic purposes. Differences in 
chemical composition and concentration will affect efficacy and have implications for 
safety. Figure 13 presents the interconnectivity between quality, efficacy and safety of 
Ginseng. 
 
 
Figure 13: Quality, efficacy and safety of Ginseng 
Quality 
Safety 
Factors affecting quality 
 Species differentiation 
 Seasonal variation 
 Environment 
 Cultivation method 
 Harvesting 
 Storage 
 Manufacturing 
- Contamination 
   - Environmental pollutants 
    - Heavy metals 
    - Bacterial toxins 
- Adulteration 
    - Foreign plants 
    - Pharmaceutical agents 
- Substitution  
    - Alternate species 
 Regulation 
 Quality control  
 Good agricultural 
practices (GAP) 
 Good manufacturing 
practices (GMP) 
Sub-standard 
products may 
lead to less 
effective 
products 
Poor 
manufacturing 
process may 
lead to adverse 
events 
Efficacy 
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3.7 Ginseng products on the market  
Many forms of Ginseng are on the market, these include: raw plant material; granulated 
extracts; liquids extracts; and standardised extracts. Ginseng is one of the top selling 
herbs with sales in the USA worth over $7,000,000 annually (91). The quality of 
Ginseng products is variable and reports have indicated ginsenoside content between 
0% and 9% (92). A search of the Therapeutic Goods Administration’s (TGA) Australian 
Register of Therapeutic Goods (ARTG) on 27 September 2012 identified 395 listed 
products containing Panax ginseng as an active ingredient. Of these, only 14 products 
contained Panax ginseng alone. The other items were combinatorial products containing 
Ginseng with other herbal medicines and/or vitamins and minerals. The 14 Ginseng 
products listed on the ARTG are presented in Table 11. 
 
3.8 Ginseng research 
Ginseng is one of the most researched herbs and there is a significant body of literature 
evaluating its effect for many health conditions (75). Chapter 5 presents the results from 
RCTs evaluating Ginseng. Briefly, Ginseng was found to have the most promising 
effect for moderating the immune response particularly cell mediated immunity, and for 
glucose metabolism. These results may have implications for several diseases such as 
chronic respiratory conditions and type 2 diabetes (11).  
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Table 11: Ginseng products listed on the ARTG 
Product % 
ginsenosides 
Recommended 
dose 
Effect and indications 
Blackmores® Korean Ginseng 1.86% 500 mg bid Improves mental and physical capacities. 
Ginsana® G115 4%  100 mg bid Improves energy and fights fatigue. Strengthens the 
immune system. 
Ginsana® Tonic Oral Liquid 
(also listed as Pharmaton Ginsana 
G115 Oral Liquid) 
4% 15 mL qd Helps relieve nervous tension and stress. Can increase the 
oxygen intake capacity and reduce blood lactate levels. 
GNC Ginseng Gold™  3% 500 mg qd Improves mental and physical vitality. 
KGAC Co Cheong-Kwan-Jang, 
powders, pills and tablets (5 products)  
Not specified  1 g bid or tid 
 
Enhances stamina and endurance. Strengthens the immune 
system. 
Nutra-Life®  Korean ginseng 2500 1.67% 2.5 g qd  Helps relieve nervous tension and stress. Enhances stamina 
and endurance. 
Korean Ginseng 500 mg Super 
Strength 
Not specified 500 mg qd Improves general well-being. 
Nature's Own® Korean Ginseng  Not specified 500 mg bid Helps relieve stress. Enhances stamina. 
Nature’s Path standardised Korean 
Ginseng 
Not specified 150 mg bid Enhances stamina and endurance. 
Nature's Sunshine™ Korean Ginseng Not specified 410 mg qid Improves general well-being. Improves energy and fights 
fatigue. 
Well Herb Panax ginseng 
(capsules and liquid) 
Not specified 240 mg bid 
80 mg/ml 
Improves energy and fights fatigue. Strengthens the 
immune system. 
Peking Panax ginseng extract Not specified 10 mL bid Improves general well-being. Enhances endurance. 
RPS ANG COX GINSENG 150MG 
Panax ginseng 
Not specified 150 mg  No specific indications 
Note: Product information, % ginsenosides, recommended dose and indications are taken from the product label and company webpages. 
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3.9 Safety of Ginseng  
Ginseng has an overall good safety profile. The WHO monograph, the Chinese 
pharmacopoeia and the European Scientific Cooperative on Phytotherapy (ESCOP) 
indicate Ginseng is safe with no contraindications (83, 93, 94). Systematic reviews 
indicate Ginseng is safe at the recommended dose of 0.5–2 g/ day (90, 95). Clinical 
trials and case studies have reported rare occurrences of minor transient adverse events 
including diarrhoea, sleeplessness, palpitations, headache and nausea (95). The 
systematic review in Chapter 5 presents events from RCTs.  
 
There is a need to establish the safety of Ginseng during pregnancy and lactation. The 
current literature is scarce and recommendations of caution are based on isolated case 
reports of hormonal activity and results from animal and in vitro studies (96).   
 
Ginseng has been shown to interact with cytochrome P450 (97). This enzymes is 
involved in the metabolism of many drugs and caution needs to be taken when Ginseng 
is combined with other medications (97). There are four documented cases of Ginseng-
drug interaction in humans. The monoamine oxidase inhibitor, phenelzine interacted in 
three cases and the anti-coagulant, warfarin in another [Table 12].  The significance and 
clinical implications of these interactions is hard to determine.  
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Table 12: Reported cases of Ginseng-drug interaction 
Drug Number 
of cases 
Ginseng 
product 
Dose of 
Ginseng 
Adverse 
effects 
Outcome of the 
event 
Phenelzine 
(98) 
1 NatrolHigh: 
Combination 
product 
containing 
Ginseng and 
other 
ingredients 
Unspecified Trembling, 
headache 
and 
insomnia 
 
Resolved after 
discontinuation 
of Ginseng 
containing 
product 
Phenelzine 
(98) 
1 Ginseng tea Unspecified Trembling, 
headache 
and 
insomnia 
 
Resolved after 
discontinuation 
of Ginseng 
containing 
product 
Phenelzine 
(99) 
1 Ginseng 
unspecified 
(Patient was also 
taking triazolam, 
lorazepam and bee 
pollen) 
Unspecified Hypomania, 
and 
worsening 
depression 
Depression not 
improved after 
cessation of 
Ginseng 
product 
Warfarin 
(100) 
1 G115 
(Panax ginseng 
standardised product 
manufactured by 
Ginsana SA) 
3 capsules 
daily  
Decline in 
INR which 
was 
previously 
stable 
INR returned to 
normal after 
cessation of 
ginseng 
INR: International normalised ratio 
 
3.10 Pharmacology of Ginseng  
Ginseng exerts a range of complex pharmacological activities on the immune, 
endocrine, cardiovascular and central nervous systems (10). Cellular processes and 
activities of Ginseng are diverse due to the complex mix of compounds. The extent of 
its actions and mechanisms has not been fully elucidated however it is described as an 
“adaptogen”, increasing the body’s defence and enhancing stamina and endurance (83).  
 
Ginseng’s major active components, the ginsenosides, have demonstrated ability on 
numerous tissues as well as initiating multiple actions within the same tissue (10). The 
diverse actions of Ginseng are thought to rely on its ability to influence the 
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hypothalamic-pituitary-adrenal axis and target plasma membrane receptors as well as 
intracellular steroid receptors (10). Ginseng is a functional ligand of the glucocorticoid 
receptor and displays synergistic effects with cyclic AMP (101, 102). Evidence suggests 
it has glucocorticoid-like activity and can regulate gene transcription. Ginseng may have 
an effect on inflammatory diseases, diabetic conditions, steroid resistance, and cancers.  
 
3.10.1 Immune system 
Ginseng has anti-inflammatory and immune-modulatory actions. Ginseng may 
modulate inflammation through multiple immune system components including 
regulation of cell mediated and humoral immune response increasing phagocytosis and 
reducing mediators (103). These effects may have implications for local and systemic 
inflammation.  
 
Ginseng has multiple actions on inflammatory pathways. Predominantly, Ginseng 
affects NF-B and TNF-α production. Ginseng can regulate DNA binding, 
transcriptional activity, release of cytokines, and regulation of intracellular cAMP 
pathways (71). Ginseng can down regulate the expression and release of TNF-α (65), 
IL-6, and IL-8 (104) as well as increase T-cell numbers and natural killer cell activity 
(105). Anti-inflammatory effects of Ginseng also relate to its ability to act as an anti-
oxidant. In vitro studies have found that ginsenosides can activate antioxidant enzymes 
(106), protect cells from free radical damage (107) and inhibit lipid peroxidation (108).  
 
Furthermore, animal studies have found that ginsenosides were able to increase 
adrenocorticotropic hormone (ACTH) from the pituitary and increase serum 
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corticosterone (109). This may have implications for inflammation, as corticosterone is 
an anti-inflammatory agent. The activation of these mediators and pathways has been 
linked to several inflammatory diseases, including COPD, rheumatoid arthritis, and 
inflammatory bowel disease (59, 110). Figure 14 highlights the potential effects of 
Ginseng on inflammatory pathways. 
 
 
Figure 14: Potential effects of Ginseng on inflammatory pathways 
 
Anti-carcinogenic and anti-neoplastic effects of Ginseng are thought to rely on its 
ability to suppress inflammatory pathways. In vitro and in vivo studies have shown 
several ginsenosides including Rh2 and Rg3 can inhibit tumour cell growth (10). 
Clinical trials have also indicated that Ginseng can reduce the incidence and recurrence 
of cancer in at risk individuals (111, 112).  
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3.10.2 Glucose metabolism 
Ginseng lowers blood glucose by regulating glucose metabolism, improving insulin 
sensitivity, and stimulating hepatic glucose utilisation (113). Clinical trials evaluating 
the effect of Ginseng on healthy individuals and in type 2 diabetics have demonstrated a 
decrease in circulating glucose. These actions have implications for reducing 
hyperglycaemia and treating diabetes. However, conclusive results have not been 
established (11). The specific mechanisms and anti-diabetic actions are complex and 
still under investigation. Most notably, Ginseng can improve glucose homeostasis (114), 
activate pancreatic β-cells, increase insulin secretion, improve metabolic rate and 
glucose removal (113). Another mechanism of ginsenosides may be their ability to 
increase cellular energy. They are able to increase the capacity of muscles to oxidize 
free fatty acids instead of glucose therefore yielding more energy and endurance (115).  
 
3.10.3 Cardiovascular system  
The full extent of Ginseng’s effect on the cardiovascular system is unclear. Ginseng is 
thought to modulate vasomotor function, reduce platelet adhesion, influence ion 
channels (Ca
2+
 and K
+
), reduce vascular smooth muscle dysfunction and dilate blood 
vessels (116). Furthermore, oxidative stress is a factor in cardiovascular disease. 
Ginseng can ameliorate damage and reduce oxidative stress as well as enhancing nitric 
oxide production leading to vasodilation (117, 118). Clinical studies have yet to 
demonstrate a significant effect of Ginseng on any of the promising mechanisms found 
in vitro and in animal studies.  
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3.10.4 Central nervous system  
Ginseng may modulate neurotransmission and improving memory (10). The beneficial 
effects are thought to involve nitric oxide and scavenging of free radicals, reducing 
central nervous system cell apoptosis and inflammation and preventing the detrimental 
effects of aging (119, 120). Specifically, Ginseng and ginsenosides (Rb1, Rg1, Rg3) can 
affect the hippocampus, increasing acetylcholine and corticosterone (109, 121). Clinical 
trials are yet to conclusively demonstrate Ginseng’s effect on memory enhancement or 
neurodegenerative disorders such as Alzheimer’s disease and dementia (122). Some 
positive effects have been noted but clinical implications are difficult to interpret (11).   
 
3.11 Summary  
Ginseng is one of the most popular herbal medicines worldwide. It is used for an array 
of health conditions including respiratory and gastrointestinal diseases and general well-
being. It is safe and generally well tolerated. The current literature is diverse and there 
are a comprehensive array of pharmacological actions of Ginseng and ginsenosides. 
Diverse mechanisms of individual ginsenosides and whole root extracts may explain 
non-specific effects and the multitude of actions.  Positive results from pre-clinical and 
clinical research indicate that Ginseng may have potential application in many diseases.  
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Chapter 4: Search and analysis of classical literature on Chinese herbal medicine 
for COPD 
 
4.1 Foreword  
Chinese medicine (CM) theories and treatments have been widely used and preserved 
for over 2,000 years. There is a growing body of clinical evidence for the efficacy of 
CM, particularly Chinese herbal medicine (CHM) for certain disorders including 
respiratory, metabolic and cardiovascular conditions (8, 11). However, evidence-based 
CM practice is still undergoing development.  
 
The classical literature is voluminous, offering a diverse range of references based on 
the practice of healers over many centuries. These works offer a range of CHM 
treatments for a diversity of health conditions and continue to inform the use of CM in 
the contemporary setting. 
 
There term ‘classical’ applies to ancient works that formed the foundation of CM theory 
and practice. It generally relates to works written and/or published in dynastic China 
compared to works produced in modern China. The shift from classical to modern 
cannot be dated exactly. The fall of the Qing Dynasty and the beginning of the Republic 
of China (1911) marks the political end of the traditional period but the modernisation 
of CM occurred following the establishment of the People’s Republic of China in 1949. 
In this study the literature was considered to belong to the ‘classical’ period of Chinese 
medicine up until 1949.  
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The earliest extant CM works arose in the period up to and including the Han Dynasty 
(206 B.C. – A.D. 220). The principal works include the Huang Di Nei Jing ‘Yellow 
Emperor’s Internal Classic’, Nan Jing ‘Classic of Difficulties’ and the Shen Nong Ben 
Cao Jing ‘Farmer God’s Materia Medica’ all of which are of unknown authorship (79, 
123).  
 
The most influential herbal medicine work is considered to be the Shen Nong Ben Cao 
Jing ‘Farmer God’s Materia Medica’ compiled between 206 B.C. – A.D. 220. It was 
named in attribution to the renowned deity Shennong who is believed to have taught 
agriculture practices and herbal medicine to the ancient people of China. The Shen Nong 
Ben Cao Jing includes details of herbal medicines coupled with their application and 
indications. The book summarises 365 plant, animal and mineral medicines (79). 
 
Over the ensuing millennia, the materia medica grew exponentially creating a vast body 
of knowledge. Significant texts include the Ben Cao Jing Ji Zhu ‘Annotations on 
Materia Medica’ and the Ben Cao Gang Mu ‘Compendium of Materia Medica’(124). 
Modern CM practices have maintained the fundamental theories and concepts presented 
in ancient texts and enhanced early understanding by incorporating up to date scientific 
knowledge.   
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4.2 Introduction 
Search and analysis of the classical literature in a systematic and organised way is an 
approach to selecting herbs and herbal formulae with potential efficacy for inclusion in 
drug discovery efforts and/or in clinical trials (125-127). Classical literature citations 
may lead to new drug development similar to that which lead to the anti-malarial drug, 
artemisinin (128). 
 
Chronic obstructive pulmonary disease (COPD) is a modern disease and classical CM 
literature does not refer to this condition as it is understood today. Therefore, the terms 
COPD, chronic bronchitis and emphysema cannot be found in the classical texts. The 
terms used in CM are more general than in modern medicine with less specificity for a 
particular disease. However, classical Chinese manuals include conditions broadly 
similar to the modern conception of COPD. Typical terms for such conditions include: 
fei zhang ‘Lung distension’;  jiu ke ‘chronic cough’;  jiu chuan ‘long-term dyspnea ’; zhi 
yin ‘chest tightness’; chuan zheng ‘dyspnea’; and ke chuan ‘cough and dyspnea’ (129). 
Within these concepts it is conceivable that some of the conditions treated would now 
be considered COPD and the herbal treatments used may have contained herbs that 
were efficacious for the relief of the condition. In this study, a large sample of the 
classical literature was searched for instances of the use of herbal formulae for treating a 
condition that was most likely COPD. Within this subgroup of references the most 
commonly used formulae and herbs are identified and form a basis for selecting herbs 
requiring further investigation to inform future drug development (125).  
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In this section ‘formula’ refers to a prescription or recipe of a combination of herbal 
ingredients. These may include herbs from plant, animal and/or mineral origin. 
Formulae are usually constructed by combining a number of herbs that address different 
aspects of a health condition. Traditionally formula are prepared by decoction, that is, 
by boiling the herbs in water, used as powders or formed into pills. 
The Chinese names for formula, herbs and books have been transliterated into pin yin 
and are italicised (except in tables where they are in regular text). Chinese characters are 
not included in the text. Chinese terms and names are presented as follows: 
 Chinese terms are written in lower case, for example fei zhang 
 Herb names are written in lower case, for example ren shen 
 Herbal formula are written in sentence case, for example Shen qi wan 
 Book names are written in title case, for example, Jin Gui Yao Lue 
 
The classical literature is often combined into compendia that comprise extracts from 
many CM books. They provide a convenient body of data that can be searched and 
linked to original references. There is no complete collection of the classical CM 
literature however several large collections and compendia are available that cover a 
wide variety of publications (130, 131). 
 
The Zhong Yi Fang Ji Da Ci Dian (ZYFJDCD) is a collection of formulae citations 
derived mainly from classical books. The formulae have been categorised and indexed 
against diseases and symptom names. The ZYFJDCD includes extracts from at least 
685 books. In 11 volumes, it is the largest collection of Chinese herbal formulae. It 
contains 96,592 entries, each referring to at least one herbal formula, Figure 15 (131). 
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The Nanjing Chinese Medicine Institute compiled the ZYFJDCD and first published it 
in 1993. 
 
The ZYFJDCD was selected in this search as it is easy to access, comprehensive and 
includes CM literature spanning over 2,000 years (c. 206 B.C. – A.D. 1985). 
 
 
Figure 15: Zhong Yi Fang Ji Da Ci Dian  
 
4.3 Aims and hypothesis 
The aim of the study was to search and analyse the classical literature to identify herbs 
and CHM formulae that had been referenced and indicated for the treatment of 
conditions analogous to COPD. Additionally, the study aimed to reveal the most 
frequently used CHM formulae and individual herbs for conditions similar to COPD.  
 
Photo at left, the ZYFJDCD volume 1 front cover. Photo at right, the ZYFJDCD 11 volumes. 
Image source © Johannah Shergis 
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It is hypothesised that the six search terms: fei zhang, jiu ke, jiu chuan, zhi yin, chuan 
zheng, and ke chuan are good matches for COPD and at least some of the extracted 
citations are consistent with COPD. 
 
 
4.4 Methods  
4.4.1 Search strategy 
The search method was based on previously published procedures (125). COPD is a 
modern classification of disease and identical classical terms are not available. Classical 
CM texts do not refer to COPD specifically, however similar terms include fei zhang 
(Lung distension) and chuan zheng (panting pattern). These terms alone were not 
sufficient to search the traditional literature. Therefore, it was necessary to develop a set 
of terms based on key symptoms. The terms were developed by consulting an 
authoritative CM dictionary, Zhong Xi Yi Bing Ming Dui Zhao Da Ci Dian (132). 
Additionally respiratory experts and medical manuals were consulted. The ZYFJDCD 
was searched using the following terms.  
 fei zhang ‘Lung distension’ 
  jiu ke ‘chronic cough’ 
 jiu chuan ‘long-term dyspnea ’ 
 zhi yin ‘chest tightness’ 
 chuan zheng ‘dyspnea’ 
 ke chuan ‘cough and dyspnea’ 
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The classical literature search was restricted to the dynastic and republican periods and 
included books written and published up until 1949.  
 
The ZYFJDCD is written in Chinese, therefore experienced researchers who were 
native Chinese speakers and proficient in English language undertook extraction of data. 
The contribution of Xiankun Chen and Nicole Chang is acknowledged. 
 
4.4.2 Data extraction 
Each search term was indexed in the ZYFJDCD. In most cases, one reference was 
associated with a single herbal formula but in some cases a reference referred to more 
than one formula, additionally some references were not relevant to their indexed term. 
Therefore, only the references that were specific to the index term and included an 
herbal formula were considered an ‘entry’. One ‘entry’ contains one formula. Entries 
were given an identification number and the details of each entry were entered onto 
Microsoft
®
 Excel spread sheets. 
 
Extracted data included: 
 index term  
 formula name 
 name of individual herbs in the formula  
 instructions for preparation and/or use 
 syndrome or disorder for which the formula was intended  
 book title where formula was found 
 authorship of the book (when available) 
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 year the book was written. 
Issues with inconsistent and unclear data were addressed by comparing them with other 
classical CM literature sources. 
 
4.4.2.1 Dating classical books 
Classical books were dated according to the listing of books in the ZYFJDCD (volume 
11). If the year of publication was not clear other CM sources were consulted (124, 
133). If the year could still not be determined, it was assigned the year of the author’s 
death and if this was unavailable the last year of the historical period (dynasty).  
 
4.4.3 Classification of citations 
Citations fall broadly into two types, those that refer to a particular case or series of 
cases, and information on the general use of the formula. In some cases, the type is 
unclear. 
 
4.4.4 Classification of symptoms 
The search terms selected reflect the main symptoms of COPD. However, there is no 
certainty that the condition listed in the citation is consistent with the modern 
understanding of the disease so the search will find references that are not relevant. 
Citations are often brief and the information provided does not give enough insight to 
draw firm conclusions as to the application of the formula. In other cases, the 
description is detailed enough to allow inference as to the identity of the condition. 
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To identify citations likely to refer to COPD, a set of inclusion and exclusion criteria 
were developed. The symptoms selected were those that would be observed when 
making a clinical diagnosis of COPD. To develop the inclusion and exclusion criteria as 
well as the related scoring system expert opinion was sought and modern medical 
literature and clinical manuals were consulted (1, 134). 
The selected COPD symptoms were: 
 dyspnea, including shang qi ‘difficulty breathing’ 
 cough 
 sputum production 
 chest tightness, including fei zhang ‘Lung distension’.  
 
4.4.5 Exclusion criteria 
Excluded citations were:  
 citations in books published after 1949 
 citations specifically relating to women’s disorders 
 citations specifically indicated for postpartum conditions 
 citations specifically indicated for children 
 citations indicated for acute disorders, trauma or other disorders unrelated to 
COPD 
 citations indicated for haemoptysis 
 
In cases where there was an acute complication of a chronic condition the citation was 
included. Table 13 presents the scoring system for excluding citations.  
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Table 13: Scoring system for excluding citations 
Children or women at childbirth or postpartum Code 
1. No mention 0 
2. Specific for Children 1 
3. Specific for women and/or disorders at childbirth or 
postpartum 
2 
Acute disorder  
1. No mention 0 
2. No, chronic disorder 1 
3. Yes, acute disorder 2 
4. Yes, injury or trauma 3 
5. Yes, shang han (generally refers to acute conditions) 4 
Haemoptysis  
1. No mention 0 
2. No haemoptysis 1 
3. Yes, indicated for haemoptysis 2 
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4.4.6 Global score 
Citations were judged as a whole with reference to all the details, including index and 
entry terms, formula ingredients, use, indication and any other information. They were 
given a global score to rank their likelihood of being similar to COPD [Table 14]. The 
scores were: 0 ‘not enough information to decide’; 1 ‘other disease unlike COPD’; 2 
‘possibly COPD’; 3 ‘possible complication of COPD’; or 4 ‘most likely COPD’.  
 
Two independent reviews judged the citations. One reviewer was an experienced 
Chinese medicine practitioner and the other an experienced researcher in Classical 
Chinese literature.  
 
Table 14: Scoring system for the global score 
Description Global score 
1. Not enough information to decide 0 
2. Other disease unlike COPD 1 
3. Yes, possible COPD 2 
4. Yes, possible complication of COPD (for example right 
heart failure, lower limb oedema, cyanosis, or weight loss) 
3 
5. Yes, most likely COPD 4 
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4.4.7 Data analysis 
Source data was entered into Microsoft
®
 Excel spread sheets. The data was then 
prepared and entered into SPSS (IBM
®
 SPSS
®
 Statistics Version 20, 2010) for statistical 
analysis. Descriptive data was converted to numeric entries and each formula and herb 
was identified by a code. For example, the herbal formula Da fu pi san was assigned the 
code 343 as per existing data sets developed by Dr Brian May, RMIT University 
(unpublished). The century and dynasty of the citation was also coded. 
 
Frequencies of formulae and herbs were evaluated from the total data set. Duplicate 
entries and those from modern books (post 1949) were excluded from further analysis.  
 
Citations that were not consistent with COPD were excluded in a stepwise fashion. 
Citations referring to women’s disorders, postpartum conditions or children were 
excluded, followed by citations referring to acute conditions. Finally, citations referring 
to haemoptysis were excluded.  
 
Frequencies of formulae and herbs were calculated at each step and evaluated against 
the six COPD symptoms. The six search terms referred to in the search strategy were 
also cross-linked to the six COPD symptoms.  
 
Citations were grouped in levels of specificity according to their strength and likelihood 
of being consistent with COPD. The levels were then compared with the global scores. 
To ensure consistency lists of the most frequent formulae and herbs were generated 
from citations showing higher levels of consistency with COPD.  
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4.5 Results 
4.5.1 Search results 
In total 1,557 entries were extracted from the ZYFJDCD.  After exclusion of modern 
books (post 1949) and duplications (n= 65), there were 1,492 formulae citations and 
513 distinct herbs within the formulae. Two hundred and seven (207) distinct books 
located the citations, written from A.D. 206 to 1949. The earliest book was the Shang 
Han Lun c. A.D. 206 and the most recent book was the Xiao Er Zhu Re Bian published 
in 1949.  
 
The search term ke chuan located the majority of citations (n=796), followed by chuan 
zheng (n=500), jiu ke (n=127), zhi yin (n=35), fei zhang (n=27) and jiu chuan (n=7) 
[Table 15]. On inspection of the citations, dyspnea was mentioned in 982 citations, the 
term shang qi in 294, cough in 862, sputum production in 319, chest tightness in 297 
and fei zhang in 32. 
 
Table 15: Number of citations located by each search term  
Search term Number of citations 
ke chuan 796 
chuan zheng 500 
jiu ke 127 
zhi yin 35 
fei zhang 27 
jiu chuan 7 
Total 1,492 
 
 
 
80 
 
4.5.2 Results after exclusions 
To refine the data set it was necessary to exclude citations not consistent with COPD, 
these were: 
 women’s disorders, postpartum conditions or children’s disorders (n=119) 
 acute or other unrelated disorders (n= 156) 
 haemoptysis (n= 70). 
 
After exclusions, the total number of formulae citations was 1,147 derived from 180 
books written from A.D. 206 to 1937.  The included formulae were composed of 455 
distinct herbs, with an average of 8.6 herbs per formula.  
Figure 16 presents the flowchart of citation selection.  
 
81 
 
 
Figure 16: Flowchart of citation selection  
  
Development of a set 
of COPD terms and 
set of exclusion terms 
Identification of search terms based 
on classical terms for COPD 
symptoms 
ZYFJDCD searched using 
search terms 
Search terms: 
1. Fei zhang ‘Lung distension’ 
2. Jiu ke ‘chronic cough’ 
3. Jiu chuan ‘long-term dyspnea’ 
4. Zhi yin ‘chest tightness’ 
5. Chuan zheng ‘dyspnea’ 
6. Ke chuan ‘cough and dyspnea’ 
 
Citations extracted 
N = 1,557 
Duplicates and modern books 
removed 
n = 65 
Citations not consistent with 
COPD removed 
1. Women’s disorders, postpartum 
conditions or children (n = 119) 
2. Acute or other disorders (n = 156) 
3. Haemoptysis (n = 70) 
Citations rated according to 
COPD symptoms  
Citations analysed 
 (n =1,147)  
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4.5.3 Characteristics of citations  
The data set after exclusions comprised 1,147 citations each comprising a single 
formula that was indexed as applicable when treating at least one of the search terms. 
There were 902 distinct formulae and 426 distinct herbs within the formulae. Table 16 
presents the data. 
  
Table 16: Characteristics of citations after exclusions 
Total 
number of 
formulae 
Number 
of 
distinct 
formulaea 
Number 
of herbs 
Number of 
distinct 
herbsa 
Search term frequencies  
 
fei 
zhang 
 
jiu ke jiu 
chuan 
 
zhi yin 
 
chuan 
zheng 
 
ke 
chuan 
 
 
1,147 
 
902 
 
9,863 
 
426 
 
22 
 
105 
 
6 
 
35 
 
413 
 
566 
 
a 
Distinct formulae and herbs refers to the number of different formulae and herbs represented.  
 
4.5.3.1 Frequency of formulae 
The frequency of formulae are summarised in Table 17. The formulae are listed with 
their ingredients and the number of citations. The top three formulae were referenced on 
10 or more occasions. Shen qi wan(2) was the most frequent formula (n=16). It was first 
mentioned in the Jin Gui Yao Lue c. A.D. 206. It contains eight herbs and treats chronic 
conditions, with the ability to warm the body and tonify the Kidney. The second most 
frequently used formulae were Mai men dong tang(1) (n=10) and Xiao qing long 
tang(2) (n=10). Mai men dong tang(1) first appeared  in Wai Tai Mi Yao c. A.D. 752 it 
is used to treat the Lung and is indicated for cough, wheezing, and phlegm. Xiao qing 
long tang(2) first appeared in the Shang Han Lun c. A.D. 206. It is used for coughing 
and descends the flow of Qi and warms the Lung, although it is commonly used for 
acute conditions it can also be used for chronic conditions (81).  
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Table 17: Most frequent formulae  
Rank Formula name Name of herbs in the formula Frequency 
1 Shen qi wan (2) Gan di huang, Shan yao, Shan zhu yu, Ze 
xie, Fu ling, Mu dan pi, Gui zhi, Fu zi. 
Cooked with honey and taken with rice 
wine.  
16 
2 Mai men dong tang (1) Mai men dong, Ban xia, Ren shen,  Gan 
cao, Ji mi, Da zao 
10 
3 Xiao qing long tang (2) Ma huang, Shao yao, Xi xin, Gan jiang, 
Gan cao, Gui zhi, Wu wei zi, Ban xia 
10 
4 Wu ji san Cang zhu, Jie geng, Zhi qiao, Chen pi, Shao 
yao, Bai zhi, Chuan xiong, Dang gui, Gan 
cao, Rou gui, Fu ling,  Ban xia, Hou pou, 
Gan jiang  
6 
5 Ze xie tang Ze xie, Bai zhu  5 
6 Si mo tang Ren shen, Bin lang, Chen xiang, Wu yao 5 
7 Si mo yin Wu yao, Zhi shi, Bin lang  5 
8 Guan yin ren shen hu tao 
tang 
Ren shen, Hu tao rou 5 
9 Jiu bao san Da fu pi, Rou gui, Gan cao, Zi su, Xing ren, 
Sang bai pi, Ma huang,  Chen pi, Bo he, 
Wu mei, Gan jiang.  
5 
10 Ze xi tang (1) Ban xia, Zi shen, Ze qi, Sheng jiang,  Bai 
qian, Gan cao, Huang qin, Ren shen, Gui 
zhi  
5 
11 Du qi wan Shu di huang, Shan yao, Shan zhu yu, Mu 
dan pi, Ze xie, Bai Fu ling, Wu wei zi 
5 
12 Yi shi li yu tang Xing ren, Bei mu, Rou gui, Ju pi,  Ren 
shen, Zhi gan cao, Zhi hou po, Ma huang, 
Fu ling, Hu ma, Bai qian,  Sheng jiang, Ban 
xia. Cook carp together with herbs and take 
out the fish in the end.  
4 
13 Sheng xian tang Huang qin, Zhi mu, Chai hu, Jie geng, 
Sheng ma   
4 
14 Liu mo yin Zhi qiao, Bin lang, Wu yao, Ren shen, Mu 
xiang, Chen xiang 
4 
15 An shen wan (1) Rou gui, Wu yao, Tao ren, Bai ji li, Ba ji 
tian, Shan yao, Fu ling, Zhi Rou cong rong 
(soaked in rice wine),  Zhi shi hu, Bi xie, 
Bai zhu, Po gu zhi.  Cook with honey. 
4 
16 Zhen wu tang Fu ling, Shao yao, Sheng jiang, Bai zhu, Fu 
zi 
4 
17 Wu hu tang Ma huang, Xing ren, Gan cao, Shi gao 4 
18 Zi su zi tang (2) Zi su zi, Ban xia, Qian hu, Hou po, Gan 
cao, Dang gui, Ju pi, Da zao, Sheng jiang, 
Rou gui  
4 
Note: To distinguish formulae with the same name but different herbal ingredients a number has been 
placed next to them. For example, the data set contained four formulae named Mai men dong tang, all 
with different ingredients. Therefore, they are distinguished by placing a number next to their name. 
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4.5.3.2 Frequency of herbs  
Table 18 presents the top 20 most frequently cited herbs. The citations did not indicate 
which herbs in a formula were specific for COPD and which were used for other 
reasons. The highest frequency items were ginger, jiang (Zingiber officinale) and 
licorice, gan cao (Glycyrrhiza uralensis). Although these herbs were commonly used in 
the citations, they were not necessarily specific for Lung conditions.   
 
Certain herbs are added during the preparation of formulae but are not part of the main 
ingredients. The data were further analysed to evaluate the most frequently cited herbs 
after the exclusion of added herbs, results are presented in Table 19. From the table it is 
clear that excluding added herbs changed the order of their frequencies. It revealed that 
feng mi ‘honey’ was no longer included in the top 20 herbs. Honey is often used in the 
preparation of herbal pills and is not part of the formula itself. Additionally da zao was 
no longer in the top 20 herbs, which is often added during the decoction process in 
many formulae. The high frequency of gan cao may be due to its generic use in most 
formulae. Traditionally it is used to harmonise the other ingredients and often does not 
have a specific action for the condition being treated (81). Typically ban xia is used 
with ginger, sheng jiang, they are combined to harmonise each other. Therefore the use 
of sheng jiang for respiratory conditions may not be specific (81).  
 
Therefore after the removal of non-specific herbs the six most frequently cited herbs 
were xing ren (n=386), ban xia (n=314), ren shen (n=283), sang gen bai pi (n=256), wu 
wei zi (n=214) and ma huang (n=202).  
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Xing ren, dried apricot seed (Prunus armeniaca) was first mentioned in formulae in the 
Shang Han Lun c. A.D. 206. It is indicated for coughing and is able to dissipate phlegm. 
The second most frequent herb was ban xia, (Pinellia ternate) its main function is to 
remove phlegm and is indicated for cough with copious sputum (81). Ban xia is slightly 
toxic in the raw form and is therefore processed into zhi ban xia. Ren shen, Ginseng root 
(Panax ginseng) was the third most frequent herb. It was first mentioned in formulae in 
the Jin Gui Yao Lue c. A.D. 206. In comparison to Xing ren and ban xia, ren shen 
functions to tonify the Lung and strengthen the body, therefore it is indicated for Lung 
conditions, particularly chronic Lung conditions (81). Other frequently cited herbs 
include sang gen bai pi, mulberry bark (Morus alba) which is indicated for cough and 
wheeze and is particularly useful for phlegm and heat in the Lung (81). Wu wei zi, 
(Schisandra chinensis) is used to treat cough, particularly chronic cough and finally ma 
huang, ephedra stem (Ephedra sinica) which is predominantly indicated for wheezing 
and asthma. 
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Table 18: The 20 most frequently cited herbs  
Rank Scientific name Chinese name Frequency 
1 Zingiber officinale (fresh or dried rhizome) Gan jiang/Sheng jiang 642 
2 Glycyrrhiza uralensis or G. glabra (dried root) Gan cao 538 
3 Prunus armeniaca (dried seed) Xing ren 386 
4 Pinellia ternata (dried processed rhizome) Ban xia (zhi) 314 
5 Poria cocos (dried sclerotium) Fu ling 294 
6 Citrus reticulata or C. tangerine (dried peel) Chen pi 289 
7 Panax ginseng (dried root) Ren shen 283 
8 Morus alba (dried bark) Sang gen bai pi 256 
9 Cinnamomum cassia (dried bark) Rou gui/Gui zhi 246 
10 Honey Feng mi 217 
11 Schisandra chinensis (dried fruit) Wu wei zi 214 
12 Perilla frutescens or P. crispa (dried herb) Zi su geng/Zi su zi/Zi su ye 203 
13 Ephedra sinica (dried herb) Ma huang 202 
14 Ziziphus jujuba (dried fruit) Da zao 182 
15 Platycodon grandiflorum (dried root) Jie geng 156 
16 Tussilago farfara (dried flower) Kuan dong hua 148 
17 Aster tartaricus (dried root) Zi wan 146 
18 Fritillaria cirrhosa (dried rhizome) Bei mu 143 
19 Citrus aurantium (dried fruit) Zhi shi 140 
20 Ophiopogon japonicus (dried rhizome) Mai men dong 130 
 
Table 19: The 20 most frequently listed herbs after exclusion of added herbs 
Rank Scientific name and part used  Chinese name Frequency 
1 Glycyrrhiza uralensis or G. glabra (dried root) Gan cao 533 
2 Prunus armeniaca (dried seed) Xing ren 382 
3 Pinellia ternata (dried processed rhizome) Ban xia (zhi) 314 
4 Zingiber officinale (fresh or dried rhizome) Gan jiang/Sheng jiang 303 
5 Poria cocos (dried sclerotium) Fu ling 293 
6 Citrus reticulata or  C. tangerine (dried peel) Chen pi 285 
7 Panax ginseng (dried root) Ren shen 277 
8 Cinnamomum cassia (dried bark) Rou gui/Gui zhi 246 
9 Morus alba (dried bark) Sang gen bai pi 231 
10 Schisandra chinensis (dried fruit) Wu wei zi 213 
11 Ephedra sinica (dried herb) Ma huang 202 
12 Perilla frutescens or P. crispa (dried herb) Zi su geng/Zi su zi/Zi su ye 192 
13 Platycodon grandiflorum (dried root) Jie geng 156 
14 Tussilago farfara (dried flower) Kuan dong hua 148 
15 Aster tartaricus (dried root) Zi wan 144 
16 Fritillaria cirrhosa (dried rhizome) Bei mu 142 
17 Citrus aurantium (dried fruit) Zhi shi 140 
18 Ophiopogon japonicus (dried rhizome) Mai men dong 127 
19 Atractylodes macrocephala (dried rhizome) Bai zhu 117 
20 Rehmannia glutinosa (dried root) Di huang/ Shu di huang/ 
Sheng di huang/ Gan di huang  
102 
Note: Herbs were ‘recoded’ to combine cases that were the same species, yet prepared differently. For example, gan jiang is the dried form 
of sheng jiang therefore they were grouped. Scientific names are referenced from: Bensky, Chinese herbal medicine: materia medica, 2004 
(81).Added herbs are those that are not included in the core herbal formula however are added during or at the end of decoction. For 
example, da zao is generically used in many formulae to harmonise the other ingredients and often it does not have a specific action for the 
condition being treated. 
87 
 
4.5.4 Botanical identity of herbs 
The citations extracted from the ZYFJDCD are from classical texts. The scientific 
names of the herbs are not listed in the classical literature therefore the scientific names 
were referenced from modern CM materia medica books (81). Accurately describing the 
botanical identity is not always straightforward. For instance, Perilla frutescens and the 
variety Perilla crispa are difficult to distinguish when referencing the classical literature 
alone. To alleviate the confusion, herbs that were from a similar species or from the 
same species but prepared differently were combined and recoded in the data set. For 
example, dried jiang (gan jiang) and fresh jiang (sheng jiang) were grouped and 
recoded into one item. In Table 18 and Table 19, the herbs are listed together if they are 
from the same species but prepared differently.   
 
4.5.5 Distribution of data by historical period 
The frequency of formulae citations and books are grouped according to dynastic period 
in Table 20, and by century in Figure 17. In the early periods, a small number of books 
dominated and located many of the formulae citations. For instance before the Tang 
Dynasty the 67 citations were from three books, Shang Han Lun, Jin Gui Yao Lue and 
the Zhou Hou Bei Ji Fang. This was expected as large classical books predominated 
over certain periods (133).  
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Table 20: Number of formulae citations and books grouped by dynastic period 
Dynastic period
a
 Number of formula citations Number of distinct books 
Full data set After exclusions 
Before Tang Dynasty (before 618) 78 67 3 
Tang and 5 Dynasties (618–960) 127 90 4 
Song and Jin Dynasties (961–1271) 666 503 36 
Yuan Dynasty (1272–1368) 39 32 9 
Ming Dynasty (1369–1644) 340 267 50 
Qing Dynasty (1645–1911) 206 161 69 
Republic of China (1912–1949) 37 27 10 
Modern (1950 onwards) 64 0 0 
Total 1,557 1,147 181 
a The dynastic periods were allocated a historical period to remove overlapping years.  
 
The majority of formulae were cited from the Song Dynasty (961–1271) followed by 
the Ming Dynasty (1369–1644). During the Song Dynasty medical publishing 
expanded. Major medical classics were edited and published for wide-spread 
distribution (135). Most notably the Song Dynasty delivered the first official medical 
encyclopaedia the Sheng Ji Zong Lu, covering diverse aspects of medicine with 
references to approximately 20,000 formulae (135). After the Song Dynasty new 
medical works dropped off until the Ming Dynasty when a number of works were 
produced, including the famous Ben Cao Gang Mu (124).  
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Figure 17: Formula grouped by century of publication before and after exclusions 
 
The years 1100–1199 produced the most citations. This period includes the Song and 
Jin Dynasties. As mentioned above, during this period medical publishing expanded. 
There was no real difference between the data set before and after exclusions. One 
noteworthy difference was in the period from 1900–1999. Citations after 1949 were 
excluded, therefore the number of formulae after exclusions was greatly reduced 
compared to before exclusions.  
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4.5.5.1 Search terms  
All the search terms were productive in locating citations. Ke chuan located the majority 
of citations, followed by chuan zheng, jiu ke, zhi yin, fei zhang and jiu chuan.  The 
frequency and use of the search terms has changed over time. Figure 18 presents the 
distribution of terms.  
 
Ke chuan ‘cough and dyspnea’ was the most productive in locating relevant citations 
and it was used throughout the whole data set. Chuan zheng ‘dyspnea’ was seldom used 
before A.D. 800. After this time, it peaked until 1200 then peaked again after 1400. Zhi 
yin ‘chest tightness’ was first mentioned in 200–299 but not again until 900–999 and 
then seldom used in the remaining centuries. Jiu chuan ‘long-term dyspnea’ was not 
used until 1100–1199. Jiu ke ‘chronic cough’ was similarly used from A.D. 800 
onwards. Then use dropped off from 1700 in favour of ke chuan and chuan zheng.  
 
Fei zhang ‘Lung distension’ and chuan zheng ‘Panting pattern’ are considered the 
translational terms for COPD (129). It was thought these terms would match the 
classical literature and be able to locate citations similar to what is known today as 
COPD. This was not the case for fei zhang, which was rarely used. It located only a 
minimal number of citations predominantly from 1400 onwards. Chuan zheng was more 
successful in locating relevant citations and was used throughout the historical periods.  
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Figure 18: Distribution of search terms by century 
 
4.5.5.2 Frequency of search terms and symptoms  
Table 21 presents the frequencies of the six search terms and six symptoms. Dyspnea 
and cough were the most frequent symptoms. Dyspnea was referenced in 776 out of the 
1,147 citations (67.7%), cough 648 (56.5%), sputum production 252 (21.9%), chest 
tightness 236 (20.6%), shang qi (19.9%), and fei zhang 23 (2%). Shang qi appears to 
have a similar meaning to ‘dyspnea’. In the case of fei zhang, its meaning as a symptom 
is less clear. ‘Lung distension’ is the term provided by modern medical references 
however the meaning appears similar to ‘chest tightness’ (129).   
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Table 21: Frequency of search terms against symptoms 
Symptom Number of citations 
Fei zhang Jiu ke Jiu chuan Zhi yin Chuan zheng Ke chuan 
1. Dyspnea 
No mention 8 91 1 24 96 151 
No 0 0 0 0 0 0 
Dyspnea 12 14 5 11 315 414 
Worse with 
exercise 
2 0 0 0 2 1 
Severe dyspnea 0 0 0 0 0 0 
2. Shang qi ‘difficulty breathing’ 
No mention 17 96 5 30 304 466 
Yes 5 9 1 5 109 100 
3. Cough 
No mention 11 1 5 25 374 83 
No 0 0 0 0 0 0 
Yes 11 2 0 10 37 462 
Chronic or long 
term cough 
0 102 1 0 2 21 
4. Sputum production 
No mention 20 92 5 33 326 380 
No 0 1 0 0 0 1 
Yes 0 6 1 1 69 165 
Chronic sputum 
production 
0 6 0 0 1 3 
CM phlegm 
syndrome 
2 0 0 1 17 17 
5. Chest tightness 
No mention 17 98 6 21 321 448 
No 0 0 0 0 0 0 
Yes 5 7 0 14 92 118 
6. Fei zhang ‘Lung distension’ 
No mention 2 105 6 35 410 563 
Disease 9 0 0 0 0 0 
Symptom 9 0 0 0 3 2 
Not sure 2 0 0 0 0 1 
Total 132 630 36 210 2478 3396 
 
The data was consistent with the expectation that when a search term located a formula 
the indications of that formula would match the search term. However, there were some 
anomalies. For example, one citation was indexed under the term jiu chuan ‘long-term 
dyspnea’ yet the indication for use made no mention of dyspnea. However it was 
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indicated for ‘shang qi’ which is a similar term for dyspnea. Furthermore, 96 citations 
indexed under chuan zheng ‘dyspnea’ did not mention dyspnea as an indication. Fifty-
six (56) did mention shang qi. The reasons for the remaining 40 citations indexed under 
chuan zheng, may include variations in the indexing authors’ definitions and 
interpretation of terms, predominately overlap with terms such as choking (zhi xi, 窒息) 
or throat blockage (yan hou zu sai, 咽喉阻塞) and tachypnea (hu xi ji cu, 呼吸急). 
These terms could be broadly defined as relating to dyspnea but such terms were not 
included within the scope of ‘dyspnea’ in our scoring system. There were two occasions 
when the search term fei zhang did not mention the ‘symptom’ fei zhang. Similarly, one 
citation was indexed under jiu ke ‘chronic cough’ yet it did not mention cough as an 
indication.  
 
4.5.6 Global score  
A global score was used to rank the citations.  Forty-nine (49) were ranked as ‘0’, that 
is, they did not provide enough information to decide, 311 were classified as ‘other 
diseases unlike COPD’, 27 were ‘possible complications of COPD’, 735 were ‘possibly 
COPD’ and 25 were ‘most likely COPD’.  
 
Table 22 presents the citations ranked as ‘possibly COPD’ against the search terms that 
located the citations and the symptoms mentioned in the citations. Table 23 presents the 
citations ranked as ‘complications of COPD’ and Table 24 presents the citations ranked 
as ‘most likely COPD’.  
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The 25 citations that were most likely COPD all referred to different formula. They 
were derived from 15 books written between c. 992 and 1933. The formulae were made 
up of 104 distinct herbs and the top 20 herbs are presented in Table 25. Ke chuan was 
the best predictor of the citation being ranked as ‘most likely COPD’ with 16 out of the 
25 (64%) being located by this search term. Dyspnea and cough were better predictors 
and were referenced in 24 and 22 citations, respectively. Shang qi and fei zhang were 
less commonly used, referenced in two and one citations, respectively [Table 24].  
 
Table 22: Citations ranked as ‘possibly COPD’ by search term and symptom 
frequency 
Search term Number of 
citations, (%) 
Symptoms
a
 Number of 
citations, (%) 
Fei zhang 17 (2.3%) Dyspnea 543 (36%) 
Jiu ke 89 (12.1%) Shang qi  150 (10%) 
Jiu chuan 5 (0.7%) Cough 468 (31%) 
Zhi yin 13 (1.8%) Sputum production 180 (12%) 
Chuan zheng 249 (33.9%) Chest tightness 160 (10%) 
Ke chuan 362 (49.3%) Fei zhang (as a symptom) 20 (1%) 
Total citations 735 Total citations  735 
a 
Several symptoms were often referred to in the one citation. 
 
Citations ranked as ‘possibly COPD’ (n=735) were mostly located by the search term ke 
chuan, 49.3%. Jiu chuan was the least successful in locating citations, 0.7%. The 
majority of citations referenced dyspnea and cough, 36% and 31%, respectively. Fei 
zhang was the least referenced 1%. 
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Table 23: Citations ranked as ‘complications of COPD’ by search term and 
symptom frequency 
Search term Number of 
citations, (%) 
Symptoms
a
 Number of 
citations, (%) 
Fei zhang 1 (4%) Dyspnea 22 (38%) 
Jiu ke 1 (4%) Shang qi  4 (7%) 
Jiu chuan 0 (0%) Cough 17 (29%) 
Zhi yin 5 (18%) Sputum production 6 (10%) 
Chuan zheng 7 (26%) Chest tightness 8 (14%) 
Ke chuan 13 (48%) Fei zhang (as a symptom) 1 (2%) 
Total citations 27 Total citations  27 
a 
Several symptoms were often referred to in the one citation. 
 
Ke chuan located the most citations ranked as ‘complications of COPD’. Complications 
include symptoms of right heart failure (you xin shuai jie, 右心衰竭), lower limb 
oedema (xia zhi shui zhong, 下肢水肿), cyanosis (zi gan, 紫绀), and weight loss (ti 
zhong xia jiang, 体重下降). The search term jiu chuan expectedly did not locate 
citations in this category as it refers to long-term dyspnea. Similar to citations ranked as 
‘possibly COPD’ [Table 22], the majority of citations referenced dyspnea and cough, 
38% and 29%, respectively.   
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Table 24: Citations ranked as ‘most likely COPD’ by search term and symptom 
frequency 
Search term Number of 
citations, (%) 
Symptoms
a
 Number of 
citations, (%) 
Fei zhang 1 (4%) Dyspnea 24 (33%) 
Jiu ke 4 (16%) Shang qi  2 (3%) 
Jiu chuan 0 (0%) Cough 22 (30%) 
Zhi yin 0 (0%) Sputum production 15 (21%) 
Chuan zheng 4 (16%) Chest tightness 9 (12%) 
Ke chuan 16 (64%) Fei zhang (as a symptom) 1 (1%) 
Total citations 25 Total citations  25  
a 
Several symptoms were often referred to in the one citation. 
 
Citations ranked as ‘most likely COPD’ were located by the search term Ke chuan in 16 
out of the 25 citations, 64%. Jiu chuan and zhi yin did not locate any of these citations. 
Although ke chuan and chuan zheng located the most citations, the hit rate for these 
terms was not as high as for fei zhang. Fei zhang had the highest hit rate, from 22 
citations in the full data set one was ‘most likely COPD’, 4.5%, compared to jiu ke four 
from 105, 3.8%, ke chuan 16 from 566, 2.8% and chuan zheng 4 from 413, 0.9%.    
 
All of the citations referenced dyspnea and 22 out of the 25 referenced cough. This is 
not surprising as these are the main symptoms associated with COPD. Modern CM texts 
refer to COPD as two characteristic patterns fei zhang and chuan zheng. However, the 
classical literature did not reflect these terms, fei zhang only located one citation, and 
chuan zheng located four, much less than expected. 
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Table 25: The 20 most frequently cited herbs from the 25 citations ranked as ‘most 
likely COPD’ and after exclusion of added herbs 
Rank Scientific name and part used  Chinese name Frequency 
1 Glycyrrhiza uralensis or G. glabra (dried root) Gan cao 12 
2 Prunus armeniaca (dried seed) Xing ren 11 
3 Zingiber officinale (fresh or dried rhizome) Gan jiang/Sheng jiang 7 
4 Citrus reticulata or  C. tangerine (dried peel) Chen pi 7 
5 Pinellia ternata (dried processed rhizome) Ban xia (zhi) 7 
6 Panax ginseng (dried root) Ren shen 6 
7 Ephedra sinica (dried herb) Ma huang 6 
8 Perilla frutescens or P. crispa (dried herb) Zi su geng/Zi su zi/Zi su ye 6 
9 Tussilago farfara (dried flower) Kuan dong hua 6 
10 Angelica sinensis (dried root) Dang gui 4 
11 Poria cocos (dried sclerotium) Fu ling 4 
12 Anemarrhena asphodeloides (dried rhizome) Zhi mu 4 
13 Citrus aurantium (dried fruit) Zhi shi 4 
14 Alunite Bai fan 4 
15 Arisaema heterophyllum or A. consanguineum 
(prepared rhizome) 
Dan nan xing/Tian nan xing 3 
16 Paeonia lactiflora (dried root) Bai shao 3 
17 Platycodon grandiflorum (dried root) Jie geng 3 
18 Asarum heterotropoides (dried rhizome) Xi xin 3 
19 Terminalia chebula (dried herb) He zi R 3 
20 Atractylodes macrocephala (dried rhizome) Bai zhu 2 
Note: Herbs were ‘recoded’ to combine cases that were the same species, yet prepared differently. For example gan jiang is the dried form of sheng jiang 
therefore they were grouped. Scientific names are referenced from: Bensky, Chinese herbal medicine: materia medica, 2004 (81).  
Added herbs are those that are not included in the core herbal formula however are added during or at the end of decoction. For example, da zao is generically 
used in many formulae to harmonise the other ingredients and does not have a specific action for the condition being treated.  
 
The 20 most frequently listed herbs from the 25 citations ranked as ‘most likely COPD’ 
were comparatively different to the full data set after exclusions [Table 19]. Restricting 
the data set cut the frequency of herbs. Thirteen (13) herbs were the same however 
ranked slightly different. The remaining seven herbs were not included in the full data 
set top 20. Several herbs relevant to COPD were no longer included, these were, sang 
gen bai pi, wu wei zi, zi wan, bei mu, and mai men dong. The herbs included in their 
place were still applicable for the treatment of COPD. Dang gui and bai shao are tonics 
used for chronic conditions, zhi mu nourishes the Lung, bai fan, nan xing, xi xin and he 
zi remove phlegm and he zi stops cough. Therefore, the herbs included in Table 25 are 
similar to what would be used in modern CM for the treatment of COPD.       
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4.5.7 Ranking the formulae citations  
The citations were organised into levels of strength of specificity according to the four 
key COPD symptoms: dyspnea, cough, sputum production, and chest tightness. The 
formula were not ranked using shang qi and fei zhang. These terms were seldom used in 
the citations and are often included under the other key symptom terms. A stepwise 
process was used to ranked the citations and create levels of increasing strength, that is, 
if they contained dyspnea plus one other symptom, followed by dyspnea plus two other 
symptoms, and finally dyspnea plus three other symptoms. The levels were refined by 
limiting the citations to ‘chronic’ cough or sputum production. Table 26 presents the 
levels of strength and likelihood the citation refers to COPD. 
 
Table 26: Analysis of strength and likelihood the citation refers to COPD 
Level Inclusion criteria Number of 
formulae 
Number of 
distinct 
formulae 
Number 
of herbs 
Number 
of 
distinct 
herbs 
Citation 
year(s) 
Global 
score 4 
‘most 
likely 
COPD’ 
(%) 
1 dyspnea  
+ cough  
441 426 4,147 363 206-1936 21 (4.8%) 
2 dyspnea  
+ sputum production 
201 193 1,943 277 206-1929 11 (5.5%) 
3 dyspnea  
+ chest tightness 
175 170 1,545 211 206-1924 8 (4.6%) 
4 dyspnea  
+ cough  
+ sputum production 
141 137 1,462 258 206-1892 13 (9.2%) 
5 dyspnea  
+ cough  
+ chest tightness 
98 97 941 172 206-1863 7 (7.1%) 
6 dyspnea  
+ sputum production  
+ chest tightness 
54 54 515 133 206-1863 6 (11.1%) 
7 dyspnea  
+ chronic cough  
+ sputum production 
8 8 84 54 1078-
1753 
8 (100%) 
8 dyspnea  
+ cough  
+ chronic sputum production 
4 4 43 34 1172-
1687 
4 (100%) 
9 dyspnea  
+ cough  
+ chronic sputum production  
+ chest tightness 
1 1 9 9 1406 1 (100%) 
10 dyspnea  
+ chronic cough  
+ chronic sputum production  
+ chest tightness 
1 1 17 16 1186 1 (100%) 
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4.5.7.1 Description of the levels of formulae citations 
Levels 1, 2 and 3 capture 441, 201 and 175 formulae citations, respectively. These 
citations include dyspnea plus one other symptom. The formulae at these levels were 
numerous however many were not specific for COPD. At level 4, citations included 
dyspnea plus two other symptoms. Levels 5 and 6 revealed a similar number of citations 
to level 4. However level 4 was considered to be a more appropriate judge of 
consistency with COPD as it contained the three key COPD symptoms, dyspnea, cough 
and sputum production. Changing the second symptom to chest tightness instead of 
sputum production at level 5 reduced the number of citations but did not increase the 
specificity. Similarly, at level 6 the number of citations was knocked down yet the 
specificity did not increase substantially. At these levels, it was difficult to draw any 
conclusions about the citations consistency with COPD. The citations from levels 1 to 6 
had limited consistency with COPD as judged by a global score of 4, ‘most likely 
COPD’, at these levels the consistency was below 12%.  
 
At level 4 there was a large number citations, 141 formulae and 258 distinct herbs. The 
data spanned from c. 206 to 1892 and the top 20 most frequently listed herbs are 
presented in Table 27. The consistency of citations ranked as a global score of 4, ‘most 
likely COPD’ was moderately low, 9.2%. When comparing the frequency of cited herbs 
at level 4 with the full data set after exclusions [Table 19] the herbs were essentially the 
same. However at level 4 the frequency was reduced and the 20 herbs were ranked in a 
different order. When compared to the top 20 herbs ranked as ‘most likely COPD’ 
[Table 25] the herbs at level 4 were closer to the full data set.  
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Table 27: The 20 most frequently listed herbs at level 4 and after the exclusion of 
added herbs 
Rank Scientific name and part used  Chinese name Frequency 
1 Glycyrrhiza uralensis or G. glabra (dried root) Gan cao 75 
2 Pinellia ternata (dried processed rhizome) Ban xia (zhi) 59 
3 Prunus armeniaca (dried seed) Xing ren 57 
4 Zingiber officinale (fresh or dried rhizome) Gan jiang/Sheng jiang 44 
5 Citrus reticulata or  C. tangerine (dried peel) Chen pi 43 
6 Panax ginseng (dried root) Ren shen 39 
7 Schisandra chinensis (dried fruit) Wu wei zi 35 
8 Morus alba (dried bark) Sang gen bai pi 35 
9 Poria cocos (dried sclerotium) Fu ling 33 
10 Perilla frutescens or P. crispa (dried herb) Zi su geng/Zi su zi/Zi su ye 30 
11 Platycodon grandiflorum (dried root) Jie geng 29 
12 Fritillaria cirrhosa (dried rhizome) Bei mu 27 
13 Cinnamomum cassia (dried bark) Rou gui/Gui zhi 25 
14 Anemarrhena asphodeloides (dried rhizome) Zhi mu 25 
15 Ephedra sinica (dried herb) Ma huang 23 
16 Atractylodes macrocephala (dried rhizome) Bai zhu 22 
17 Tussilago farfara (dried flower) Kuan dong hua 22 
18 Aster tartaricus (dried root) Zi wan 18 
19 Citrus aurantium (dried fruit) Zhi shi 18 
20 Angelica sinensis (dried root) Dang gui 17 
Note: Herbs were ‘recoded’ to combine cases that were the same species, yet prepared differently. For example gan jiang is the dried form 
of sheng jiang therefore they were grouped. Scientific names are referenced from: Bensky, Chinese herbal medicine: materia medica, 2004 
(81).  
Added herbs are those that are not included in the core herbal formula however are added during or at the end of decoction. For example, 
da zao is generically used in many formulae to harmonise the other ingredients and does not have a specific action for the condition being 
treated. 
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4.5.7.2 Description of level 7 formulae citations 
The data set was limited as the levels increased and citations became more consistent 
with COPD. Level 7 refined the citations by specifying ‘chronic’ cough. This produced 
100% specificity as measured by the global score but greatly reduced the data set to 
eight formulae. These citations were consistent with COPD, having symptoms of 
dyspnea, chronic cough and sputum production. All of the eight formulae were given a 
global score for 4 ‘most likely COPD’. Table 28 presents the details of the eight 
formulae. Additionally, Table 29 presents the herbs included in the eight formulae.  
 
There were 50 distinct herbs used in the eight formulae at level 7. They were seldom 
used more than once. The top 10 herbs are similar to the top 10 at level 4, Table 27. 
Level 7 is more specific than Level 4, as all citations are ranked as a global score 4 
‘most likely COPD’. However, for herb selection the data set at level 4 is more useful. 
The frequency of herb references is higher at level 4 and at level 7 only four herbs are 
referenced more than three times.  
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Table 28: Analysis of formulae consistent with COPD and satisfying level 7 criteria  
Formula Book title Book 
year 
Search 
term  
Symptoms Global 
score 
Indications  
Hua lao tang 
(modified Liu jun zi 
tang) 
 
Bian Zheng 
Lu 
1687 jiu ke 1. Dyspnea 
2. Chronic cough 
3. Chronic sputum production 
4 This formula is used for disease caused by phlegm. The 
symptoms are, chronic cough, phlegm that is yellow in colour 
and congealed in the throat, the airways are not clean and it is 
hard to expectorate the phlegm.  
E jiao san (4) 
 
Yi Xue Ru 
Men 
1575 jiu ke 1. Dyspnea 
2. Chronic cough 
3. Sputum production 
4 This formula is used for symptoms of deficiency of the Lung 
Qi caused by chronic cough, rapid breathing with phlegm and 
nausea. 
Kuan qi wan (1) 
 
Su Wen Bing 
Ji Qi Yi Bao 
Ming Ji 
1186 
 
jiu ke 1. Dyspnea 
2. Chronic cough 
3. Chronic sputum production 
4. Chest tightness  
4 The formula is used for symptoms of chronic cough and 
dyspnea with phlegm and oedema caused by lung diseases. 
Ren shen run fei wan 
 
Tai Ping Hui 
Min He Ji Ju 
Fang 
1078 ke 
chuan 
1. Dyspnea 
2. Chronic cough 
3. Sputum production 
4. Chest tightness 
4 The formula is used for four indications: 
1) deficiency of Lung Qi with cough, dyspnea, rapid 
breathing, chest fullness, anxiety, thick sputum production and 
dry mouth; 2) dizziness with loss of vitality; 3) deficiency of 
Lung and Stomach Qi with chronic cough, weakness, 
emaciation, chest fullness, shortness of breath, dyspnea with 
exercise and reduced appetite; 4) chronic or acute cough. 
Xian ren zhi wan 
 
Huang Di Su 
Wen Xuan 
Ming Lun 
Fang 
1172 ke 
chuan 
1. Dyspnea 
2. Chronic cough 
3. Sputum production 
4. Chest tightness 
4 This formula is used for sputum production and dyspnea with 
chest fullness. It is also used for chronic cough caused by 
birthing, no matter cold or heat factor.  
Ning sou bai hua gao 
 
Huo Ren Fang 1753 ke 
chuan 
1. Dyspnea 
2. Chronic cough 
3. Sputum production 
4 This formula is used for cold phlegm in the Lung with 
constant phlegm and cough. It is used for chronic paroxysmal 
dyspnea with cough. 
Zhong ru wan (5) 
 
Shi Yi De 
Xiao Fang 
1328 ke 
chuan 
1. Dyspnea 
2. Chronic cough 
3. Sputum production 
4 This formula is used for chronic or acute cough and dyspnea 
with thick phlegm. The symptoms persist day and night and it 
is difficult for the patient to lie down. 
Xin tian ban xia gua lou 
wan 
 
Huang Di Su 
Wen Xuan 
Ming Lun 
Fang 
1172 ke 
chuan 
1. Dyspnea 
2. Chronic cough 
3. Chronic sputum production 
4 This formula is used for chronic or acute cough with phlegm. 
There is also non-stop dyspnea with anxiety. 
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Table 29: Herbs listed at level 7  
Number Chinese name (pin yin) Frequency 
1 Gan cao 5 
2 Xing ren 5 
3 Ren shen, Zi tuan shen 5 
4 Kuan dong hua 4 
5 Zhi mu 3 
6 Bai zhu 2 
7 Fu ling 2 
8 Rou gui/Gui zhi 2 
9 Chen pi 2 
10 Ma huang 2 
11 Ma dou ling 2 
12 Dan nan xing/Tian nan xing 1 
13 Gou qi zi 1 
14 Chai hu 1 
15 Dang gui 1 
16 Shu di huang/sheng di huang/gan di huang 1 
17 Ze xie 1 
18 Ban xia (zhi) 1 
19 Mai men dong 1 
20 Di gu pi 1 
21 Dan shen 1 
22 Bai shao 1 
23 Mu li 1 
24 E jiao 1 
25 Mu xiang 1 
26 Jie geng 1 
27 Zi wan 1 
28 Xuan shen 1 
29 Yu li ren 1 
30 Bai jie zi 1 
31 Xi xin 1 
32 Jiang mi 1 
33 Qing pi 1 
34 Wu mei 1 
35 Shi zhong ru 1 
36 Fang ji 1 
37 Qian niu zi 1 
38 Bai fan 1 
39 Ge jie 1 
40 Qian hu 1 
41 Bing lang 1 
42 Zi su geng/Zi su zi/Zi su ye 1 
43 Nan sha shen/bei sha shen 1 
44 Sang gen bai pi 1 
45 Hua shi 1 
46 E zhu 1 
47 Ting li zi 1 
48 Gua lour en/ gua lou pi 1 
49 Ying su ke 1 
50 Shi di 1 
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4.5.7.3 Description of levels 8 to 10 formulae citations 
Four formulae were identified at level 8, dyspnea, plus cough, plus chronic sputum 
production. The four formulae were given a global score for 4 ‘most likely COPD’. 
Level 8 contained the formulae identified at level 7 minus four formulae that did not 
mention chronic sputum production.  
 
Only one formula was associated with level 9, dyspnea, plus cough, plus chronic 
sputum production, plus chest tightness. The global score was ranked as 4 ‘most likely 
COPD’. The formula is named Qing jin dan which contains nine herbs. It is indicated 
for ‘cough and dyspnea with sputum, chronic phlegm accumulation, stabbing pain in the 
chest and hypochondria as well as epigastric distension and a choking sensation in the 
throat’.  
 
At level 10 one formula was identified, it was ranked as 4 ‘most likely COPD’. The 
formula is named Kuan qi wan and contains 17 herbs. The formula is indicated for 
‘chronic cough and dyspnea with phlegm and oedema caused by Lung Qi deficiency’.  
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4.6 Discussion 
Search and analysis of the classical literature is a relatively new approach developed in 
the last few years (125). The method was developed at RMIT University by experts in 
the field.   
 
The search revealed a considerable number of classical literature citations for conditions 
consistent with COPD. The exclusion criteria were effective in removing non-specific 
citations and the search terms accurately located relevant formulae. Ke chuan and jiu ke 
were successful in locating many citations that were most likely COPD. Fei zhang is 
considered the modern term for COPD, however the search terms ke chuan and jiu ke 
located the most citations. When evaluating the hit rate of the terms against those that 
were ranked as ‘most likely COPD’, fei zhang had the highest hit rate, followed by jiu 
ke, ke chuan, and chuan zheng. Jiu chuan and zhi yin did not locate any citations that 
were most likely COPD. At level 7 there were eight citations consistent with COPD, 
they were located by ke chuan and jiu ke. This confirms that these terms were the most 
productive in the classical literature for identifying citations that were most likely 
COPD.   
 
Duplicate formulae were seldom found and it was difficult to analyse the formulae data 
in detail or draw any firm conclusions for which formulas were more or less commonly 
used. The analysis of the individual herb frequencies was more productive in informing 
the researchers of what treatments were used for conditions broadly consistent with 
COPD. The citations did not include which herbs were specifically used for COPD, 
therefore pharmacopoeias were used to reference the indications of the herbs (81). The 
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formulae and herbs are similar to what is in modern use (81, 136). According to 
pharmacopoeias, many of the 20 highest frequency herbs are indicated for COPD. These 
include xing ren, ban xia, ren shen, kuan dong hua and sang gen bai pi.  
 
While, a number of formulae were indicated for conditions broadly consistent with 
COPD, the classical literature is limited in its description of symptoms and detailed 
information is not provided. For example, details of the severity and stage of symptoms 
and the possible cause are not included. Therefore, the citations could not be aligned to 
stable COPD or exacerbated COPD and there was no way to decipher if the citations 
referred to comorbid conditions such as asthma or tuberculosis. The inferences made in 
the retrospective analysis of the classical literature is limited, however conditions 
broadly consistent with COPD were treated throughout the historical period from c. 
A.D. 206 –1949.   
 
Smoking is the major risk factor for COPD and although citations were broadly 
consistent with COPD it is difficult to find any representative data of the possible rates 
of smoking historically. Smoking is prevalent today, however an assumption cannot be 
made regarding its ancient use. Indoor air pollution including biomass smoke from 
stoves run by wood, coal or animal dung may be a more likely risk factor in ancient 
times. This may be an explanation of citations consistent with COPD, despite limited 
knowledge of smoking rates. 
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4.6.1 Limitations 
The classical literature is vast. This search and analysis was only conducted on one 
published collection and the type and scope of the search was limited to six select terms. 
The ZYFJDCD is comprehensive and representative of a wide range of books across the 
span of eras yet it is not all-inclusive and the data does not represent all the possible 
books available.   
 
Searching classical literature is productive if the disease has identifiable classical terms. 
Defining search terms can be an issue as terms change over time. The search terms used 
in this review are the best match and aligned with classical terms. However, citations 
may have been missed or incorrectly included due to interpretation when indexing the 
ZYFJDCD.   
 
The formulae citations listed in the ZYFJDCD are often brief. Some data including 
book titles and year were difficult to determine. Two experienced reviewers manually 
extracted the data. This offered a buffer for mistakes however misinterpretation or 
mistakes may have occurred. Overall these limitations should be few and not affect the 
data in a significant way or change the overall data set.  
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4.6.2 Summary of findings 
The search terms were able to locate citations in the ZYFJDCD that were consistent 
with COPD. The data was distributed throughout the classical literature from A.D. 206 
to 1949. The majority of citations were extracted from books written/published in the 
Song and Jin Dynasties (961–1271). However, each term also located numerous 
citations that were inconsistent with COPD.  
 
After the application of exclusion criteria, 1,147 citations remained. Three formulae 
were frequently used, Shen qi wan, Mai men dong tang and Xiao qing long tang with 
the remaining not being used on more than five occasions. The top 20 herbs were 
sometimes non-specific for lung conditions however after the removal of herbs that 
were non-specific, six herbs recurred frequently: xing ren, ban xia, ren shen, sang gen 
bai pi, wu wei zi and ma huang.  
 
Twenty-five (25) citations were most likely COPD as judged by the global score. After 
ranking citations into levels of specificity, eight were broadly consistent with COPD. 
These approaches agreed in that all eight citations located using the ranking method 
were also classified as ‘most likely COPD’ using the global scoring method. Terms for 
dyspnea and cough were referenced in all these citations. The relevant citations were 
mostly located by the search terms ke chuan and jiu ke. 
  
Formulae and herbs identified in this review are similar to what is used in modern 
clinical manuals and in clinical trials for COPD (8, 129). Recent systematic reviews 
identified herbal formulae effective in treating COPD (8, 9, 66). The formulae names 
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are different to what was identified in this review however there were commonalities in 
the herbal ingredients, including: ren shen, wu wei zi, xing ren, ban xia, and sang bai pi. 
 
Ren shen was one of the most commonly used herbs in the classical literature for 
COPD. It is one of the most commonly researched CHM for COPD (8, 9). Studies have 
shown a promising effect on improving lung function and quality of life (9, 66). 
Combined with herbs such as xing ren and wu wei zi, ren shen has often been used in 
clinical trials (66). 
 
Huang qi is recommended for use in COPD (129). The search of the classical literature 
did not identify huang qi as a common herb for conditions consistent with COPD. 
Huang qi is often a substitute for ren shen, it grows quicker, is hardier and is thus less 
expensive (83). In the historical periods ren shen may have been more readily available 
and cheaper compared to today, therefore a substitute such as huang qi was not needed.   
 
4.7 Conclusions and implications  
The search and analysis of the traditional literature revealed many citations that were 
broadly consistent with COPD. The method used was rational and systematic and the 
search terms were able to locate relevant formulae and herbs. The results indicate that 
the formulae and herbs used in the classical literature were broadly similar to what is 
used in the modern setting. This group of herbs may guide further clinical and 
experimental research.  
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Chapter 5: Systematic reviews on Panax ginseng for COPD 
 
5.1 Foreword  
This chapter provides three reviews. These include, an overview of preceding 
systematic reviews, a systematic review of Panax ginseng in RCTs, and a review of the 
effect of Panax ginseng on reducing inflammation and oxidative stress and the possible 
implications for COPD. 
 
5.2 Introduction  
Health care policy makers, practitioners and consumers require evidence to make 
informed choices. Systematic reviews are important in health care to provide a snapshot 
of the evidence as well as identifying limitations in the literature.  
 
Standardised methods are applied when systematically reviewing the literature to limit 
bias, critically appraise, synthesise, and address specific questions. Commonly 
systematic reviews include a set of predefined inclusion criteria used to search databases 
and literature sources. Studies are identified, analysed and judged for their quality and 
risk of bias. Synthesis and précis of results often include meta-analysis to combine 
studies (137).  
 
Poor reporting in systematic reviews is common (137). Organisations and collaborations 
have endeavoured to guide and standardise the processes of conducting systematic 
reviews, one well regarded method is the Cochrane Collaborations Handbook for 
systematic reviews of interventions (13). It also includes a risk of bias tool that is 
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comprehensive and addresses six domains of bias and is more rigorous than other 
published tools, particularly those that use a scoring system. 
 
5.3 Overview of systematic reviews on Ginseng  
 
5.3.1 Objective 
The objective of this overview was to review systematic reviews and evaluate the 
effects of Panax ginseng for any health condition. 
 
5.3.2 Search strategy  
A literature search was conducted to identify systematic reviews of the effectiveness 
and safety of Panax ginseng for any health condition. Databases searched were 
MEDLINE, EMBASE and the Cochrane Library. The search period ranged from the 
databases’ inception until 5 October 2012. Search terms used were Panax ginseng, 
Ginseng, Panax, Red Ginseng, Korean Red Ginseng and review, systematic review, 
meta-analysis.  
 
Studies published in English were included. Systematic reviews were defined as articles 
that included a clear and repeatable methodology. Non-systematic reviews were 
excluded.  
 
5.3.3 Data extraction  
Details from the included studies were extracted onto data collection forms set up in 
Microsoft
®
 Excel. 
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5.3.4 Quality assessment 
The quality of the included systematic reviews was assessed using the assessment of 
multiple systematic reviews tool (AMSTAR) (138). There are more than 20 tools that 
assess systematic review methodology (139). Many are not used widely as they are 
complicated, lengthy and out of date. The AMSTAR was developed to improve 
shortfalls in previous tools and limit bias, therefore it was selected in this review (138). 
Each systematic review was evaluated against the 11 items. The items were recorded as; 
included, not included or cannot answer. Overall quality was evaluated as a percentage, 
where higher percentage equates to better quality, that is, 100% indicates all items were 
reported. 
 
5.3.5 Results 
The search revealed 247 articles, of which 234 were excluded. Thirteen (13) systematic 
reviews met the inclusion criteria [Figure 19]. Health conditions examined were COPD 
(66), cardiovascular risk factors (140), quality of life (141), cognition (122), blood 
pressure (142), ischemic heart disease (143), erectile dysfunction (144), type 2 diabetes 
(145), Alzheimer’s disease (146), any health condition (11, 147, 148) and safety (95). 
Table 30 presents the systematic reviews.  
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Figure 19: Flow diagram of study selection 
245 records identified through database searching 
2 additional records identified through other 
sources 
52 duplicate records removed  
 
175 records excluded 
Not English (n=12) 
Not Panax ginseng (n= 51) 
Not systematic review (n=99) 
Review not in humans (n=13) 
 
20 full-text articles assessed for eligibility 7 full-text articles excluded 
Not systematic review (n=6) 
Not Panax ginseng (n=1) 
 
13 reviews included in analysis  
195 records screened 
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Table 30: Systematic reviews of Panax ginseng 
Author, year 
(reference) 
Health condition Number 
of 
studies 
AMSTAR 
quality 
score*, % 
Conclusion 
Jia, 2012 (143) Ischemic heart 
disease (angina 
pectoris) 
18 9, 82% Promising evidence that Ginseng is more effective than nitrates for treating angina 
pectoris. However studies included in the review had small sample sizes and poor 
methodological quality. 
Shergis, 2012 (11) Any condition 65 8, 73% Promising evidence for glucose metabolism and moderating the immune response. 
An, 2011 (66) COPD 12 7, 64% Promising evidence of lung functions and quality of life improvement. However studies 
were low quality. 
Kim, 2011c (145) Type 2 diabetes 
mellitus 
4 6, 55% No compelling evidence despite some positive results. 
Lee, 2011 (147) Any condition 57 4, 36% Promising evidence for glucose metabolism, psychomotor function, and pulmonary 
disease, but not for physical performance enhancement. 
Geng, 2010 (122) Cognition 9 11, 100% Lack of convincing evidence. 
Hur, 2010 (142) Blood pressure in 
patients with 
hypertension 
5 6, 55% Limited evidence for the treatment of high blood pressure. 
Lee, 2009 (146) Alzheimer’s Disease 2 7, 64% No compelling evidence. 
Jang, 2008 (144) Erectile dysfunction 7 7, 64% Promising evidence however no definitive conclusions could be drawn due to small sample 
sizes and poor methodological quality. 
Buettner, 2006 (140) Cardiovascular risk 
factors 
34 3, 27% No compelling evidence despite some small reductions in blood pressure. 
Coleman, 2003 (141) Quality of life 9 2, 18% No compelling evidence despite some positive results. 
Coon, 2002 (95) Safety and adverse 
events 
146 2, , 18% Panax ginseng is rarely associated with adverse events or drug interactions. 
Vogler, 1999 (148) Any condition 16 5, 55% No compelling evidence for any particular condition. 
*Quality score is based on the 11 item AMSTAR tool. High percentage (%) indicates higher quality, where 100% indicates all items were reported.  
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Three reviews evaluated Ginseng for any health condition or indication (11, 147, 148). 
All three authors concluded promising findings for Ginseng however, the evidence was 
not compelling due to poor methodological quality and small sample sizes. One review 
evaluated Ginseng for COPD (66). The authors reported some promising evidence of 
improved lung functions and QoL. However, the quality of the RCTs was poor.  
 
Cardiovascular conditions were reviewed in three studies (140, 142, 143). The evidence 
was limited and the majority of studies had methodological short falls.  Type 2 diabetes 
mellitus was evaluated in one review and the authors reported some positive results 
however the included studies were heterogeneous prohibiting conclusive results (145).  
Alzheimer’s disease was evaluated in one review (146) and cognition (122) in another. 
There was a lack of convincing evidence in both reviews despite some positive results.  
Erectile dysfunction (144) and QoL (141) were evaluated in one review each. Authors’ 
concluded some promising evidence however poor methodological quality prohibited 
definitive conclusions. Safety of Ginseng was evaluated and Ginseng was rarely 
associated with adverse events or drug interactions (95). 
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5.3.5.1 Quality of the included systematic reviews  
The quality of the included systematic reviews was variable. The AMSTAR ratings 
ranged from two to 11 (out of a maximum of 11). The mean percentage score was 47%.  
 
The majority of systematic reviews did not report a priori design methods and only two 
articles reported the likelihood of publication bias (122, 143). However, it should be 
noted that the majority of authors did not conduct a meta-analysis. All authors provided 
characteristics of the included studies. A comprehensive literature search was performed 
in all studies except for one which did not disclose the keywords or terms used to 
perform the search (147). Only one study provided the list of excluded studies (122). 
Table 31 presents the AMSTAR analysis of the systematic reviews. 
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Table 31: AMSTAR analysis of the systematic reviews  
AMSTAR items 
Jia  
2012 
(140) 
Shergis 
2012 
(10) 
An  
2011 
(65) 
Kim 
2011c 
(142) 
Lee 
2011 
(144) 
Geng 
2010 
(121) 
Hur 
2010 
(139) 
Lee 
2009 
(143) 
Jang 
2008 
(141) 
Buettner 
2006 
(137) 
Coleman 
2003 
(138) 
Coon 
2002 
(93) 
Vogler 
1999 
(145) 
1. Was an ‘a priori’ design 
provided? 
Yes No No No No Yes No No No No No No No 
2. Was there duplicate study 
selection and data extraction? 
Yes Yes Yes Yes No Yes Yes Yes Yes No No No Yes 
3. Was a comprehensive 
literature search performed? 
Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes 
4. Was the status of publication 
(i.e. grey literature) used as an 
inclusion criterion? 
No Yes No No No Yes No Yes Yes No No No Yes 
5. Was a list of studies (included 
and excluded) provided? 
No No No No No Yes No No No No No No No 
6. Were the characteristics of the 
included studies provided? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
7. Was the scientific quality of 
the included studies assessed 
and documented? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No Yes 
8. Was the scientific quality of 
the included studies used 
appropriately in formulating 
conclusions? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No 
9. Were the methods used to 
combine the findings of studies 
appropriate? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No 
10. Was the likelihood of 
publication bias assessed? 
Yes No No No No Yes No No No No No No No 
11. Was the conflict of interest 
stated? 
Yes Yes Yes No No Yes No No No No No No No 
Note: Yes indicates the item was included in the publication and no indicates the item was not included. 
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5.3.5.2 Quality of evidence in the RCTs 
From the primary data RCTs, the risk of bias and methodological quality was evaluated 
using the Jadad scale in four reviews (140, 146-148), using the Cochrane risk of bias 
assessment tool in two (11, 122) and using both the Jadad and Cochrane tools in five 
(66, 142-145). Risk of bias was not evaluated in two reviews (95, 141). Methodological 
quality was poor in the majority of RCTs and the risk of bias was mostly unclear or 
high. 
 
5.3.6 Discussion  
This research provides an overview of systematic reviews. Panax ginseng has been 
studied for a broad range of health conditions and indications. From the 13 systematic 
reviews included, five presented promising efficacy, six lacked convincing evidence and 
one showed no significant effect. Panax ginseng was considered safe. Overall, the 
included systematic reviews were unable to establish conclusive results.  
 
Pooling of data from RCTs and meta-analysis was not possible in the majority of 
reviews. Heterogeneity and inconstancy between studies limited the ability to draw firm 
conclusions.  
 
The methodological quality of the included studies was variable, they were all 
considered systematic reviews and their methodology was explicit. However, five 
reviews were considered to have major flaws in that they did not report more than five 
of the AMSTAR items, seven had minor flaws, reporting between 6–9 items and one 
review had minimal or no flaws reporting all 11 items.  
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The methods used to conduct this overview of systematic reviews is in line with the 
recommendations of The Cochrane Collaboration (13). However, the analysis may have 
limitations. This overview identified systematic reviews with some methodological 
shortfalls. Comprehensive searches were conducted however, there is no guarantee that 
all the relevant systematic reviews were located. Additionally only articles published in 
English were included. Panax species and Eleutherococcus senticosus were combined 
with Panax ginseng in several of the reviews. This approach does not engender 
conclusive results as different species contain different chemical compositions. 
Promising finding from several reviews needs careful interpretation due to 
methodological weaknesses’ and risks of bias of the included RCTs. Reviewers found 
flaws in research design including inadequate reporting of allocation methods, small 
sample sizes, undisclosed power calculations and inadequate information of the herbal 
intervention.  The extant systematic review literature does not establish the efficacy of 
Ginseng for a particular health condition or indication. Ginseng does appear to have a 
good safety profile and is rarely associated with adverse events or drug interactions. 
 
5.3.7 Conclusions and implications 
Many systematic reviews have evaluated Ginseng. Despite this, clear indications for 
clinical use have not been established. The majority of systematic reviews revealed a 
lack of convincing evidence of efficacy. However, Ginseng was considered safe. Future 
research should focus on rigorous clinical trial methods for well defined health 
conditions.  
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5.4 Panax ginseng in randomised controlled trials: a systematic review  
 
5.4.1 Objective 
The objective of this systematic review was to summarise the current evidence of Panax 
ginseng in RCTs. Panax ginseng was evaluated to determine its efficacy and safety. The 
methodological quality and risk of bias was also evaluated. The review was designed to 
identify the most promising areas for future Panax ginseng research. 
 
5.4.2 Review protocol  
The search and analysis of the literature was predefined by the reviewers. The databases 
and dates were selected to capture a comprehensive list of articles and the search 
strategy was designed and tested for sensitivity by two independent reviewers. The 
eligibility criteria were designed by three reviewers to ensure precision and confidence 
in the results.  The methods presented here are in line with protocol set out prior to 
implementation. 
 
5.4.3 Method 
5.4.4 Search strategy 
A systematic search was conducted on four English databases and two Chinese 
databases. 
 
English databases:  
 MEDLINE  
 CINAHL 
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 PsychINFO 
 Cochrane library  
 
Chinese databases: 
 Wei Pu, www.cqvip.com 
 CNKI, www.cnki.net 
 
The search period ranged from the databases’ inception until 17 January 2012. 
Reference lists from the included studies were also searched to identify further 
publications. Full text articles as well as abstracts were included. Search terms were 
developed in MEDLINE using medical subject headings (MeSH) and keywords. These 
terms were modified for the other databases. A combination of synonyms for Panax 
ginseng and RCTs were used, presented in Table 32.  
 
Table 32: Search strategy to identify Panax ginseng RCTs in MEDLINE  
1.  
Panax* or ginseng.tw or Panax ginseng.tw or Radix ginseng.tw or ginsan.tw 
or jen shen.tw or shinseng.tw or renshen.tw or schinseng.tw or ninjin.tw or 
ginsenoside* or gingilone.tw or protopanaxadiol.tw or protopanaxatriol.tw 
or ginsenol.tw 
2.  
Panax notoginseng* or Eleutherococcus* or Siberian ginseng.tw or 
American ginseng.tw or Panax quinquefolium.tw  
3.  1 not 2 
4.  
Clinical Trials* or Controlled Clinical Trials* or Randomized Controlled 
Trials* or Clinical Trial.pt or Controlled Clinical Trial.pt or randomized 
controlled trial.pt or random allocation* or double blind method*  or 
placebos* or randomised clinical trial.tw  
5.  3 and 4 
(* = MeSH, medical subject heading; tw = text word; pt = publication type [and, or, not are Boolean operators] 
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5.4.5 Eligibility of studies 
Specific inclusion criteria were:  
 randomised studies 
 Panax ginseng sole preparations as the intervention 
 studies using a control group, for example placebo, conventional intervention or 
no intervention 
 studies that stated the intervention was administered orally including capsules 
liquids or powders 
 
Specific exclusion criteria were: 
 Panax ginseng combinatorial products 
 non-oral preparations, for example injected compounds or suppositories 
 compounds extracted from Panax ginseng, for example individual ginsenosides. 
 
Studies’ outcome measures and design were not restricted. The included studies were 
published in English or Chinese.  
 
The Chinese databases were searched and translated by an experienced researcher from 
RMIT University, the contribution of Dr Wenyu Zhou is acknowledged. 
 
5.4.5.1 Participants 
Participants were healthy or diagnosed with any type of disease. No restriction was 
placed on age, gender or other demographics.   
 
123 
 
5.4.6 Selection of studies 
One reviewer assessed all titles and abstracts against pre-defined inclusion criteria, the 
second reviewer verified the information. A third reviewer resolved any disagreements 
over a study inclusion. 
 
5.4.7 Data extraction 
Details from the included studies were extracted using a standard form (Appendix 1):  
Details included: 
• first author, year of publication, country where study was conducted 
• title     
• source of participants 
• trial design 
• condition treated 
• number of participants 
• age and gender of participants 
• intervention and control 
• dosage and treatment duration 
• outcomes 
• results (mean and standard deviation or number of events) 
• adverse events 
• authors conclusions 
 
One reviewer extracted the data and the other verified the data against the standard 
form. Any disagreements were resolved by consensus.  
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5.4.8 Assessment of risk of bias  
For each study, risk of bias was evaluated using the Cochrane Collaboration’s Risk of 
Bias tool, with reference to the Cochrane Handbook (13).  
 
Two reviewers independently extracted information on the six domains of bias 
(selection, performance, detection, attrition, reporting and other) from seven sources of 
bias [Table 33]. A third reviewer resolved any disagreements on risk of bias. 
For ‘other’ bias, the chief focus was on the risk of bias due to sources of funding and 
other support, such as supply of drugs and the role of the funders. Authors were 
contacted where publications did not provide enough information to judge risk of bias. 
Nine authors were contacted and three responded (149-151).  
 
Table 33: The Cochrane Collaborations domains and sources of bias 
Domain Source of bias 
Selection bias Random sequence generation 
Allocation concealment 
Performance bias Blinding of participants and personnel 
Detection bias Blinding of outcome assessment 
Attrition bias Incomplete outcome data 
Reporting bias Selective reporting 
Other bias Other (including baseline imbalance and source of 
funding) 
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5.4.9 Assessment of quality method 
5.4.9.1 Introduction  
As the gold standard of research, RCTs should minimise selection and allocation bias 
and increase the generalisability of the findings. The reporting of methodology in herbal 
RCTs is often inadequate (152).  
 
The Consolidated Standards of Reporting Trials (CONSORT) statement and checklist 
were developed to help improve RCT methodology (153). Published RCTs should 
address checklist items. The first version, published in 1996, included a checklist of 21 
items and a flow diagram (154). In 2001, a new item was added and the flow diagram 
was updated (155). It was revised again in 2010, with wording changes and 25 items, 
including new items and modifications from previous checklists (153). The CONSORT 
statement was not developed as a specific evaluation tool however, it can highlight the 
reporting quality of RCTs.  
 
Further to the CONSORT statement and checklist, an extension was developed to 
address underreporting in herbal medicine RCTs. The extension includes specific items 
relevant to herbal interventions (156).  
 
5.4.9.2 Objective of quality assessment 
The objective of the quality assessment was to evaluate the methodological and 
reporting quality of Panax ginseng RCTs. Specific examination was undertaken to 
determine quality changes relating to time, outcomes, preparation type, sample size and 
geographic origin. 
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5.4.9.3 Eligibility of studies   
The eligibility of the studies is detailed in section 5.4.4 above. However, quality 
assessment was only performed on full text articles. 
 
5.4.9.4 Data extraction 
The two independent reviewers entered each item from the two checklists onto spread 
sheets. Checklist items were scored as 1– included in the report, 0 – not included in the 
report, or N/A – not applicable to the study. A third reviewer resolved any 
disagreements. 
 
5.4.9.5 Data analysis  
Studies were grouped according to their primary outcome(s). Mean difference and 95% 
confidence intervals were calculated between groups at the end of treatment for 
continuous data. Relative risk (RR) was calculated for dichotomous data. Where 
insufficient information was provided, results were recorded as not estimable.  
 
Meta-analysis was planned using RevMan 5.0 software. Studies that featured similar 
health conditions, outcome measures, Panax ginseng dose and lengths of treatment were 
combined. However, due to the high level of heterogeneity in the studies reviewed, data 
synthesis was limited and meta-analysis could not be performed. 
 
Each study’s methodological quality was assessed using the CONSORT checklist 2010 
(153), and the extension for herbal interventions checklist (156). Studies were grouped 
and compared according to publication date, that is, before CONSORT (pre 1995), after 
127 
 
its publication and review (from 1996–2006), and after 2007. The CONSORT extension 
for herbal interventions checklist was published in 2006, and manuscripts were 
compared with those published before and after 2006.  
 
The CONSORT checklist was designed primarily to guide two-group parallel RCTs 
however, it can be applied to any design by making allowances for specific items (155). 
Therefore, one item was added, ‘Cross-over studies should be justified, why was this 
design used?’ Including this item was necessary as several studies used cross-over 
designs.  
 
Each item was categorised as reported, not reported, or not applicable and presented as a 
percentage of the overall for that section.  
 
Publications were grouped and assessed according to: 
 publication period (before or after CONSORT) 
 outcomes 
 type of Panax ginseng preparation 
 sample size 
 whether or not the article was published in a CONSORT promoter journal 
 location where the research was undertaken  
 
Mean, standard deviation, and percentage were calculated for the grouped studies. 
Potential group differences were examined using analysis of variance (ANOVA), with p 
< 0.05 indicating significance.  
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5.4.10 Results  
5.4.11 Identification of Studies 
Searches identified 1,778 studies, 183 were duplicates, and therefore 1,595 were 
screened for eligibility. One thousand five hundred and twenty-five (1,525) studies were 
excluded. Seventy (70) full-text articles were assessed and three were excluded as they 
were not RCTs (157-159). Finally, 65 English and two Chinese studies were identified.  
Figure 20 illustrates study selection. 
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Figure 20: Flow diagram of study selection 
 
  
Records identified through 
database searching 
English n=440 
Chinese n=1,303 
English n=35 
Chinese n=0 
Records after duplicates removed  
English n=329 
Chinese n=1,266 
 
Records assessed 
English n=329 
Chinese n=1,266 
Records excluded 
English n=261 
Chinese n=1,264 
 Not randomised (n=202) 
 Combination Panax 
ginseng products (n=392)  
 Not published in English 
or Chinese (n=35) 
 Not Panax ginseng (n=99) 
 Animal studies (n=249) 
 Reviews (n=46) 
 Not relevant (n=502) 
 
 
Full-text articles assessed  
English n=68 
Chinese n=2 
Studies included in 
analysis 
English n=65 
Chinese n=2 
 
Full-text articles 
excluded 
English n=3 
Chinese n=0 
 Non randomised (n=3) 
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5.4.12 Description of the Studies  
The data from the 67 studies is presented in Table 34. The included studies investigated 
the following 13 health related areas:  
 psychomotor performance (17 studies) 
 physical performance (10 studies) 
 circulatory conditions (9 studies) 
 glucose metabolism (6 studies) 
 respiratory conditions (5 studies) 
 erectile dysfunction (4 studies) 
 immunomodulation (4 studies) 
 quality of life and mood (4 studies) 
 antioxidant function (2 studies) 
 cancer (2 studies) 
 menopausal symptoms (2 studies) 
 dry mouth (1 study) 
 ulcerative colitis (1 study) 
 
All 67 studies were described by the authors as ‘randomised’, 57 were labelled ‘double 
blind’, three were labelled ‘single-blind’, four were described as ‘open-label’ and three 
studies didn’t state blinding. Most studies (n=44) were designed as parallel and 23 were 
cross-over studies. Twenty-nine (29) studies were conducted in Asia, a further 20 in 
Europe/UK, 15 in North America, and one from each, Australia, Israel and Brazil.  
 
Studies were published between 1983 and 2011. 
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5.4.12.1 Participants  
In total 3,961 participants were involved in these studies. The sample size ranged from 
6–643, with a median sample of 32.  
 
Thirty-nine (39) studies assessed the use of Panax ginseng among healthy people. The 
remaining studies assessed 15 conditions: COPD/chronic bronchitis (3 studies), erectile 
dysfunction (4 studies), menopausal women (3 studies), type 2 diabetes (3 studies), 
Alzheimer’s disease (2 studies), cancer (2 studies), hypertension (2 studies), myocardial 
infarction (2 studies), allergic rhinitis (1 study), cardiac valve replacement (1 study), 
chronic atrophic gastritis (1 study), dry mouth (1 study), glaucoma (1 study), ischemic 
stroke (1 study) and ulcerative colitis (1 study). 
 
The age range of participants was between 18 and 80 years. 
 
5.4.12.2 Interventions  
The interventions in all 67 studies used the root of Panax ginseng for oral 
administration. 
 
Twelve (12) different types of preparations or extracts were used across the studies: 
Ginsana G115 (24 studies); undeclared preparation types (16 studies); Red Ginseng 
extract (15 studies); Korean Red Ginseng (4 studies); Gerimax™ (2 studies); Cheong 
Kwan Jang™ (2 studies). The following six preparations were each used in one study: 
Korean Red Ginseng rootlet; fermented Red Ginseng; Sun Ginseng; tissue-cultured 
mountain Ginseng extract; 60% ethanolic extract and PKC 169/79. Two studies 
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included two different preparations of Panax ginseng: Ginsana G115 plus Cheong 
Kwan Jang™ (160), and Ginsana G115 plus PKC 169/79 (161). Therefore, 69 
preparations were used in total. 
 
In 60 studies, Panax ginseng preparations were given as capsules. In four studies, they 
were given as loose powder and in one study as liquid. Four studies did not state 
preparation type. Panax ginseng dosage ranged from 100–600 mg per day for 
standardised extracts, 1–60 g per day for powdered extracts and 4 mL per day for liquid 
extracts. 
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Table 34: Characteristics of the included studies 
 
Psychomotor performance 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions  
Intergroup difference MD [95% CI] 
D'Angelo, 1986, Italy (162) DB, PG Healthy individuals T: 16 C: 16 G115/ P 
200 mg/ 12 weeks 
1. Psychomotor performance 
2. Auditory reaction time 
3. Visual reaction time 
4. Adverse events 
 
Improved mental arithmetic only. 
1. NE 
2. NE 
3. NE 
4. T: 0 C: 0 
Fulder, 1984, Korea (163) 
 
DB, CO Healthy elderly 
individuals 
T&C: 49 KRG/ P 
15 g/ 10 days 
1. Psychomotor performance 
2. Adverse events 
 
 
Certain aspects of psychomotor performance improved. 
1. NE 
2. 1 (group not specified) 
Heo, 2008, Korea (164) 
 
OL, PG Alzheimer's disease T(4.5g): 15  
T (9g): 15  
C: 31 
RG/ SC 
4.5, 9 g / 12 weeks 
1. ADAS  
2. MMSE 
3. CDR battery 
4. Adverse events 
9g dose improved the ADAS and CDR. 
1. -3.59[-10.01,2.83]  
2. 2.71[0.32,5.10] 
3. -0.03[-0.37,0.31] 
4. T(4.5g):2 T(9g):2 C:3 
Kennedy, 2001, UK (165) 
 
DB, CO Healthy individuals T&C: 20 G115/ P 
200, 400, 600 mg/ 1 
day 
1. Quality of memory 
2. Accuracy of attention 
3. CDR battery 
4. Bond-Lader VAS-alert 
5. Adverse events 
400mg dosage improved quality of memory. 
1. 0.12[-45.06,45.30] 
2. -9.10[-11.38,-6.82] 
3. NE 
4. -30.38[-35.89,-24.87] 
5. NS 
Kennedy, 2002, UK (166) 
 
DB, CO Healthy individuals T&C: 20 G115/ P 
400 mg/ 1 day 
1. Quality of memory 
2. CDR battery 
3. Bond-Lader VAS-alert  
4. Mental arithmetic tasks 
5. Adverse events 
 
Improved secondary memory, speed of performance, 
memory tasks and accuracy of attention. 
1. 14.12[-18.92,47.16] 
2. 17.33[4.26,30.40] 
3. -1.51[-11.68,8.66] 
4. -0.83[-2.63,0.97] 
5. NS 
Kennedy, 2003, UK (167) 
 
DB, CO Healthy individuals T&C: 15 G115/ P 
200 mg/ 1 day 
1. EEG 
2. Adverse events 
 
Modulation of cerebro-electrical activity. 
1. NE 
2. NS 
Kennedy, 2007, UK (150) 
 
DB, CO Healthy individuals T&C: 18 Panax ginseng/ P 
200 mg/ 8 weeks 
1. Quality of memory 
2. Accuracy of attention 
3. Bond-Lader VAS-alert 
4. HbA1c 
5. WHOQOL BREF-psyc  
6. Adverse events 
Improved working memory and rating of mood and QoL. 
1. -0.72[-33.93,32.49] 
2. 0.86[-6.91,8.62] 
3. 8.94[-3.44,21.32] 
4. 0.17[0.01,0.33] 
5. 0.08[-0.70,0.86] 
6. NS 
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Table 34: Characteristics of the included studies continued 
Lee, 2008(b), Korea (168) 
 
OL, PG Alzheimer's disease T: 58 C: 39 Panax ginseng/ SC 
4.5 g/ 12 weeks and 12 
weeks follow-up 
1. ADAS  
2. MMSE 
3. Adverse events 
Improved cognitive performance on both scales. 
1. -1.75[-4.80,1.30] 
2. 1.33[-0.26,2.92] 
3. T: 7 C: 6 
Reay, 2005, UK (169) 
 
DB, CO Healthy individuals T&C: 30 G115/ P 
200, 400 mg/ 1 day 
1. Mental arithmetic tasks 
2. RVIP reaction time  
3. Blood glucose 
4. Rate of fatigue 
5. Adverse events 
 
 
Some improvement in cognitive performance and 
subjective feelings of mental fatigue. Decreased blood 
glucose. 
1. -0.13[-2.00,1.74] 
2. 0.01[-0.01,0.04] 
3. -0.10[-0.65,0.45] 
4. -10.77[-22.52,0.99] 
5. NS 
Reay, 2006, UK (170) 
 
DB, CO Healthy individuals T&C: 27 G115/ P 
200 mg/ 1 day 
1. Mental arithmetic tasks 
2. RVIP reaction time  
3. Blood glucose 
4. Rate of fatigue 
5. Adverse events 
Enhanced cognitive performance and decreased blood 
glucose. 
1. -0.78[-1.70,0.14] 
2. 0.02[-0.02,0.06] 
3. 0.25[-0.08,0.57] 
4. -7.37[-20.45,5.71] 
5. NS 
Reay, 2008, UK (151) 
 
DB, CO Healthy individuals T&C: 25 G115/ P 
200 mg/ 8 weeks 
1. CDR battery 
2. Blood glucose 
3. Adverse events 
 
Improved working memory and aspects of cognitive 
performance and mood. 
1. NE 
2. NE 
3. NS 
Reay, 2010, UK (171) 
 
DB, CO Healthy individuals T&C: 30 G115/ P 
200, 400 mg/ 8 days 
1. Bond-Lader VAS-alert 
2. Adverse events 
 
No significant effect. 
1. -1.15[-11.99,9.69] 
2. NS 
Scholey, 2002, UK (172) 
 
DB, CO Healthy individuals T&C: 20 G115/ P 
200, 400, 600 mg/ 1 
day 
1. CDR battery 
2. Adverse events 
 
400mg improved subtraction tasks. 
1. NE 
2. NS 
Sorensen, 1996, Denmark 
(173) 
 
DB, PG Healthy individuals T: 55 C: 57 Gerimax/ P 
400 mg/ 8 to 9 weeks 
1. Auditory reaction time 
2. Visual reaction time 
3. Finger tapping test 
4. Adverse events 
 
Improved simple reactions and abstract thinking. 
1. -13.00[-24.87,-1.13] 
2. -10.00[-21.69.1.69] 
3. -1.60[-5.12,1.92] 
4. T: 0 C: 0 
Sotaniemi, 1995, Finland 
(174) 
 
DB, PG NIDDM T (100mg): 12  
T (200mg): 12 
C: 12 
Gerimax/ P 
100, 200 mg/ 8 weeks 
1. Psychomotor performance 
2. Total cholesterol 
3. OGTT 
4. HbA1c 
5. Adverse events 
 
Improved mood, physiological performance and reduced 
fasting blood glucose (100mg only). 
1. -9.20[-15.55,-2.85] 
2. 0.20[-0.76,1.16] 
3. -0.60[-1.49,0.29] 
4. 0.00[-1.40,1.40] 
5. T: 0 C: 0 
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Table 34: Characteristics of the included studies continued 
Sunram Lea, 2005, UK (175) 
 
DB, CO Healthy individuals T&C: 30 G115/ P 
400 mg/ 1 day 
1. Quality of memory 
2. Adverse events 
Improved speed of attention. 
1. -5.14[-30.56,20.28] 
2. NS 
Ziemba, 1999, Poland (176) 
 
DB, PG Healthy individuals T: 7 C: 8 Panax ginseng/ P 
350 mg/ 6 weeks 
1. Visual reaction time 
2. Heart rate 
3. Adverse events 
 
 
Improved psychomotor performance during exercise. 
1. -10.10[-12.54,-7.46] 
2. 2.00[-6.57,10.57] 
3. 3. NS 
Physical performance 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Allen, 1998, USA (177) 
 
DB, PG Healthy individuals T:13 C:15 Panax ginseng/ P 
200 mg/ 3 weeks 
1. VO2 peak 
2. Adverse events 
 
No significant effect. 
1. 2.90[1.26,4.54] 
2. T: 2 C: 0 
Cherdrungsi, 1995, Thailand 
(178) 
 
DB, PG Healthy individuals T:20 C:21 Panax ginseng/ P 
300 mg/ 8 weeks 
1. VO2max 
2. Heart rate 
3. Adverse events 
No significant effect. 
1. 0.70[-0.95,2.35] 
2. -1.10[-1.71,-0.49] 
3. T: 2 C: 0 
Engels, 1996, USA (179) 
 
DB, PG Healthy individuals T:10 C:9 G115/ P 
200 mg/ 8 weeks 
1. VO2max 
2. Heart rate 
3. Adverse events 
No significant effect. 
1. -1.00 [-7.98, 5.98] 
2. -2.80 [-10.26, 4.66] 
3. T: 2 C: 0 
Engels, 1997, USA (180) 
 
DB, PG Healthy individuals T (200mg):12  
T (400mg):12 
C:12 
G115/ P 
200, 400 mg/ 8 weeks 
1. VO2max 
2. Heart rate 
3. Adverse events 
No significant effect. 
1. 1.50 [-4.90,7.90] 
2. -1.30[-2.88,0.28] 
3. T200mg:0 T400mg:3 C:0 
Engels, 2001, USA (181) 
 
DB, PG Healthy individuals T:12 C:12 G115/ P 
400 mg/ 8 weeks 
1. Peak power output 
2. Rate of fatigue 
3. Adverse events 
No significant effect. 
1. -0.04[-1.00,0.92] 
2. -2.54[-9.18,4.10] 
3. T: 1 C: 0  
Engels, 2003, USA (182) 
 
DB, PG Healthy individuals T:19 C:19 G115/ P 
400 mg/ 8 weeks 
1. Peak power output 
2. Absolute s-IgA 
3. Adverse events 
No significant effect. 
1. 0.20[-0.36,0.76] 
2. -20.00[-54.51,14.51] 
3. T: 0 C: 0 
Knapik, 1983, USA (183) 
 
DB, PG Healthy individuals T:5 C:6 Panax ginseng/ P 
2 g/ 4 weeks 
1. VO2max 
2. Adverse events 
No significant effect. 
1. NE 
2. NS 
Kulaputana, 2007, Thailand 
(184) 
 
DB, PG Healthy individuals T:30 C:30 KRG/ P 
3 g/ 8 weeks 
1. Lactate threshold 
2. Adverse events 
 
No significant effect. 
1. 7.20[-4.43,18.83] 
2. T: 0 C: 0 
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Table 34: Characteristics of the included studies continued 
Ping, 2011, Malaysia (185) 
 
DB, CO Healthy individuals T&C: 9 Panax ginseng/ P 
200 mg/ 1 day 
1. Time to exhaustion 
2. Plasma glucose 
3. Plasma insulin 
4. Heart rate 
5. Adverse events 
No significant effect. 
1. 0.20[-0.15,0.55] 
2. -0.15[-0.53,0.23] 
3. -0.40[-1.27,0.47] 
4. -1.00[-8.12,6.12] 
5. T: 0 C: 0 
Teves 1983, USA (186) 
 
DB, PG Healthy individuals T:6 C:6 Panax ginseng/ P 
2 g/ 4 weeks 
1. VO2max 
2. Adverse events 
No significant effect. 
1. NE 
2. NS 
Circulatory conditions 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Ahn, 2011, Korea (187) 
 
SB, PG Myocardial 
infarction 
T:25 C:25 RG/ P 
3 g/ 8 weeks 
1. CFR 
2. Angiogenic cells 
3. IL-6  
4. TNFa 
5. Total cholesterol 
6. Adverse events 
Increased CFR and angiogenic cells. Decreased 
inflammatory markers. 
1. 0.24[-0.23,0.71] 
2. NE 
3. -0.78[-1.58,0.02] 
4. -0.83[-2.41,0.75] 
5. 0.09[-0.44,0.62] 
6. T:1 C:1 
Caron, 2002, USA (188) 
 
DB, PG Healthy individuals T:15 C:15 G115/ P 
200 mg/ 4 weeks 
1. ECG parameters 
2. BP- diastolic 
3. Adverse events  
Modulation of certain ECG intervals and decreased 
diastolic BP at certain time intervals only. 
1. 0.01[-0.01,0.02] 
2. 3.10[-2.11,8.31] 
3. T:1 C:0  
Chen, 1993, China (189) NS, PG Silent myocardial 
ischemia 
T:30 C:28 RG/ SC 
6g/ 15 days 
1. (ECG Monitor) Minutes 
lasted each time of MI 
2. (ECG Monitor) Times of 
MI occurred in 24 hrs 
3. Level of MI (mV) by ECG 
Monitor 
4. 15 days MI improvement 
5. 6 month MI improvement 
6. Adverse events 
1. NE 
2. NE 
3. NE 
4. RR 2.71 [1.64, 4.47] 
5. RR 2.59 [1.48, 4.55] 
6. NS 
Jovanovski, 2010, Canada 
(190) 
 
DB, CO Healthy individuals T&C:17 RG/ P 
3 g/ 1 day 
1. Augmentation Index  
2. Diastolic BP  
3. Adverse events 
Lowered Augmentation Index.  
1. -5.19[-6.58,-3.80] 
2. NE 
3. T:0 C:0 
Kim, 2010, Korea (191) 
 
DB, CO Glaucoma T&C:36 Cheong Kwan Jang / P 
4.5 g/ 12 weeks 
1. Visual ocular blood flow 
2. Adverse events 
 
Improved retinal peri-papillary blood flow. 
1. NE 
2. T:1 C:2 
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Table 34: Characteristics of the included studies continued 
Lee, 2008(a), Korea (192) 
 
OL, PG Ischemic stroke T:17 C:17 Panax ginseng/ SC 
1.5 g/ 2 weeks 
1. Prothrombin time  
2. INR – peak 
3. Adverse events 
No significant effect. 
1. 0.81[-1.72,3.34] 
2. 0.11[-0.19,0.41] 
3. T: 0 C: 0 
Lee, 2010, Korea (193) 
 
DB, CO Cardiac valve 
replacement 
T&C:31 RG/ P 
1 g/ 6 weeks 
1. Prothrombin time 
2. Adverse events  
 
Ginseng could be used in patients who take warfarin. 
1. -0.39[-0.91,0.13] 
2. NS 
Rhee, 2011, Korea (194) 
 
DB, PG Essential 
hypertension 
T:40 C:40 RG/ P 
3 g/ 12 weeks 
1. Diastolic BP  
2. Total cholesterol 
3. Adverse events 
No significant effect. 
1. 3.00[-1.69,7.69] 
2. -11.00[.32.15,10.15] 
3. T: 5 C:2 
Sung, 2000, Korea (195) 
 
DB, PG Essential 
hypertension 
T:10 C:10 RG/ No treatment 
4.5 g/ 21 to 27 months 
1. Vascular endothelial 
function  
2. Adverse events 
No significant effect. 
1. NE 
2. T:0 C:0 
Glucose metabolism 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
De Souza, 2011, Canada 
(196) 
 
DB, CO Healthy individuals  T&C:16 Panax ginseng/ P 
3 g/ 1 day 
1. Glycaemic response iAUC 
2. Peak postprandial 
glycaemia 
3. Adverse events  
Reductions of overall glycaemic response.  
1. -33.42[-41.04,-25.80] 
2. 0.27[0.15,0.39] 
3. T:0 C:0 
Ma, 2008, Hong Kong (197) 
 
DB, CO Type 2 diabetes T&C:20 KRG/ P 
2.2 g/ 4 weeks 
1. OGTT 
2. Plasma glucose 
3. Lipid peroxidation - MDA 
4. HOMA-IR 
5. Adverse events 
Decreased HOMA-IR and fasting glucose. 
1. 0.60[-0.91,3.40] 
2. -2.10[-4.52,0.32] 
3. 0.10[-0.18,0.38] 
4. NE 
5. T:2 C:0 
Reay, 2009, UK (160) 
 
DB, CO Healthy individuals  Study1 T&C:25  
Study2 T&C:18 
Study1:G115/ P 200 
mg/ 8 weeks Study2: 
Cheong Kwan Jang / P 
200 mg/ 8 weeks 
1. Plasma insulin 
2. HbA1c 
3. Adverse events 
 
No significant effect. 
1. 0.47[-5.51,6.45] 
2. 0.08[-0.16,0.32] 
3. NS 
Sievenpiper, 2003, Canada 
(198) 
 
SB, CO Healthy individuals  Study 1 
T&C:14  
Study 2 
T&C:11 
Panax ginseng/ P 
1, 2, 3, 6, 9 g/ 1 day 
1. OGTT 
2. Adverse events 
Higher two hour plasma glucose.  
1. NE 
2. Study1: T:1 C:0; Study2: NS 
Sievenpiper, 2006, Canada 
(199) 
 
DB, CO Healthy individuals  Study 1 T&C:7 
Study 2 
T&C:12 
Panax ginseng/ P 
2, 4, 6 g/ 1 day 
1. OGTT 
2. Adverse events 
2 g rootlets reduced postprandial glycaemia. 
1. NE 
2. NS 
Vuksan, 2008, Canada (200) 
 
DB, CO Type 2 diabetes T&C:39 RG/ P 
6 g/ 12 weeks 
1. OGTT 
2. Plasma glucose 
3. HbA1c 
4. Adverse events 
No significant effect. 
1. -0.61[-1.26,0.05] 
2. -0.33[-0.97,0.32] 
3. 1.96[-0.16,1.14] 
4. T:1 C:2 
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Table 34: Characteristics of the included studies continued 
Respiratory conditions 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Gross, 2002, Israel (12) 
 
DB, PG COPD T:51 C:43 G115/ P 
200 mg/ 12 weeks 
1. FEV1 
2. FVC 
3. VO2max 
4. Adverse events 
Improved lung function tests and VO2max.  
1. 20.00[15.62,24.38] 
2. -8.50[-11.00,-6.00] 
3. 9.50[4.19,14.81] 
4. T:0 C:0 
Jung, 2011(b), Korea (149) 
 
DB, PG Allergic rhinitis T:33 C:33 Fermented RG/ P 
1.5 g/ 4 weeks 
1. TNSS 
2. Overall RQoL 
3. Total IgE 
4. Adverse events 
Improved nasal congestion and reduced skin reactivity to 
allergens. 
1. -0.30[-0.64,0.04] 
2. -0.76[-2.26,0.74] 
3. 16.39[-11.41,44.19] 
4. T:1 C:2 
Scaglione, 1994, Italy (201) 
 
DB, PG Chronic bronchitis T:20 C:20 G115/ P 
200 mg/ 8 weeks 
1. Phagocytosis index 
2. Intra cellular killing 
3. Adverse events 
Improved immune response. 
1. 0.38[0.24,0.52] 
2. 0.20[0.08,0.32] 
3. NS 
Scaglione, 1996, Italy (202) 
 
DB, PG At risk of influenza T:114 C:113 G115/ P 
200 mg/ 12 weeks 
1. NK cell activity 
2. Number of common colds 
3. Anti-body titres 
4. Adverse events 
Improved immune response and decreased common colds. 
1. 16.70[13.83,19.57] 
2. RR 0.35 [0.21, 0.60] 
3. 52.70[33.74,71.66] 
4. T:8 C:1 
Scaglione, 2001, Italy (203) 
 
OL, PG Chronic bronchitis T:38 C:37 G115/ Antibiotics 
200 mg/ 9 days 
1. Bacterial count 
2. Adverse events 
Improved bacterial count. 
1. -0.80 [-0.94, -0.66] 
2. NS 
Erectile dysfunction 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Choi, 1995, Korea (204) 
 
SB, PG Erectile dysfunction T: 30 
C(P):30 
C(SC):30 
RG/ P or SC 
200 mg/ 12 weeks 
1. Erection and sexual 
satisfaction 
2. Adverse events 
Rigidity, girth, libido and satisfaction improved. 
1. NE 
2. T:0 C:0 
de Andrade, 2007, Brazil 
(205) 
 
DB, PG Erectile dysfunction T:30 C:30 Panax ginseng/ P 
3000 mg/ 12 weeks 
1. IIEF-5 
2. Testosterone 
3. Total cholesterol 
4. GAS 
5. Adverse events 
IIEF-5 total score improved 
1. 3.30[0.28,6.32] 
2. 51.20[-3.38,105.78] 
3. -10.00[-33.06,13.06] 
4. 0.30[-0.16,0.76] 
5. T:3 C:0 
Hong, 2002, Korea (206) 
 
DB, CO Erectile dysfunction T&C:45 RG/ P 
2.7 g/ 8 weeks 
1. IIEF-5 
2. RigiScan 
3. Adverse events 
IIEF-5 total score improved, RigiScan showed 
improvement. 
1. 2.37[-0.08,4.82] 
2. 4.09[-8.11,16.29] 
3. T:1 C:0 
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Table 34: Characteristics of the included studies continued 
Kim, 2009, Korea (207) 
 
DB, PG Erectile dysfunction T:75 C:68 Tissue cultured 
mountain Ginseng 
extract/ P 
2 g/ 8 weeks 
1. IIEF-5 
2. Testosterone 
3. Adverse events 
 
IIEF-5 erectile function and overall satisfaction improved. 
1. 6.53[0.81,12.25] 
2. 0.53[-0.36,1.42] 
3. T:3 C:NS 
Immunomodulation  
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Gaffney, 2001, Australia 
(208) 
 
DB, PG Healthy individuals T:10 C:10 Panax ginseng/ P 
4 mL/ 6 weeks 
1. Lymphocyte count 
2. Testosterone 
3. Adverse events  
No significant effect. 
1. -0.01[-0.53,0.51] 
2. 0.00[-5.83,5.83] 
3. NS 
Jung, 2011(a), Korea (209) 
 
DB, PG Healthy individuals T:9 C:9 RG/ P 
60 g/ 10 days 
1. CK 
2. IL-6  
3. OGTT 
4. Adverse events 
Decreased CK, IL-6 and glucose levels. 
1. -39.50[-65.98,-13.02] 
2. -0.07[-0.18,0.04] 
3. 1.40 [0.52, 2.28] 
4. NS 
Scaglione, 1990, Italy (161) 
 
DB, PG Healthy individuals Study1 
T:20 C:20 
Study2 
T:20 C:20 
Study1: G115/ P 
200 mg/ 8 weeks 
Study2: PKC/ P 
200 mg/ 8 weeks 
1. Chemotaxis 
2. Intra cellular killing 
3. Total lymphocytes 
4. Adverse events 
Stimulation of an immune response, G115 was more 
active. 
1.    G115 0.53[0.19,0.87] 
1.    PKC  0.52 [0.19, 0.85] 
2.    G115 -3.65 [-12.26, 4.96] 
2.    PKC-12.95[-21.31,-4.59] 
3.    G115 5.74 [-0.20, 11.68] 
3.    PKC 5.82 [0.89, 10.75] 
4.    NS 
Srisurapanon, 1997, Thailand 
(210) 
 
DB, PG Healthy individuals T:10 C:10 Panax ginseng/ P 
300 mg/ 8 weeks 
1. Leukocyte counts 
2. Lymphocyte count 
3. Total WBC 
4. Adverse events 
No significant effect. 
1. NE 
2. NE 
3. NE 
4. NS 
Quality of life and mood 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Cardinal, 2001, USA (211) 
 
DB, PG Healthy individuals T (200mg):22  
T (400mg):27 
C:34 
G115/ P 
200, 400 mg/ 8 weeks 
1. PANAS 
2. POMS 
3. Adverse events 
No significant effect. 
1. NE 
2. NE 
3. NS 
Ellis, 2002, USA (212) 
 
DB, PG Healthy individuals T:15 C:15 G115/ P 
200 mg/ 8 weeks 
1. SF-36 – physical 
2. SF-36 – mental 
3. Adverse events 
 
Improved aspects of mental and social functioning after 4 
weeks of treatment. 
1. -1.70[-4.69,1.29] 
2. 2.10[-3.42,7.62] 
3. T:4 C:2 
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Table 34: Characteristics of the included studies continued 
Kim, 2006, Korea (213) 
 
DB, PG Cancer T:32 C:21 Sun Ginseng/ P 
3 g/ 12 weeks 
1. WHOQOL BREF – 
psychological  
2. GHQ-12 
3. Adverse events 
Improved psychological and physical health domains of 
the WHOQOL-BREF. Improved GHQ-12 total score. 
1. -0.50[-3.00,2.00] 
2. 0.00[-3.66,3.66] 
3. T:0 C:0 
Wiklund, 1999, Sweden 
(214) 
 
DB, PG Post-menopausal 
women 
T:193 C:191 G115/ P 
200 mg/ 12 weeks 
1. PGWB 
2. WHQ 
3. Menopause symptoms VAS 
4. Adverse events 
Improved sub scales of depression and well-being. 
1. 0.40[-2.72,3.52] 
2. -1.20[-4.08,1.68] 
3. 0.50[-2.29,3.29] 
4. T:2 C:2 
Antioxidant function 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Kim, 2001, Korea (215) 
 
DB, PG Healthy smokers T:3 C:3 RG/ P 
1.8 g/ 4 weeks 
1. Triacylglycerol 
2. Lipid peroxidation - MDA 
3. Total cholesterol 
4. Adverse events  
No significant effect. 
1. 12.49[-27.48,52.46] 
2. 0.07[-0.69,0.83] 
3. 2.61[-12.19,17.41] 
4. NS 
Kim, 2011(a), Korea (216) 
 
DB, PG Healthy individuals T(1g):27 
T(2g):28  
C:27 
Panax ginseng/ P 
1, 2 g/ 4 weeks 
1. Lipid peroxidation - MDA 
2. Serum levels ROS  
3. SF-36-mental 
4. Adverse events 
Some antioxidant properties.  
1. -1.50[-2.97,-0.03] 
2. -17.00[-35.30,1.30] 
3. -3.40[-9.63,2.83] 
4. T(1g):0 T(2g):2 C:0 
Cancer 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Suh, 2002, Korea (111) 
 
NS, PG Stage III gastric 
cancer 
T:22 C:20 RG/ P  
4.5 g/ 6 months and 
4.5 years follow-up 
1. Recurrence of cancer 
2. Total leukocytes 
3. Total lymphocytes 
4. Adverse events 
Increased five year survival rate. 
1. RR 0.49 [0.25, 0.98] 
2. 1.60[0.33,2.87] 
3. -0.50[-6.56,5.56] 
4. T:0 C:0 
Yun, 2010, China (112) 
 
DB, PG Chronic atrophic 
gastritis 
T:325 C:318 RG/ P 
1 g per week/ 3 years 
and 8 years follow-up 
1. Incidence of cancer 
2. Adverse events 
Preventive effects on cancer in males only. 
1. RR 0.49 [0.21, 1.13] 
2. T:19 C:23 
Menopausal Symptoms 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Kim, 2011(b), Korea (217) 
 
DB, PG Menopausal women T:36 C:36 RG/ P 
3 g/ 12 weeks 
1. Kupperman index 
2. Serum estradiol 
3. Total cholesterol 
4. Adverse events 
Kupperman index improved, Cholesterol decreased. 
1. NE 
2. NE 
3. NE 
4. NS 
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Table 34: Characteristics of the included studies continued 
Oh, 2010, Korea (218) 
 
DB, CO Menopausal women T&C:32 RG/ P 
3 g/ 8 weeks 
1. GAQ 
2. FSFI – arousal level 
3. Testosterone 
4. Adverse events 
Improved GAQ and FSFI. 
1. NE 
2. 0.10[-0.01,0.21] 
3. NE 
4. T:2 C:0 
Dry Mouth 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Park, 2010, Korea (219) 
 
DB, PG Subjective dry 
mouth 
T:50 C:50 KRG/ P 
6 g/ 8 weeks and 2 
weeks follow-up 
1. Dry mouth VAS 
2. Salivary flow rate 
3. Adverse events 
No significant effect. 
1. 0.24[-0.66,1.14] 
2. -0.02 [-0.08, 0.04] 
3. T:7 C:9 
Ulcerative Colitis 
Author, Year, Country Design Condition No. of Subjects  
T / C  
T/ C 
Daily dose/ Duration 
Outcomes Author’s conclusions.  
Intergroup difference MD [95% CI] 
Lu, 2009, China (220) NS, PG Severe ulcerative 
colitis  
T:30 C:30 Panax ginseng/ SC 
15-20g/ 15 days 
1. Carbon Dioxide Combining 
Power 
2. Blood electrolytes (K+) 
3. Blood electrolytes (Na+) 
4. End of treatment 
improvement 
5. Deaths 
6. Adverse events 
1. 1.75 [0.01, 3.49] 
2. 1.03 [0.79, 1.27] 
3. 10.28 [9.44, 11.12] 
4. RR 2.17 [1.37, 3.43] 
5. RR 0.27 [0.10, 0.71] 
6. T:0 C:0 
ADAS: Alzheimer’s Disease Assessment Test, BP: Blood Pressure, C: Control, CDR: Clinical Dementia Rating, CFR: Cardiac Flow Reserve, CI: Confidence Interval, CK: Creatine Kinase, CO: Cross Over, COPD: 
Chronic Obstructive Pulmonary Disease, DB: Double Blind, ECG: Electrocardiogram, EEG: Electroencephalogram, FEV1: Forced expiratory volume in 1 second, FSFI: Female Sexual Function Index, FVC: Forced 
Vital Capacity, GAQ: Global Assessment Questionnaire, GHQ-12: Global Health Questionnaire, HOMA-IR: Homeostatic Model Assessment –Insulin Resistance, iAUC : Incremental Area Under the Curve, IgE: 
Immunoglobulin-E, IIEF-5: International Index of Erectile Function questionnaire, IL-6: Interleukin-6, INR: International Normalised Ratio, K+: Potassium , KRG: Korean Red Ginseng, MD: Mean Difference, 
MMSE: Mini Mental Status Examination, Na+: Sodium , NE: Not Estimable, NIDDM: Non-Insulin Dependent Diabetes Mellitus, NK: Natural Killer, NS: Not Stated, OGTT: Oral Glucose Tolerance Test, OL: Open 
Label, P: Placebo, PANAS: Positive and Negative Affect Schedule, PG: Parallel Group, PGWB: Physiological General Wellbeing Index, PKC: Panax ginseng extract manufactured by Pharmaton, POMS: Profile Of 
Mood States, QoL: Quality of Life, RG: Red Ginseng, RQoL: Rhinitis Quality of Life Questionnaire, SB: Single Blind, SC: Standard Care, SD: Standard Deviation,  SF-36: Short Form (36) health survey, T: 
Treatment, TNSS: Total Nasal Symptom Score, VAS: Visual Analogue Scale, WBC: White Blood Cell, WHOQOL-BREF: World Health Organisation quality of life-BREF questionnaire, WHQ: Women’s Health 
Questionnaire 
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5.4.13 Risk of bias 
Risk of bias was judged using the Cochrane Collaboration’s Risk of Bias tool. The 
results are summarised in  
Figure 21. From the 67 studies, 402 potential sources of bias were judged. The majority 
were categorised as unclear (209, 52%), low (176, 44%) and high (17, 4%). These are 
outlined below. 
• Random sequence generation: high in one study; low in 22 studies; and unclear in 44 
studies. 
• Allocation concealment: high in four studies; low in 13 studies; and unclear in 50 
studies.  
• Blinding of participants and personnel: high in eight studies; low in 52 studies; and 
unclear in seven studies. 
• Blinding of outcome assessment: high in no studies; low in six studies; and unclear in 
61 studies. 
• Incomplete outcome data: high in three studies; low in 26 studies; and unclear in 38 
studies. 
• Selective reporting: high in one study; low in 57 studies; and unclear in nine studies. 
 
Other sources of bias were not included in  
Figure 21. However, authors in six studies (160, 169-171, 173, 214) reported industry 
sponsorship by the manufacturer of the interventional product and the risk of bias was 
unclear. One study (175) was co-authored by an employee of the manufacturer of the 
interventional product and the risk of bias was judged as unclear. 
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Figure 21: Risk of bias summary and graph 
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5.4.14 Quality assessment 
Data from 60 out of the 67 studies were assessed for quality. Seven studies (151, 162, 
163, 183, 186, 204, 217) did not have full text articles available and could not be 
included.  
 
The studies included in this review were inherently randomised. However, only 33 
(55%) mentioned randomisation in the title or abstract as recommended in the 
CONSORT checklist. Fifty-one (51) studies were described as double blind, two as 
single-blind, four as open-label and three didn’t describe randomisation. Thirty-seven 
(37) studies were designed as parallel studies, and 23 as cross-over studies.  
 
5.4.14.1 Methodological quality using the CONSORT checklist 
The CONSORT checklist sections are summarised in Table 35 and the individual 
CONSORT items are described in Table 36. Analysis of the included studies showed 
that on average 47.9% of the recommended items were reported. Kim et al 2010 
reported the highest percentage of recommended items, 78% and Sotaniemi et al 1995 
reported the lowest percentage of recommended items, 19%. Twenty-six (26) studies 
reported between 50% and 75%, and 32 reported between 20% and 49% of the 
recommended items. 
 
Abstracts were structured appropriately in 74.2% of included studies and introductions 
were structured appropriately in 81.7%. Seventeen (17) items were recommended to be 
reported in the methods sections, overall these items were under reported. They were 
reported in just 40.9% of included studies [Table 35]. 
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The results section included a participant flow diagram in five studies (8.3%), 
mentioned analysis by originally assigned groups and intention-to-treat in nine (15.0%), 
losses and exclusions after randomisation in 24 (40.0%), and adverse event reporting in 
33 (55.0%).  
 
Three items relate to the discussion section. These items were reported in 53.9% of the 
included studies [Table 35]. Information regarding trial registration number was 
reported in 5.0% of the studies, availability of the full protocol in 0% and funding 
source in 38.3%. Justification for using a cross-over design was reported in 21 out of the 
23 relevant studies.  
 
Studies published after the CONSORT checklist was disseminated in 1996 reported 
more items. Specifically, until 1995, 10.3 ± 4.9 (32.8%); from 1996–2006, 14.6 ± 3.3 
(32.8%); and from 2007 onwards, 16.9 ± 4.5 (53.5%), (p = 0.005, ANOVA F = 5.73). 
Significance identified in ANOVA is due to a difference between studies published up 
until 1995 and those published from 2007 onwards, mean difference 6.7, p=0.009. 
 
The studies reporting the items were those that evaluated QoL and mood, had sample 
sizes between 51 and 100, were conducted in North America and published in journals 
that promote the CONSORT [Table 38]. 
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Table 35:  CONSORT items reported in the 60 studies 
CONSORT  
Section Number of 
items 
Reported Not reported Not applicable 
Title and abstract 2 74.2% 25.8% 0.0% 
Introduction  2 81.7% 18.3% 0.0% 
Methods  17 40.9% 41.9% 17.2% 
Results  10 30.9% 41.8% 27.3% 
Discussion  3 53.9% 46.1% 0.0% 
Other information 3 14.4% 85.6% 0.0% 
Additional 1 35.0% 3.3% 61.7% 
Total  38 40.0% (47.9%)
a
 43.2% 16.8% 
CONSORT extension for herbal interventions  
Section Number of 
items 
Reported Not reported Not applicable 
Title and abstract  1 46.7% 53.3% 0.0% 
Introduction  1 85.0% 15.0% 0.0% 
Methods  17 26.8% 59.4% 13.8% 
Results  1 15.0% 85.0% 0.0% 
Discussion  3 40.5% 59.5% 0.0% 
Total 23 31.4% (35.0%)
a
 58.5% 10.1% 
% was calculated from all 60 studies. The total number of items reported from each section (numerator) was divided by the total possible 
number of items that could be reported (denominator). 
a % was calculated from the total number of items reported (numerator) divided by the total number of items that could be reported  
(denominator). Some items aren’t relevant to all studies, so the total number of items that could be reported is less than the total possible 
number of items. For example, for 60 studies, the total number of individual CONSORT items (38) would be multiplied by 60, which equals 
2280. If 1000 items were reported and 100 items weren’t relevant, the % would be calculated as 1000 divided by 2280 (2280 – 100), which 
equals 45.9%.  
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Table 36: Individual CONSORT items and number of studies reporting items 
Section 
Item 
number 
Item description 
Number of 
studies reporting 
items
 
and  % 
a
 
Title/Abstract 1 Study was identified as a randomised trial in the title. 33, 55.0% 
2 Included a structured summary of trial design, methods, results and conclusions. 56, 93.3% 
Introduction 3 Included a scientific background and explained the rationale for the study. 43, 71.7% 
4 Included specific objectives or hypotheses. 55, 91.7% 
Methods 5 Described trial design (such as parallel or factorial), including allocation ratio. 59, 98.3% 
6 Stated important changes to methods after the trial started (such as eligibility criteria), with reasons. N/A 
7 Listed eligibility criteria for participants. 46, 76.7% 
8 Stated settings and locations where data were collected. 36, 60.0% 
9 
Described interventions for each group, including how and when they were administered, with enough detail to let researchers 
replicate the study. 
50, 83.3% 
10 Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed. 56, 93.3% 
11 Stated any changes to trial outcome measures after the trial started, with reasons. N/A 
12 Stated how the sample size was determined. 11, 18.3% 
13 When applicable, explained any interim analyses and guidelines for stopping the study. N/A  
14 Described the method used to generate the random allocation sequence. 14, 23.3% 
15 Described the type of randomization and any restrictions (such as blocking and block size). 20, 33.3% 
16 
Described how the random allocation sequence was implemented (such as by using sequentially numbered containers), 
including any steps taken to conceal the sequence until interventions were assigned. 
15, 25.0% 
17 Stated who generated the random allocation sequence, enrolled participants and assigned participants to interventions. 3, 5.0% 
18 
If relevant, stated who was blinded after interventions were assigned (such as participants, care providers and/or people 
assessing outcomes) and how. 
18, 30.0% 
19 If relevant, described how interventions were similar. 31, 53.4% 
20 Described statistical methods used to compare groups for primary and secondary outcomes. 55, 91.7% 
21 Described methods for further analyses, such as sub-group and adjusted analyses. 4, 44.4% 
Results  
 
 
 
 
 
22 
Included a participant flow diagram showing the numbers of participants who were randomly assigned, received intended 
treatment, and were analysed for the primary outcome for each group. 
5, 8.3% 
23 Listed losses and exclusions after randomisation and the reasons for these, for each group. 24, 40.7% 
24 Listed dates of recruitment and follow-up periods. 16, 26.7% 
25 Stated why the trial ended. N/A 
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Table 36 Continued 
Section 
 
Item 
number 
 
Item description 
Number of 
studies reporting 
items
 
and  % 
a
 
Results 
26 Included a table showing the baseline demographic and clinical characteristics for each group. 
 
27, 45.0% 
27 
Stated how many participants (denominator) were included in each analysis and if participants were analysed in originally 
assigned groups. 
9, 15.0% 
28 
For each primary and secondary outcome, gave results for each group and estimated effect size and precision (such as 95% 
confidence interval). 
45, 75.0% 
29 For binary outcomes, stated absolute and relative effect sizes. 1, 14.3% 
30 
Gave results from any other analyses, including subgroup analyses and adjusted analyses, distinguishing pre-specified from 
exploratory. 
2, 50.0% 
31 Listed all important harms or unintended effects in each group. 33, 55.0% 
Discussion 32 Listed trial limitations (such as addressing sources of potential bias, imprecision and, if relevant, multiplicity of analyses). 21, 35.0% 
33 Trial findings were generalisable (such as external validity and applicability). 36, 60.0% 
34 Interpretation was consistent with results, balanced benefits and harms, and considered other relevant evidence. 40, 66.7% 
Other 
information 
35 Stated registration number and the name of the trial registry. 3, 5.0% 
36 Stated where the full trial protocol can be accessed, if available. 0, 0.0% 
37 Listed sources of funding and other support (such as supply of drugs), and the role of funders. 23, 38.3% 
Additional  38 Cross-over studies should be justified. Including explanation of why they used this design. 21, 91.3% 
a
 % was calculated from the total number of studies reporting the item (numerator) divided by the total number of studies (denominator). Some items aren’t relevant to all studies, 
so the total number of studies may be less. If the number of studies is originally 60, and the particular item isn’t relevant in 3 studies. The % would be calculated as the total 
number of studies reporting the item. For example 26 divided by the total number of studies where item is relevant, that is, 57 (60–3), which equals 45.6%.    
N/A = Not applicable 
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5.4.14.2 Methodological quality using the CONSORT extension for herbal 
interventions 
Overall, the checklist items were not satisfactorily reported. On average only 35.0% of 
the 23 items were reported [Table 35]. The individual CONSORTextension for herbal 
medicine items are described in Table 37. 
 
It is recommended that the title or abstract states the herbal medicine’s Latin binomial 
name, part of the plant used and preparation type. This was reported in only 28 (46.7%) 
of the included studies. Introductions satisfied the criteria in 85.0% of the studies. 
Research methods were poorly described, on average only 26.8% of the items were 
reported. In particular, three items were never reported, these are:  
 a description of how traditional theories and concepts were maintained 
 outcomes that reflect these traditional theories and concepts 
 a description of any special or purity testing (e.g., heavy metal)  
 
Items in the results and discussion sections were also under reported. In particular, those 
relating to the generalisability of results and use in self-care and clinical practice were 
reported in just eight studies (13.3%). After the CONSORT extension for herbal 
interventions was published in 2006, RCT quality improved, although not significantly. 
Until 2005, 7.3 ± 3.2, 35.2% of the items were reported, and from 2006 onwards, 7.6 ± 
2.3, 37.3% were reported (p=0.64). The studies reporting the most recommended items 
were those that investigated G115 or Cheong Kwan Jang extracts, were conducted in 
North America and published in CONSORT promoting journals. Table 38 presents the 
characteristics of the included studies.  
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Table 37: Individual CONSORT checklist items for herbal interventions and number of studies reporting items 
Section 
Item 
# 
Item description 
Number of 
studies reporting 
items
 
and  % 
a
 
Title/ Abst 1 The title or abstract, or both, state the herbal medicinal product’s Latin binomial, and part of the plant and preparation type used. 28, 46.7% 
Introducti
on 
2 Includes a brief explanation of the reasons for the trial, which refers to the specific herbal medicinal product being tested and, if 
applicable, whether new or traditional indications are being investigated. 
51, 85.0% 
Methods 
 
 
3 If a traditional indication is being tested, describes how the traditional theories and concepts were maintained. For example, participant 
inclusion criteria should reflect the theories and concepts underlying the traditional indication. 
0, 0.0% 
4 States the Latin binomial, botanical authority, family and common names for each herbal ingredient.  22, 36.7% 
5 States the proprietary product name (i.e. brand name) or extract name (e.g. EGb-761) and the name of the manufacturer of the product. 30, 69.8% 
6 States if the product used is authorised (e.g. licensed or registered) in the country in which the study was conducted. 4, 6.7% 
7 States the part(s) of plant used to produce the product or extract. 20, 33.3% 
8 States the type of product used (e.g. raw – fresh or dry – extract). 49, 81.7% 
9 States the type and concentration of extraction solvent used (e.g. 80% ethanol, 100% H2O, 90% glycerine) and ratio of herbal drug to 
extract (e.g. 2 to 1). 
14, 23.3% 
10 States how the raw material was authenticated and by whom; the lot number of the raw material; if a voucher specimen (i.e. retention 
sample) was kept, and if so, where it is and what its reference number is. 
5, 8.8% 
11 States the product’s dose and duration of administration, and how these were determined. 60, 100.0% +  
12 Lists the content (e.g. as weight or concentration – may be given as range where appropriate) of all quantified herbal product 
constituents, native and added, per dose unit form. Added materials, such as binders, fillers and other excipients (e.g. 17% 
maltodextrin, 3% silicon dioxide per capsule), are also listed. 
2, 3.3% 
13 For standardized products, states the quantity of active/marker constituents per dose unit form. 15, 25.0% 
14 States the product’s chemical fingerprint, how this was analysed (e.g. equipment and chemical reference standards) and by whom (e.g. 
laboratory name). Also states if a sample of the product (i.e. retention sample) was kept, and if so, where it is. 
1, 1.7% 
15 Describes any special testing/purity testing (e.g. heavy metal or other contaminant testing) done, which unwanted components were 
removed and how. 
0, 0.0% 
16 Describes what was standardised (e.g. which chemical components of the product) and how (e.g. chemical processes or 
biological/functional measures of activity). 
6, 10.0% 
17 Includes the rationale for the control or placebo type used. 45, 75.0% 
18 Describes the practitioners (including their training and practice experience) who were part of the intervention. 5, 8.3% 
19 Outcome measures reflect the intervention and indications tested, and consider, where applicable, underlying theories and concepts. 0, 0.0% 
Results 20 Baseline data includes concomitant medicines, including herbal and complementary medicines. 9, 15.0% 
Discussion 21 Results are interpreted in light of the product and dose regimen used. 38, 63.3% 
22 Where possible, herbal products and the dose regimen used are discussed in relation to what is used in self-care and/or practice. 8, 13.3% 
23 Trial results are discussed in relation to trials of other available products. 27, 45.0% 
a
 % was calculated from the total number of studies reporting the item (numerator) divided by the total number of studies (denominator). Some items aren’t relevant to all studies, 
so the total number of studies may be less. If the number of studies is originally 60, and the particular item isn’t relevant in 3 studies. The % would be calculated as the total 
number of studies reporting the item. For example 26 divided by the total number of studies where item is relevant, that is, 57 (60–3), which equals 45.6%.    
+ 
All studies reported product dose and duration of administration. However, only 33 out of 60 (55%) reported how the dose and duration were determined. 
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Table 38: Characteristics of included studies, evaluated using the CONSORT 
checklist and extension for herbal interventions 
Study element 
Number 
of studies, 
% 
CONSORT items 
reported
a
 
Mean (SD), % 
Extension for herbal 
interventions
 
items reported
b
 
Mean (SD), % 
Publication period of the CONSORT checklist 
Up to 1995 (before CONSORT) 5, 8.3% 10.3 (4.9), 32.8% - 
1996–2006 (CONSORT published 
and revised) 
30, 50.0% 14.6 (3.3), 46.1% - 
2007–present (CONSORT revised) 25, 41.7% 16.9 (4.5), 53.5% - 
Publication period of the extension for herbal interventions 
Up to 2005 (before extension) 35, 58.3% - 7.3 (3.2), 35.2% 
2006–present (after extension) 25, 41.7% - 7.6 (2.3), 37.3% 
Health-related sub-categories 
Psychomotor performance 14, 23.3% 13.6 (4.5), 42.6% 7.6 (2.4), 36.6% 
Physical performance 8, 13.3% 15.8 (1.6), 50.2% 9.3 (3.1), 44.3% 
Circulatory system 9, 15.0% 18.1 (4.6), 57.8% 7.5 (2.7), 37.0% 
Glucose metabolism 6, 10.0% 16.5 (5.8), 51.0% 8.2 (2.8), 40.2% 
Respiratory system 5, 8.3% 13.2 (4.8), 42.6% 5.4 (2.1), 25.7% 
Immunomodulation 4, 6.7% 13.5 (1.7), 42.9% 7.8 (2.9), 37.3% 
Quality of life/Mood 4, 6.7% 17.5 (4.0), 55.6% 6.5 (3.7), 31.7% 
Erectile dysfunction 3, 5.0% 14.0 (2.0), 43.8% 5.0 (2.6), 23.8% 
Anti-oxidant function 2, 3.3% 13.0 (4.2), 41.3% 6.5 (4.9), 31.7% 
Cancer 2, 3.3% 15.0 (5.7), 46.9% 6.5 (3.5), 31.7% 
Menopausal symptoms 1, 1.7% NA, NA, 50.0% NA, NA, 30.0% 
Dry mouth 1, 1.7% NA, NA, 69.7% NA, NA, 45.5% 
Ulcerative colitis 1, 1.7% NA, NA, 34.2% NA, NA, 4.3% 
Panax ginseng preparation*  
G115™ 22, 35.5% 15.3 (3.9), 48.3% 8.4 (2.8), 40.3% 
Panax ginseng (undeclared) 14, 22.6% 15.1 (3.6), 47.5% 7.3 (2.3), 35.3% 
Red Ginseng extract 13, 21.0% 14.8 (3.9), 46.7% 5.9 (2.5), 29.1% 
Korean Red Ginseng 3, 4.8% 16.0 (8.2), 50.0% 7.3 (3.8), 35.5% 
Gerimax™ 2, 3.2% 10.5 (6.4), 33.3% 4.5 (3.5), 21.4% 
Cheong Kwan Jang™ 2, 3.2% 21.5 (4.9), 67.2% 8.5 (2.1), 40.5%  
Korean Red Ginseng rootlet 1, 1.6% NA, NA, 75.0% NA, NA, 42.8% 
Fermented Red Ginseng 1, 1.6% NA, NA, 55.1% NA, NA, 42.8% 
Sun Ginseng 1, 1.6% NA, NA, 43.8% NA, NA, 20.0% 
Tissue-cultured mountain extract 1, 1.6% NA, NA, 43.8% NA, NA, 40.0% 
60% ethanolic extract  1, 1.6% NA, NA, 43.8% NA, NA, 57.1% 
PKC 169/79 (Pharmaton) 1, 1.6% NA, NA, 35.5% NA, NA, 33.3% 
Sample size 
0–10 2, 3.3% 13.0 (4.2), 40.6% 4.5 (2.1), 21.4% 
11–50 38, 63.3% 15.1 (4.8), 47.6% 7.8 (2.9), 37.6% 
51–100 15, 25.0% 15.8 (3.4), 50.2% 7.2 (2.9), 34.8% 
101+ 5, 8.3% 16.2 (2.2), 51.6% 6.6 (2.1), 32.0% 
Journal  
Promotes CONSORT  13, 21.7% 15.8 (4.3), 50.1% 7.7 (3.5), 37.2% 
Does not promote CONSORT  47, 78.3% 15.1 (4.3), 47.8% 7.4 (2.6), 35.5% 
Geographical location where study was conducted 
Asia 26, 43.3% 15.7 (4.2), 49.7% 6.5 (2.6), 31.9% 
Europe 18, 30.0% 13.3 (4.4), 41.9% 7.2 (2.4), 34.1% 
North America 13, 21.7% 17.5 (3.6), 54.9% 9.6 (2.4), 46.9% 
Other 3, 5.0% 14.7 (3.1), 46.3% 6.7 (1.2), 30.8% 
a The CONSORT statement includes 38 items, b The CONSORT extension for herbal interventions includes 23 items. 
% was calculated from the total number of items reported (numerator) divided by the total possible number of items that could be reported (denominator). For 
example, if 5 studies were included, the maximum number of CONSORT items would be 38 multiplied by 5, which equals 190. Some items aren’t relevant to all 
studies. For example, if 20 items from these 5 studies weren’t relevant, the total possible number of items equals 170 (190 – 20). If the numbers of items reported 
by these five studies were 10, 20, 20, 30 and 30, the total reported items would be 110. The % would be calculated as 110 divided by 170 (64.7%).    
* Two studies reported on two different Panax ginseng preparations, so there are 62 preparations. 
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5.4.15 Adverse events 
Information on adverse events was reported in 41 studies. Information on adverse 
events was not reported for 26 studies.  Of the 41 studies where adverse events were 
reported, 17 studies had no reported adverse events and 24 studies had 135 minor 
events. Minor events included headache, insomnia, diarrhoea and mild hepatic 
dysfunction. Table 39 presents a summary of the adverse events from the included 
studies.  Thirty-three (33) people withdrew from studies due to adverse events, 22 of 
these people were taking an intervention at the time of withdrawal and 11 people were 
taking a placebo. The numbers of events are outlined in Table 34.  
 
Table 39: Adverse events from the included studies 
Type of event Number of cases References 
Headache and insomnia 19 (112, 168, 202, 205, 207, 212, 216) 
Diarrhoea 7 (168, 177, 180, 219) 
Nausea and vomiting  7 (164, 168, 188, 202, 212) 
Mild feverish sensation 6 (164, 168, 191, 219) 
Itching sensation or rash 5 (112, 219) 
Increased blood pressure 4 (112) 
Mild hepatic dysfunction (ALT increased) 4 (149, 187) 
Dyspepsia 3 (219) 
Nasal bleeding 3 (112) 
Sweating 3 (112, 219) 
Epigastric discomfort  2 (202, 219) 
Gastrointestinal discomfort    2 (181, 194) 
Increased heart rate 2 (112) 
Vaginal bleeding 2 (218) 
Allergic reaction 1 (198) 
Anorexia 1 (168) 
Anxiety 1 (202) 
Dizziness 1 (168) 
Flushing 1 (194) 
Hypoglycemia 1 (200) 
Irritability 1 (212) 
The table includes specific references to reported adverse events. Some studies mentioned adverse events however group and type 
of event were not explicit, they were not included.    
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5.4.16 Effect of interventions 
5.4.16.1 Psychomotor performance 
Psychomotor performance and cognitive function were evaluated in 17 studies (150, 
151, 162-176). These studies measured 13 different outcomes, which were broadly 
categorised as reaction times, arithmetic tasks, memory and attention, psychological 
status, and subjective feelings. Of these 17 studies, two evaluated Panax ginseng’s 
effect on people with Alzheimer’s disease, one evaluated its effects on people with non-
insulin dependent diabetes mellitus, and the remaining 14 evaluated its effects on 
healthy people.  
 
In 16 studies, certain aspects of psychomotor performance improved after Panax 
ginseng treatment. Intergroup differences were only observed in four of these studies 
(166, 173, 174, 176). One study  reported a difference in immediate word recall after 
using a 400 mg single dose of G115 (MD 17.33 [4.26, 30.40]) (166). In another study, 
auditory reaction time improved after 8 weeks’ treatment with 400 mg of Gerimax (MD 
–13.00 [–24.87, –1.13]) (173). In Ziemba’s study, visual reaction time improved at the 
end of 6 weeks’ treatment with 350 mg Panax ginseng, (MD –10.10 [–12.54, –7.46]). 
Sotaniemi et al investigated psychomotor performance in people with non-insulin 
dependent diabetes mellitus. They observed an intergroup difference on overall 
psychomotor performance after 8 weeks’ of 100 mg Gerimax (MD –9.20 [–15.55, –
2.85]). Although psychomotor performance seemed to improve in people given Panax 
ginseng the clinical significance of these results is difficult to interpret. 
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5.4.16.2 Physical performance 
Physical performance was evaluated in 10 studies (177-186). Oxygen consumption 
(VO2) was the main outcome measure in six studies, peak power output measured in 
two studies, and lactate threshold and time to exhaustion primarily measured in one 
study each. All studies recruited healthy people and treatment durations ranged from 1 
day to 8 weeks. An intergroup difference for VO2peak was seen in one study (MD 2.90 
[1.26, 4.54]) (177). However, a baseline imbalance was present. Therefore, Panax 
ginseng had no significant effect on physical performance in these studies.  
 
5.4.16.3 Circulatory conditions 
Panax ginseng’s effect on the circulatory system were evaluated in 9 studies (187-195). 
The characteristics of these studies varied. Participants included healthy people or 
people with conditions such as myocardial infarction, stroke, hypertension or glaucoma. 
Panax ginseng doses also differed, ranging from 200 mg per day to 4.5 g per day. This 
made it difficult to pool results.   
 
Authors from three studies reported that Panax ginseng has no significant effect on 
prothrombin time (192), blood pressure (194), or vascular endothelial function (195). 
However, it reportedly did affect outcomes in four studies (187, 188, 191, 193), 
although intergroup differences at the end of treatment were not significant. Jovanovski 
et al compared the effect of a single dose of 3 g of Red Ginseng with placebo in healthy 
people. The Augmentation Index improved by MD –5.19 [–6.58, –3.80]. Lowering the 
Augmentation Index may help to reduce arterial stiffness and risk of cardiovascular 
disease, despite it not significantly lowering blood pressure.  
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5.4.16.4 Glucose metabolism 
Six studies evaluated Panax ginseng’s effects on glucose metabolism (160, 196-200). 
Two of these studies enrolled people with type 2 diabetes, and four enrolled healthy 
people. Authors from four studies reported positive results for Panax ginseng (196-
199). No significant results were reported from the other two studies (160, 200).  
 
Outcomes from five studies showed no intergroup differences at the end of Panax 
ginseng treatment. However, De Souza et al observed that a single 3 g dose of Panax 
ginseng significantly lowered the incremental area under the glucose curve (iAUC). 
This may indicate that Panax ginseng can help to decrease circulating glucose, which is 
often high in people with type 2 diabetes.  
 
5.4.16.5 Respiratory conditions 
Five studies evaluated Panax ginseng’s effects on the respiratory system (12, 149, 201-
203). One study used 1.5 g of fermented Red Ginseng for 4 weeks to treat allergic 
rhinitis (149). The authors reported reduced nasal congestion and skin reactivity to 
allergens, however intergroup differences were insignificant. 
 
Scaglione et al investigated the effects of 200 mg of G115 on chronic bronchitis in two 
studies. The first compared with placebo for 8 weeks (201) and the second compared 
with antibiotics for 9 days (203). The phagocytosis index (MD 0.38 [0.24, 0.52]), intra 
cellular killing (MD 0.20 [0.08, 0.32]) and bacterial clearance (MD –0.80 [–0.94, –
0.66]) improved in both studies, indicating that Panax ginseng may improve the 
immune response and quicken recovery after infection.  
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Scaglione et al also investigated the effects of 200 mg of G115 administered for 12 
weeks after an anti-influenza vaccination. Results showed that Panax ginseng improved 
the immune response by increasing the natural killer cell activity (MD 16.70 [13.83, 
19.57]). It also decreased the incidence of common colds (RR 0.35 [0.21, 0.60]). Anti-
body titres also improved (MD 52.70 [33.74, 71.66]) in people given G115, suggesting 
it has a synergistic effect with vaccination. Giving people with COPD 200 mg of G115 
for 12 weeks improved their lung function (FEV1 MD 20.00 [15.62, 24.38], FVC MD –
8.50 [–11.00, –6.00]), and exercise performance (VO2max MD 9.50 [4.19, 14.81]) (12). 
However, these results were only observed after 4 weeks of treatment and by 8 weeks of 
treatment, there was no longer any statistical significance. This indicates that Panax 
ginseng may reduce respiratory inflammation and infection, and improve lung function 
and respiratory muscle strength. 
 
5.4.16.6 Erectile dysfunction 
Four studies investigated Panax ginseng’s effect on erectile dysfunction (204-207). 
These studies used different Panax ginseng formulations. Two studies examined Red 
Ginseng, one at 200 mg for 12 weeks (204) and the other at 2.7 g for 8 weeks (206). 
Authors reported improved erectile function however there were no intergroup 
differences at the end of treatment. In the other two studies, participants reported 
significant improvement on the International Index of Erectile Function questionnaire 
(IIEF-5). One study (205) prescribed 3 g of Panax ginseng for 12 weeks, with 
improvements of MD 3.30 [0.28, 6.32]. The other prescribed 2 g of tissue-cultured 
mountain Ginseng extract for 8 weeks, with improvements of MD 6.53 [0.81, 12.25] 
(207). 
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5.4.16.7 Immunomodulation 
Panax ginseng’s effect on immunomodulation was investigated in four studies (161, 
208-210). Gaffney et al administered a 4 mL 60% Panax ginseng ethanolic extract to 
healthy endurance athletes for 6 weeks. The athletes’ lymphocyte counts and endocrine 
function were examined, but no significant effects were observed.  
 
Jung et al investigated post-exercise muscle damage and inflammation after 
administration of 60 g of Red Ginseng to healthy people for 10 days. In that time, 
creatine kinase significantly deceased (MD –39.50 [–65.98, –13.02]) indicating reduced 
muscle damage. Insulin sensitivity also improved (MD 1.40 [0.52, 2.28]) possibly due 
to reduced muscle damage.  
 
Scaglione et al conducted two studies that followed the same protocol, using 200 mg 
G115 or PKC for 8 weeks. Immune cell activity and numbers were measured at the end 
of treatment. Significance for G115 and PKC was observed, chemotaxis (G115, MD 
0.53 [0.19, 0.87] and PKC, MD 0.52 [0.19, 0.85]), and total lymphocytes (PKC, MD 
5.82 [0.89, 10.75]). 
 
In another study, blood leukocytes and lymphocytes were measured in healthy people 
after 300 mg of Panax ginseng was administered for 8 weeks. However, no significant 
changes were reported (210). 
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5.4.16.8 Quality of life and mood 
Three studies evaluated quality of life (212-214), and one evaluated mood (211). 
Studies used validated questionnaires, including the Short Form Health Survey (SF-36), 
World Health Organisation quality of life questionnaire (WHOQOL-BREF), Global 
Health Questionnaire, Physiological General Wellbeing Index, and for mood, the 
Positive and Negative Affect Schedule and Profile of mood states. Three authors 
reported improvements in certain domains of the questionnaires (212-214). However, 
intergroup differences at the end of treatment were insignificant. 
 
5.4.16.9 Antioxidant function 
Two studies evaluated Panax ginseng’s antioxidant effects (215, 216). Kim & Lee 
studied healthy smokers taking 1.8 g of Red Ginseng or placebo for 4 weeks. However, 
no significant effect was reported.  
 
Kim et al investigated the effect of Panax ginseng at 1 or 2 g per day on healthy people 
for 4 weeks. Lipid peroxidation decreased with low and high doses MD –1.50 [–2.97, –
0.03] and MD –1.80 [–3.20, –0.40], respectively. These studies provide some evidence 
of Panax ginseng’s antioxidant effect. However, other measured components, including 
total reactive oxygen species and antioxidant capacity were not significant. 
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5.4.16.10 Cancer 
Cancer recurrence was monitored in people diagnosed with stage III gastric cancer who 
were given 4.5 g per day of Red Ginseng for 6 months (111). People were followed up 
for 4.5 years after treatment and there was a significant reduction in cancer recurrence 
(RR 0.49, [0.25, 0.98]).  
 
Incidence of cancer was monitored in people with chronic atrophic gastritis who were 
given 1 g per week of Red Ginseng for 3 years (112). Participants were followed up for 
8 years after treatment and there was a notable reduction in incidence of cancer (RR 
0.49, [0.21, 1.13]). 
 
5.4.16.11 Menopausal symptoms 
Two studies investigated Panax ginseng’s effects on menopausal symptoms (217, 218).  
One study  used the Kupperman Index to evaluate menopausal symptoms and secondary 
outcomes of serum estradiol and cholesterol (217). The authors reported that Red 
Ginseng at 3 g per day for 12 weeks reduced symptoms. However, intergroup 
differences could not be analysed. Oh et al used the Global Assessment Questionnaire, 
the Female Sexual Function Index and testosterone levels to evaluate sexual arousal in 
menopausal women. Increased sexual arousal was reported. However, there were no 
significant intergroup differences at the end of treatment.  
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5.4.16.12 Dry mouth 
One study evaluated Panax ginseng’s effect on subjective dry mouth (219). Authors 
reported it had no significant effect and there were no intergroup differences for any 
outcome.  
 
5.4.16.13 Ulcerative colitis 
One study evaluated Panax ginseng’s effect on severe ulcerative colitis (220). Panax 
ginseng was compared to standard care for 15 days.  Electrolyte levels were improved 
(RR 2.17 [1.37, 3.43]). The clinical relevance of this result is difficult to interpret.  
  
5.4.17 Discussion 
This review identified 67 studies with very different designs and methodologies. This is 
not surprising as Panax ginseng has been investigated in RCTs for more than 28 years 
with 95 outcomes explored and 12 different types of Panax ginseng preparations used.  
 
Results from the included studies indicate that Panax ginseng has promising therapeutic 
effects on immunity and glucose metabolism. It moderated the immune response, 
particularly cell-mediated immunity, in several of the included studies. This could have 
significant implications for people with health conditions like COPD (12, 201, 203). 
When combined with results from pre-clinical studies, results from clinical studies in 
the sub-categories of immunomodulation and antioxidant function may give insight into 
how the immune system may be moderated by Panax ginseng. 
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Although evidence supporting Panax ginseng’s use to help balance glucose metabolism 
is limited, the positive results from the included studies give some indication of its 
effects on the overall glycaemic response and ability to lower circulating glucose. This 
area warrants further investigation, specifically looking at its mechanisms and clinical 
applicability for people with type 2 diabetes.  
 
Psychomotor performance was the most commonly investigated outcome, results were 
positive but not compelling. The most interesting psychomotor performance results 
related to improved cognitive function and glucose metabolism. Psychomotor and 
cognitive function is impaired in people with diabetes (221). Future research that aligns 
psychomotor performance and glucose control will be valuable.  
 
5.4.18 Summary of adverse events 
Authors included information on adverse events in 41 out of the 67 studies reviewed. 
Adverse events most often included headache, insomnia, and diarrhoea. However, a 
particular dose or preparation relating to adverse events could not be identified.   
 
From this review, it appears that Panax ginseng has a good safety profile. This result re-
confirms other reports of Panax ginseng’s safety (95). Interestingly, two studies (192, 
193) noted no drug-herb interaction between Panax ginseng and warfarin, which has 
been reported in other studies (95, 100).  
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5.4.19 Comparison with other systematic reviews 
The broad clinical benefit of Ginseng has been evaluated in two previous systematic 
reviews (147, 148). This review identified areas of promising findings that were similar 
to earlier reviews. However, this review clearly aligned important disease areas with 
clinical outcomes including; chronic respiratory diseases (e.g., chronic bronchitis) with 
cell-mediated immune outcomes; type 2 diabetes with circulating glucose levels, and 
psychomotor and cognitive performance. 
 
Panax ginseng was the only species included in this review. The previous two reviews 
did not evaluate Panax ginseng alone, but combined data on several Ginseng species 
including Panax quinquefolium and Eleutherococcus senticosus. Combining results 
from different plants is inappropriate. Each plant has unique active constituents, which 
potentially have different actions making results difficult to interpret. 
 
Previous reviews are out of date, Vogler’s review published in 1999 and Lee’s review 
only searched for literature published until 2009. Furthermore, Lee and Vogler used the 
Jadad scale to evaluate study quality.  The Cochrane Collaboration’s Risk of Bias tool 
was used in the current review and evaluates six domains of potential bias and more 
critically evaluates studies than the Jadad Scale.  
 
Finally, Vogler and Lee did not report results as mean differences at the end of 
treatment preferring to interpret results subjectively. By using the mean differences, the 
conclusion and interpretation of efficacy are more reliable.  
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5.4.20 Heterogeneity of the Studies 
Data synthesis for this review was limited by heterogeneity between studies. Pooling 
results would introduce confounding, so it was inappropriate. The lack of high quality 
and appropriately powered studies means it is difficult to make data relevant and able to 
be generalised. To further highlight this problem, 44 out of the 67 studies stated positive 
findings, but strong conclusions were not reported.  
 
Included studies looked at a wide variety of outcomes and participant characteristics.  
Even after grouping studies into health related sub-categories, their differences were 
still significant. Panax ginseng preparations were also diverse, with the manuscripts 
including little information about manufacturing processes. This made it difficult to 
compare studies and decide if their recommendations for dosage and length of 
administration seemed appropriate. 
 
5.4.21 Summary of risk of bias 
A number of tools are available to evaluate risk of bias (222). Many researchers use the 
controversial and often misleading scoring system tools, for example the Jadad scale 
(223). In this review the Cochrane Risk of Bias tool was used despite potential 
limitations. The main limitation being its relative newness where studies published prior 
to its dissemination are at a disadvantage (13).  
 
Classification of risk of bias in most studies was judged as “unclear”. The key issues 
identified in the studies include inadequate randomisation, allocation concealment 
procedures and blinding of outcome assessment. This does not necessarily mean the 
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authors of the studies used inappropriate research methods, but based on an evaluation 
of published studies alone, without access to full trial protocols it is difficult to properly 
judge the risk of bias in these studies with so little information provided. 
 
5.4.22 Summary of quality assessment  
This is the first time the CONSORT checklist, CONSORT extension for herbal 
interventions and risk of bias have been simultaneously used to determine the quality of 
clinical reports for a specific single herb intervention.  
 
This review revealed that less than 50% of CONSORT items were reported in Panax 
ginseng RCTs. Therefore, results need to be interpreted with caution and the value of 
results from these studies, either positive or negative, may be compromised.  
 
The major methodological issues include lack of information about participant and 
intervention allocation, insufficient statistical power and little detail about the intended 
treatment assignment. However, the context and time frame of publications needs to be 
kept in mind. For instance, trial registration before 2005 wasn’t compulsory, but is now 
mandatory (224), and intention-to-treat analysis is a relatively new method. 
 
Methodological deficiencies seen in this review have been identified in other herbal 
medicine and drug RCTs (225, 226). Herbal medicine RCTs are more challenging than 
western drug RCTs, because the herbal compounds are often in their natural form and 
quality control including authentication of constituents can be variable (227, 228). 
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Furthermore, effective application and interpretation of traditional medicine theory to 
ensure data validity is difficult.  
 
Several independent and overlapping reasons could cause under reporting of trial 
methods. For example, publishing journals often do not strictly enforce the CONSORT 
checklists. Elements of the CONSORT extension for herbal interventions may be 
difficult to address, particularly in the areas of quality control, chemical fingerprinting 
and standardisation and researchers may be inexperienced in trial design and/or have 
little understanding of herbal quality control (229). 
 
Evaluating herbal medicine RCTs using the CONSORT checklist, CONSORT 
extension for herb interventions and risk of bias simultaneously provides a detailed 
picture of the methodological quality. There are similarities in the evaluation methods, 
including the CONSORT checklist having components of randomisation and allocation 
concealment similar to that in the Cochrane Risk of Bias tool. The CONSORT checklist 
covers the fundamental methodological considerations however the CONSORT 
extension for herb interventions covers additional items. The risk of bias tool is most 
useful for determining internal validity and bias retrospectively however the CONSORT 
checklists are more appropriately applied in the guidance of prospective clinical studies.  
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5.4.23 Limitations of the review 
The review was limited to clinical trials published in journals in English and Chinese. 
To overcome this, planned future reviews on Korean literature may help to draw firm 
conclusions about Panax ginseng’s efficacy and safety in treating various health 
conditions. Also no included RCT protocols were tested more than once, which limited 
the strength of evidence and prevented the planned meta-analysis.   
 
Results from these studies are difficult to interpret, as the use of Panax ginseng is 
unjustified. Aspects of the studies varied considerably, most notably, the preparation 
method of Panax ginseng and the justification for dose and standardisation of active 
ingredients.  
 
The methodological component of this review may have some limitations. Specifically, 
35 studies were published before the CONSORT extension for herbal interventions. 
Additionally, the results may not represent other types of herbal interventions.   
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5.4.24 Conclusions and implications 
This is the most comprehensive and up-to-date systematic review of Panax ginseng in 
RCTs. Panax ginseng appeared to have some positive therapeutic effects on various 
health conditions. However, caution needs to be taken when interpreting results due to 
risks of bias, particularly for random sequence generation and allocation concealment. 
There were several different study designs and limited information on how Panax 
ginseng was prepared. There were also several methodological issues, notably small 
sample sizes with undisclosed sample calculations.  
 
A diverse range of studies evaluatimg various health conditions were found. The most 
promising evidence supports Panax ginseng’s use in moderating glucose metabolism 
and the immune response, particularly cell-mediated immunity with implications for 
chronic respiratory diseases and type 2 diabetes. 
 
Variable findings from the included studies may be attributed to inconsistency in the 
quality of the Panax ginseng products investigated, particularly in respect to the 
ginsenoside content. Future clinical studies should focus on the most promising 
outcomes identified in this review. Additionally, quality methodology and standardised 
Panax ginseng products should be used in future studies and particular attention paid to 
establishing the mechanisms of Panax ginseng.   
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5.5 Effect of Panax ginseng on reducing inflammation and oxidative stress and 
its prospective as a treatment of COPD: a review of the experimental and clinical 
literature 
 
5.5.1 Introduction  
Chronic inflammation in COPD is activated by exposure to cigarette smoke leading to 
inflammation. Inflammatory cells including macrophages, neutrophils and CD8+ T cells 
migrate to the airways and lung parenchyma (33). The inflammatory cells secrete 
chemokines and cytokines. Neutrophils degranulate and produce reactive oxygen 
species (ROS) and enzyme proteases are activated. These processes result in damage to 
epithelial cells, degradation of elastic fibres and extra cellular matrix and loss of elastic 
recoil, which induces repair and remodelling. Airways become chronically inflamed 
resulting in loss of lung clearance and mucus hyper secretion. Fibrosis occurs leading to 
further remodelling and narrowing of the airways. Chapter 2 describes the details.   
 
Panax ginseng has multiple actions and exerts a wide range of effects on inflammation 
and oxidative stress (10). Panax ginseng may have an effect on several areas including 
regulation of inflammation and oxidative stress related pathways; modulation of 
cytokines and mediators; reducing oxidative stress; and reducing the activity and 
numbers of immune cells. Understanding these actions may aid in the development of 
Ginseng products for the management of COPD. 
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5.5.2 Objective 
The objective of this review was to summarise and evaluate the existing literature on 
Panax ginseng in experimental, in vitro, in vivo and clinical studies, RCTs. The focus 
was to evaluate the mechanisms of Panax ginseng on reducing inflammation and 
oxidative stress relevant to COPD. 
 
5.5.3 Methods 
5.5.4 Search strategy 
A systematic search was conducted on five English databases: MEDLINE, EMBASE, 
CINAHL, PsychINFO and the Cochrane library. The search period ranged from the 
databases’ inception until 20 August 2012. Reference lists for further publications were 
also searched. Table 40 presents the search strategy. 
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Table 40: Search strategy to identify in vitro, in vivo and RCTs in MEDLINE 
In vitro  
1.  Panax ginseng.tw or ginsenoside.MeSH  
2.  Cell.MeSH or cell.tw or in vitro.MeSH 
3.  Inflammation.MeSH or inflammation.tw or anti-inflammatory.tw 
4.  Oxidative stress.MeSH or oxidative stress.tw or antioxidant.tw 
5.  1 and 2 and 3 
6.  1 and 2 and 4 
7.  5 or 6 
In vivo 
1.  Panax ginseng.tw or ginsenoside.MeSH  
2.  In vivo.tw 
3.  Inflammation.MeSH or inflammation.tw or anti-inflammatory.tw 
4.  Oxidative stress.MeSH or oxidative stress.tw or antioxidant.tw 
5.  1 and 2 and 3 
6.  1 and 2 and 4 
7.  5 or 6 
RCTs 
1.  Panax ginseng.tw or ginsenoside.MeSH  
2.  Inflammation.MeSH or inflammation.tw or anti-inflammatory.tw 
3.  Oxidative stress.MeSH or oxidative stress.tw or antioxidant.tw 
4.  Randomized controlled trial.MeSH or randomized clinical trial.tw or clinical trial. 
MeSH or controlled clinical trial.pt 
5.  1 and 2 and 4 
6.  1 and 3 and 4 
7.  5 or 6 
MeSH = medical subject headings, tw = text word, pt = publication type. Boolean operators: and, or, not are 
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5.5.5 Eligibility of studies  
Specific inclusion criteria were:  
 in vitro, in vivo and RCTs  
 Panax ginseng or ginsenoside(s) as the intervention 
 
Specific exclusion criteria were: 
 Panax ginseng combinatorial products 
 non English publications 
 
5.5.6 Data extraction  
Two reviewers searched the databases. Any disagreements were resolved by consensus. 
The second reviewer was an experienced researcher from RMIT University, the 
contribution of Dr Yuan Ming Di is acknowledged. 
 
5.5.7 Results  
Searches identified 880 studies [Figure 22]. Of these, 35 met the inclusion criteria; 14 
were in vitro studies (104, 230-242) [Table 41], 10 in vivo (243-252) [Table 42], and 11 
were randomised controlled trials (12, 161, 187, 201-203, 208-210, 215, 216) [Table 
43].  
 
The main effects of Panax ginseng and ginsenosides included regulation of immune cell 
activity and numbers, modulation of cytokine and mediator production, reduction in 
oxidative stress, and regulation of inflammation and oxidative stress related pathways. 
Figure 23 presents an overview.   
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Figure 22: Flow diagram of study selection 
 
 
867 records identified through database searching 
13 additional records identified through other sources 
 706 duplicates removed  
174 records screened  
126 records excluded 
Not related to COPD (n=74) 
Not ginseng alone (n=13) 
Other herbal intervention (n=5)  
Other type of publication, including reviews (n=34) 
48 full-text articles assessed for eligibility 
In vitro (n=24) 
In vivo (n=13) 
RCT (n=11) 
 13 full-text articles excluded 
Not related to COPD (n=11) 
Not Panax ginseng (n=2)  
35 studies included in the analysis 
In vitro (n=14) 
In vivo (n=10) 
RCT (n=11) 
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Table 41: Characteristics of in vitro studies 
In vitro studies 
Test agent Cell line Result  Conclusion and proposed mechanism Reference 
INFLAMMATION 
Rb1 HUVECs and human lung 
microvascular endothelial cells  
1. Decreased TNF-α 
2. Blocked THP-1 adhesion 
3. Decreased superoxide anion 
Rb1 reduced TNF-α-induced MAPKs and NF-κB 
activation. May be effective for controlling 
inflammation 
Chai, 2008, Japan 
(230) 
Rb1, Rb2, Rc human (U937) macrophages and 
(Maurine) RAW264.7 macrophage 
1. Decreased TNF-a Hypothesised decreased in TNF- α through suppression 
of cAMP PDE and regulate cGMP cell balance 
Cho, 2001, Korea 
(233) 
 
Re and PPT  Human umbilical vein endothelial 
cells (HUVECs) 
1. Reduced IP-10 
2. Increased cell viability 
3. Decreased apoptosis and DNA damage 
Re and PPT decreased influenza-induced inflammation 
and apoptosis  
Chan, 2011, China 
(231) 
 
Transgenic Panax ginseng 
root extract 
Human mast cell line 1 (HMC-1) 1. Decreased TNF-α, IL-6, and IL-8 
2. Decreased COX-2 expression 
3. Inhibited intracellular Ca2+ levels 
Ginseng can down regulate inflammation by inhibiting 
cytokine production. Mast cell activation was also 
turned down indicting Panax ginseng has an anti-
inflammatory effect.  
Kim, 2007, Korea 
(104) 
Panax ginseng root extract THP-1 monocytic leukemia cells 1. Decreased cytokine expression including TNF-
α, IL-1β, IL-6, IL-8, IL-10, and TGF-β 
Ginseng down regulated cytokine production and 
inflammation. Ultrafine granules of Panax ginseng 
were more potent inhibitors. 
Lee, 2008, China 
(239) 
Panax ginseng extract Human monocytic cells (U937) 1. Reduced IP-10 Ginseng can supress signalling proteins of cytokines, 
possible correlated with the inactivation of ERK1/2 
pathways 
Lee, 2009, China 
(238) 
Panax ginseng extract Human mast cell line 1 (HMC-1) 1. Decreased IL-6 and COX-2 
2. Suppression of NF-κB and MAPK 
Ginseng modulates the production of IL-6 and the 
expression of COX-2 through the regulation of NF-κB 
activation 
Choi, 2011(A), Korea 
(234) 
Rh1 THP-1 monocytic leukemia cells 1. Decreased MCP-1 and CCR2  
2. Attenuated the phosphorylation of MAPK 
3. Reduced adhesion of monocytes 
Rh1 inhibited  the expression of both MCP-1 and its 
receptor CCR2, which are key mediators in monocyte 
and macrophage recruitment 
Choi, 2011(B), Korea 
(235) 
Panax ginseng root extract Not specified 1. Inhibition of cAMP  May be related to biological activities Nikaido, 1984, Japan 
(240) 
ADP: adenosine diphosphate, ATP : adenosine triphosphate, cAMP : cyclic adenosine monophosphate, CCR2: chemokine receptor 2, cGMP: cyclic guanosine monophosphate, COX-2: cytochrome c oxidase 
subunit II, DNA: deoxyribonucleic acid, eNOS: endothelial nitric oxide synthase, ERK1/2:  extracellular Signal-Regulated Kinases 1 and 2, GPx: glutathione peroxidase, GR: glutathione reductase, GSH: 
glutathione, GSSG: oxidized glutathione, Hcy: homocysteine,  HMC-1: human mast cell line 1, HUVEC: Human umbilical vein endothelial cell, H2O2: hydrogen peroxide, IL: interleukin,  IP-10: interferon-
Inducible Protein 10, JNK: c-Jun N-terminal kinases, LDH: lactate dehydrogenase), MAPK: Mitogen activated protein kinase, MCP-1: monocyte chemotactic protein-1, MPP+: 1-methyl-4-phenylpyridinium, 
mRNA: messenger ribonucleic acid, NAD: nicotinamide adenine dinucleotide, NF-κB : nuclear factor kappa-light-chain-enhancer of activated B cells, NO: nitric oxide, PARP-1: poly [ADP-ribose] polymerase 
1, PDE: phosphodiesterase, ROS: reactive oxygen species, TGF-β: transforming growth factor beta, THP-1: Tamm-Horsfall protein 1, TNF-α: tumour necrosis factor-alpha, t-PA: tissue-type plasminogen 
activator  
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Table 41: Characteristics of in vitro studies continued 
In vitro studies 
Test agent Cell line Result  Conclusion and proposed mechanism Reference 
OXIDATIVE STRESS 
Rg1 SHSY5Y human neuroblastoma 
cells 
1. Reduced cell apoptosis 
2. Attenuate ROS  
 
Rg1 may exert protective effect and reduced cell 
apoptosis by inhibiting the production of ROS, 
activation of JNK and caspase-3. 
Chen, 2003, China 
(232) 
Rb1 HUVECs 1. Decreased LDH activity 
2. Increased eNOS mRNA and t-PA mRNA 
3. Increased NO 
Reduce endothelial dysfunction by reducing LDH 
activity, increase vascular relaxation by increased NO 
and prevent thrombus fibrinolysis and formation. 
He, 2007, China 
(236) 
PPT HUVECs 1. PPT reversed H2O2 induced cell death and 
LDH release. 
2. PPT reversed the depleted GSH level and total 
GSH (GSH+GSSG) levels. 
3. Partially reduce the formation of DNA strand 
breakage induced by H2O2. 
4. PARP-1 activity significantly reduced NAD+ 
levels partially prevented.  
5. ATP and ADP levels maintained. 
Modulates glutathione level by affecting related 
enzymes. 
Prevents H2O2 induced cell death. Antioxidant effects 
by up regulating GPx and GR activities. 
 
Kwok, 2010, China 
(237) 
 
Rb1 HUVECs and SVEC4-10 (mouse 
endothelial) 
1. Inhibition of Hcy Hcy can suppress endothelial cell proliferation or 
viability by inhibition the production of NO and Rb1 
10 µM blocks Hcy-induced inhibition of cell 
proliferation. 
Ohashi, 2006, USA 
(241) 
 
Rg1 Fibroblasts 1. Rg1 has a dose-dependent anti-senescence 
capacity.  
2. Rg1 protects telomeres. 
Rg1 has antioxidant activity by protecting telomeres.  
 
Zhou, 2012, China 
(242) 
ADP: adenosine diphosphate, ATP : adenosine triphosphate, cAMP : cyclic adenosine monophosphate, CCR2: chemokine receptor 2, cGMP: cyclic guanosine monophosphate, COX-2: cytochrome c oxidase 
subunit II, DNA: deoxyribonucleic acid, eNOS: endothelial nitric oxide synthase, ERK1/2:  extracellular Signal-Regulated Kinases 1 and 2, GPx: glutathione peroxidase, GR: glutathione reductase, GSH: 
glutathione, GSSG: oxidized glutathione, Hcy: homocysteine,  HMC-1: human mast cell line 1, HUVEC: Human umbilical vein endothelial cell, H2O2: hydrogen peroxide, IL: interleukin,  IP-10: interferon-
Inducible Protein 10, JNK: c-Jun N-terminal kinases, LDH: lactate dehydrogenase), MAPK: Mitogen activated protein kinase, MCP-1: monocyte chemotactic protein-1, MPP+: 1-methyl-4-phenylpyridinium, 
mRNA: messenger ribonucleic acid, NAD: nicotinamide adenine dinucleotide, NF-κB : nuclear factor kappa-light-chain-enhancer of activated B cells, NO: nitric oxide, PARP-1: poly [ADP-ribose] polymerase 
1, PDE: phosphodiesterase, ROS: reactive oxygen species, TGF-β: transforming growth factor beta, THP-1: Tamm-Horsfall protein 1, TNF-α: tumour necrosis factor-alpha, t-PA: tissue-type plasminogen 
activator  
 
 
175 
 
Table 42: Characteristics of in vivo studies 
In vivo studies 
Test agent Animal and tissue Result  Conclusion and proposed mechanism Reference 
INFLAMMATION 
Panax ginseng root extract 
 
Balb/C, C57 B1/6J and C57 B1/6J 
nu/nu, spleen cells 
 
1. Elevated immunoglobulin production IgM and 
IgG 
2. Enhanced NK cell activity 
3. Enhanced immune interferon production 
4. Inhibited lymphocyte proliferation 
Enhanced interferon production leading to stimulated 
NK cell activity.  
Jie, 1984, Switzerland 
(244) 
Rb1 and compound K male ICR mice, peritoneal 
macrophage cells 
 
1. Decreased TNF-α IL-1, IL-1β, IL-6 and  
2. Blocked expression of COX-2 and iNOS 
3. Increased IL-10 
Inhibition of pro-inflammatory cytokines and enzymes 
and increased anti-inflammatory cytokines. Anti-
inflammatory effect by blocking NF-kB and MAPK. 
Joh, 2011, Korea 
(245) 
 
Panax ginseng root extract 
 
Female B6C3f1 mice, spenocytes/ 
monocytes 
 
1. Increased NK cell activity 
2. Unchanged T and B cell response 
3. Unchanged IgM antibody production 
4. Improved host resistance  
Ginseng has some immune-modulatory properties, 
mainly associated with NK cell activity. 
Kim, 1990, USA 
(246) 
 
Ginsenoside Rg5 Male C57BL/6 mice, alveolar 
macrophages 
1. Decreased TNF-α and IL-1β 
2. Inhibition of iNOS and COX-2 
3. Decreased protein and neutrophils in broncho-
alveolar lavage  
Rg5 decreased TNF-a, IL-1β, iNOS and COX-2 
through inhibition of NF-kB. It also prevented the 
binding of bacterial molecules to macrophage receptors 
and therefore decreased lung inflammation.  
Kim, 2012, Korea 
(247) 
Panax ginseng root extract 
 
pathogen-free mice, spleen cells 1. Elevated immunoglobulin production IgM, IgG 
2. Elevated cytokine production IL-2, IFN-γ and 
IL-4 and IL-10 
Ginseng can regulate antibody production by 
augmenting Th1- (IL-2, IFN-γ) and Th2-type (IL-4, IL-
10) cytokine production 
Liou, 2004, Taiwan 
(249) 
Panax ginseng root extract 
 
male BALB/c mice, sera and spleen 
cells 
 
1. Decreased IgG, increased IgA, IgM unchanged  
2. Elevated IL-2, IFN- γ, IL-10 
3. Increased NK cell activity 
4. Reduced T-lymphocytes (CD3+, CD4+, CD8+) 
Ginseng enhances Th1-type cytokine production. This 
may enhance the immune response. 
 
Liou, 2006, Taiwan 
(248) 
 
Korean Red Ginseng powder 
extract 
female BALB/c mice, blood samples 
 
1. Increased levels of  virus specific antibodies  
2. Increased IL-4 and IL-5  
3. Decreased IL-6 
Ginseng modulates cytokine production and enhances 
the humoral immune responses. Enhanced effect when 
co-administered with influenza vaccination.   
Quan, 2007, USA 
(250) 
 
Panax ginseng root extract 
 
female Lewis rats, blood samples 
and lung histopathology 
 
1. Improved pulmonary bacterial clearance 
2. Decreased severity of lung pathology 
3. Reduced mast cell numbers 
4. Decreased IgG 
Ginseng regulated the immune response and shifted the 
altered the response by lowering serum IgG to improve 
bacterial clearance. 
 
Song, 1997, Denmark 
(251) 
 
Panax ginseng root extract Female CBA/J mice 1. Increased IFN- γ & TNF- α 
2. Decreased IL-4 
3. Decreased severity of lung pathology 
Ginseng induced at Th1-type immune response. 
 
Song, 2003, Denmark 
(252) 
OXIDATIVE STRESS 
Re Streptozotocin-induced diabetic rats 1. Increased glutathione levels 
2. Decreased malondialdehyde levels 
Ginseng can prevent the onset of oxidative stress in 
some tissues 
Cho, 2006, China 
(243) 
COX-2: cytochrome c oxidase subunit II, IFN-γ: interferon-gamma, IgG: immunoglobulin G, IgM: immunoglobulin M,  IL: interleukin, iNOS: inducible nitric oxide synthetase, NF-κB : nuclear factor kappa-
light-chain-enhancer of activated B cells, NK: natural killer, MAPK: mitogen activated protein kinase , Th1/2: T-helper cells 1 and 2, TNF-α: tumour necrosis factor-alpha 
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Table 43: Characteristics of clinical trials 
Clinical trials 
Intervention/ control/ 
dosage 
Condition treated Outcomes and Results Conclusions and implications Reference 
INFLAMMATION 
Red Ginseng/ Placebo/ 3 g/d Myocardial Infarction (MI) 1. Decreased IL-6 and TNF- α 
2. Increased cardiac flow reserve (CFR) 
Ginseng decreased inflammation in MI patients, 
thereby improving CFR and quickening recovery. 
Ahn, 2001, Korea 
(187) 
Panax ginseng (60% 
ethanolic extract)/ Placebo/ 4 
mL/d 
Healthy 1. Unchanged lymphocyte count 
2. Unchanged Hormone levels - testosterone 
No significant effect. Gaffney, 2001,  
Australia (208) 
G115/ Placebo/ 200 mg/d COPD 1. Increased lung function - FEV1, FVC 
2. Increase VO2 Max 
Ginseng increased lung function and exercise 
performance. 
Gross, 2002, Israel 
(12) 
Red Ginseng/ Placebo/ 60 g/d Healthy 1. Decrease IL-6 
2. Decreased creatine kinase 
3. Decreased glucose levels  
Ginseng blunted high intensity exercise muscle 
damage and inflammation.  
Jung, 2011(a), Korea 
(209) 
G115 or PKC/ Placebo/ 200 
mg/d 
Healthy 1. Increased chemotaxis 
2. Increased total lymphocytes neutrophil, 
CD4+ and NK cells 
3. Increased phagocytosis index 
Ginseng improved the immune response. Scaglione, 1990, Italy 
(161) 
G115/ Placebo/ 200 mg/d Chronic Bronchitis 1. Increased phagocytosis index 
2. Increased  intra cellular killing 
Ginseng improved the immune response. Scaglione, 1994, Italy 
(201) 
G115/ Matching Placebo and 
influenza vaccination/ 200 
mg/d and influenza vaccine 
At risk of influenza infection 1. Increased NK cell activity 
2. Reduced incidence of common cold 
Ginseng improved the immune response. Scaglione, 1996, Italy 
(202) 
G115/ Antibiotics 
(Amoxicillin and clavulonic 
acid)/ 200 mg/d and 
antibiotics 
Chronic Bronchitis 1. Improved bacterial count Ginseng improved bacterial clearance.  
 
Scaglione, 2001, Italy 
(203) 
Panax ginseng/ Placebo/ 
300 mg/d 
Healthy 1. Unchanged lymphocyte count, CD4+ T cell 
counts and total WBCs 
No significant effect. Srisurapanon, 1997, 
Thailand (210) 
OXIDATIVE STRESS 
Red Ginseng/ Placebo/ 1.8 g/d Healthy smokers 1. Elevated vitamin concentrations/plasma 
antioxidants 
2. Decreased lipid peroxidation using MDA 
concentrations 
3. Unchanged plasma lipids 
Ginseng increased antioxidants Kim, 2001, Korea 
(215) 
Panax ginseng/ Placebo/ 1 
or 2 g/d 
Healthy 1. Decreased serum ROS and MDA levels 
2. Unchanged serum TAC, SOD and catalase 
activities 
3. Increased total glutathione and GSH-Rd activity 
Ginseng shows antioxidant effects by decreasing ROS 
and MDA  
Kim, 2011a, Korea 
(216) 
CFR: cardiac flow reserve, FEV1: forced expiratory volume in 1 second,  FVC: forced vital capacity,  GSH: glutathione, IL: interleukin, MDA: malondialdehyde, MI: myocardial infarction, NK: natural killer, 
ROS: reactive oxygen species, SOD: superoxide dismutase, TAC: total antioxidant capacity, TNF-α: tumour necrosis factor-alpha, VO2: oxygen consumption, WBC: white blood cells 
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Figure 23: Effect of Panax ginseng on inflammation, oxidative stress and related 
pathways  
 
5.5.8 Inflammatory cells 
Results from in vivo studies  
Panax ginseng root extract can moderate inflammation (244). Jie and colleagues 
reported enhanced interferon production, antibody formation, natural killer (NK) cell 
activity and the inhibition of lymphocyte proliferation by Panax ginseng (244). In this 
mouse model the results demonstrate an immune stimulatory effect by enhancing NK 
cell activity and an immune inhibitory effect by impeding lymphocyte proliferation. In 
another study, Kim et al (1990) showed that Panax ginseng increased NK cell activity 
(246). Results indicate that Panax ginseng has the ability to boost resistance against 
infection (246). 
Inflammatory and oxidative stress related pathways  
e.g., NF-kB and MAPK 
Inflammatory mediators  
e.g., TNF-α and IL-8 
Oxidative stress 
e.g., ROS and oxygen 
radical damage 
Inflammatory cells 
e.g., NK cells & lymphocytes 
Panax ginseng 
Panax ginseng 
Panax ginseng 
Inflammation  
Panax ginseng effects several points throughout the inflammatory process, these include reducing 
inflammation through regulation of inflammatory cells (NK cells and lymphocytes) and mediators 
(TNF-α and IL-8); preventing oxidative stress (ROS and oxygen radical damage) and regulating their 
related pathway.  
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Previous in vitro studies show that ginsenosides can decrease influenza induced 
inflammation and apoptosis (231). In vivo studies have found a similar effect. Quan et al 
(2007) investigated the effect of Korean Red Ginseng on influenza infected mice (250). 
Korean Red Ginseng modulated cytokine production, interleukin (IL) 4, 5, 6 and 
increased influenza specific antibodies. 
 
Song and colleagues in 1997 and 2001 evaluated the effect of Panax ginseng extracts on 
bacterial clearance and the immune response (251, 252). In both studies Pseudomonas 
aeruginosa infected mice showed an improved response. It was hypothesised that 
Panax ginseng may decrease the level of IgG and induce a Th-1 type response, 
therefore regulating the inflammatory process and reducing the bacterial load in the 
lung. For optimal immune function there needs to be a balance between the Th1 and 
Th2 type responses (253). Panax ginseng may regulate the axis of Th1 and Th2 and 
facilitate immune regulation.  
 
Results from clinical trials 
Immune cell activity and numbers including chemotaxis, total lymphocytes and 
leukocytes were evaluated in three studies (161, 208, 210). Scaglione et al (1990) 
reported improved chemotaxis and total lymphocytes in healthy people (161). However, 
Srisurapanon et al (1997) did not report a change in lymphocytes or blood leukocytes in 
a similar population (210). Gaffney et al (2001) reported no significant changes in 
lymphocyte counts after administration of an ethanol extract of Panax ginseng (208). 
Overall, the effect of Panax ginseng was variable. 
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Chronic bronchitis and related COPD were evaluated in three studies (12, 201, 203). In 
COPD sufferers, 200 mg day of a Panax ginseng extract (G115) increased lung function 
(FEV1) and exercise performance (12). These findings are valuable for COPD sufferers 
as lung function and exercise capacity is severely reduced in COPD and even slight 
improvements can offer improved QoL. Scaglione and colleagues (1994 and 2001) 
evaluated 200 mg day of G115 for chronic bronchitis in two studies (201, 203). The 
immune response was improved in both studies, including intra cellular killing, bacterial 
clearance and the phagocytosis index.  
 
In another study the effects of G115 was evaluated on the immune response after 
influenza vaccination (202). Several pre-clinical studies have indicated that Panax 
ginseng may reduce the severity of influenza infection particularly when used as an 
adjunct to the influenza vaccination (231, 250). Scaglione et al reported that G115 
improved NK cell activity and lowered the incidence of common colds. These results 
indicate that Panax ginseng may improve the immune response and quicken recovery 
after infection.  
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5.5.9 Inflammatory mediators 
Results from in vitro studies 
During the pathogenesis of COPD, cytokines and mediators are increased. Tumour 
necrosis factor alpha (TNF-α) is a potent pro-inflammatory agent that promotes the 
migration of inflammatory cells into tissues. Cho et al (2001) evaluated the ability of 
ginsenosides Rb1, Rb2, and Rc to reduce cytokine production in U937 cells (233). 
Ginsenosides strongly decreased TNF-α production, implicating their use in TNF-α 
mediated disease. Furthermore, Lee et al (2008) found that ultra-fine granules of Red 
Ginseng inhibited cytokine production (TNF-α, IL- 6, 8, 10, 1β, TGF-β) in 
lipopolysaccharide stimulated THP-1 cells (239). These studies reveal that ginsenosides 
can down regulate the production and release of TNF-α. 
 
Inhibiting cyclooxygenase-2 (COX-2) will turn down inflammation. Kim et al (2007) 
evaluated the effect of transgenic Panax ginseng on mast cell activation (104). Panax 
ginseng down regulated cytokine production (TNF-α, IL- 6, 8) inhibited COX-2 and 
decreased Ca2+ levels.  
 
Phosphodiesterases (PDE) are a family of enzymes responsible for the regulation of 
cAMP and cGMP. In this section the focus is on cAMP selective phosphodiesterases, 
such as PDE-4, 7 and 8. Nikaido et al (1984) found that protopanaxadiol ginsenosides, 
Rb1 and Rb2 had a high inhibitory effect on cAMP PDE (240). PDE is a principal 
enzyme in cAMP degradation. Inhibiting PDE will elevate the second messengers’ 
cAMP and turn down inflammation (254).   
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Results from in vivo studies 
Further to results shown in the in vitro studies, Kim et al (2012) found that ginsenoside 
Rg5 inhibits TNF-α, IL-1β, iNOS and COX-2 through inhibition of NF-kB (247). In this 
study C57BL/6 mice alveolar macrophages were stimulated with lipopolysaccharide 
and treated with Rg5. The results showed that Rg5 reduced pro-inflammatory mediators 
by preventing the binding of lipopolysaccharide to macrophage receptors and 
decreasing lung inflammation.  
 
Liou et al (2004) injected healthy mice with an ethanol extract of Panax ginseng. 
Results demonstrated a regulation of antibody production (IgG, IgA and IgM) and 
enhanced cytokine production, IL-4, IL-10 IL-2, IFN-γ (249). Following on from this, 
Liou’s group orally administered Panax ginseng root extracts to male BALB/c mice 
(248). Antibody production was regulated, that is, IgG was reduced, IgA was increased, 
yet IgM was unchanged. Cytokine production was elevated, IL-2, IF- γ, IL-10 (Th1-
type) (248). Although these studies were not definitively conclusive, they reveal that 
Panax ginseng may have the ability to enhance and regulate inflammation. 
 
Results from clinical trials 
Panax ginseng’s effect on cytokines was evaluated in two clinical studies (187, 209). 
One study evaluated post myocardial infarction (187) and the other looked at healthy 
people (209). Ahn et al (2011) found that 3 g day of Red Ginseng for 8 weeks reduced 
the release of IL-6 and TNF-α and improved recovery after myocardial infarction (187). 
Although the pathogeneses of myocardial infarction is different to respiratory 
inflammation, the ability of Panax ginseng to reduce cytokines may have implications 
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for COPD. Jung and colleagues evaluated post-exercise muscle damage and 
inflammation after 10 days of Red Ginseng administration (209). They observed a 
decrease in IL-6 and muscle damage.  IL-6 is elevated during exercise and also plays a 
significant role in chronic inflammation. The results from this study support Panax 
ginseng as a cytokine regulator. 
 
5.5.10 Oxidative stress 
Results from in vitro studies 
Reactive oxygen species (ROS) initiate oxidation of biological structures, and 
contribute to amplification of the inflammatory response. Chan et al (2011) evaluated 
the ability of Re and its metabolite PPT to protect endothelial cells from inflammation 
and apoptosis after influenza infection (231). Interferon gamma-induced protein 10 (IP-
10) was supressed and cell viability was increased. These results indicated that the cells 
had a lessened infective burden and decreased influenza induced inflammation and 
apoptosis. The mechanism is thought to rely on the reduction of oxidative stress by 
enhancing the level of glutathione (GSH) that can stabilise ROS (231). 
 
He et al (2007) showed that ginsenoside Rb1 at high doses could prevent oxidative 
stress by decreasing nitric oxide and serine proteases (t-PA and PAI-1) (236). These 
results taken together with other studies show ginsenosides seem to reduce oxidative 
stress.  
 
Chen et al (2003) found Rg1 protected cells from MPP
+ 
induced apoptosis (232). In 
addition, MPP
+
 induced ROS production was attenuated by Rg1. Further investigation 
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found that Rg1 can partially prevent the activation of JNK and caspase-3. These results 
are comparative to the commonly used antioxidant N-acetylcysteine (NAC). Suggesting 
Rg1 may exert protective effects by inhibiting ROS production and increasing defence 
against free radical damage.  
 
Glutathione (GSH) is an important endogenous antioxidant enzyme that directly 
scavengers free radicals. Kwok et al (2010) found that PPT a metabolite of Re changed 
GSH metabolism by significantly increasing the activity of GSH reductase and GSH 
peroxidase (237). As a result, depleted levels of GSH and oxidised GSH were reversed, 
therefore preventing hydrogen peroxide (H2O2) induced change in GSH metabolism. 
Further, PPT protected HUVECs against H2O2 induced cell injury (237).  
 
Plasma homocysteine (Hcy) can suppress endothelial cell proliferation by oxidative 
stress (255). Oshani et al (2006) effectively blocked Hcy induced inhibition of cell 
proliferation using Rb1 (241). Additionally, Rb1 blocked the effect of Hcy by 
increasing superoxide anion production in mouse cell lines (241). Rb1 shows effective 
antioxidant properties by protecting endothelial cells from Hcy induced damage. 
 
Telomeres are specialised structures at the ends of linear eukaryotic chromosomes. 
Human telomeres are rich in guanine (TTAGGG) and are preferential targets of 
oxidative damage (256). Ultraviolet A (UVA) causes oxidative stress and shortens 
telomeres leading to premature aging (242). Zhou et al (2012) showed that after UVA 
irradiation and the photosensitising drug 8-MOP, fibroblasts had significantly shorter 
telomere length than the control (no UVA). Rg1 and the UVA groups were significantly 
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different to the 8-MOP group. 8-oxo-dG is a sensitive marker for oxidative DNA 
damage (242). In this study, increased concentrations of Rg1 reduced 8-oxo-dG 
concentrations, in turn protecting the telomere from oxidative DNA damage. Therefore, 
in oxidative damage by UVA, Rg1 demonstrates antioxidant properties by protecting 
telomeres. In the same study, in a stress induced premature senescence (growth arrest) 
model, Rg1 protected human fibroblasts from senescence in a dose-dependent manner 
(242). Age related biomarker SA-β-gal expression was significantly less in the Rg1 
treated group compared to the control. These finding demonstrate that Rg1 can 
significantly antagonise premature senescence in human fibroblasts.  
 
Results from in vivo studies 
The antioxidant effects of ginsenoside Re were tested in the vascular tissues of 
streptozotocin-induced diabetic rats (243). GSH is an important endogenous antioxidant 
and malondialdehyde (MDA) is an oxidative product from lipid peroxidation. Cho et al 
(2006) evaluated if Re could prevent oxidative stress in vascular tissues of diabetic rats, 
in particular kidney, eye and the aorta. Re significantly increased GSH levels and 
decreased MDA levels (243). Authors summarised that Re can improve antioxidant 
status.  
 
Results from clinical trials 
Two clinical trials evaluated the effect of Panax ginseng on oxidative stress (215, 216). 
Kim et al (2001) evaluated antioxidant effects on smokers (215), whilst Kim et al 
(2011) tested healthy people (216). In smokers, 4 weeks of Red Ginseng increased 
plasma antioxidant levels and decreased MDA (215). MDA is a marker of oxidative 
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stress which is commonly seen in smokers compared to non-smokers (257). These 
findings suggest that Red Ginseng might protect smokers from oxidative stress (215). 
This is a valuable finding for COPD sufferers as smoking is the most common risk 
factor of disease, increased antioxidant levels in the body will offer defence against 
oxidative stress. In the other study, after 4 weeks of Panax ginseng a significant 
decrease in serum ROS and MDA levels was found (216). Panax ginseng showed 
antioxidant properties and enhanced antioxidant defence. 
 
5.5.11 Inflammation and oxidative stress related pathways 
The pathogenesis of COPD involves many mechanisms. The inflammatory and 
oxidative stress pathways are particularly important, including NF-kB and mitogen 
activated protein kinases (MAPK), for example ERK1/2 and p38. 
 
Results from in vitro studies 
NF-κB and MAPK activation orchestrates the release of down-stream products such as 
cytokines. In chronic conditions like COPD, these pro-inflammatory proteins facilitate 
the recurrent inflammatory response as well as tissue-repair and re-modelling (258). 
 
Chai et al (2008) showed that Rb1 could reduce THP-1 monocyte adhesion and 
decrease superoxide anions. It is hypothesised that these effects were caused by a 
deactivation of NF-κB and MAPK gene transcription pathways and a reduction in TNF-
α (230). 
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MAPK promotes transcriptional factors inducing monocyte chemotactic protein-1 
(MCP-1) synthesis and stimulates the migration of monocytes and macrophages to the 
site of tissue injury. Choi et al (2011) and Lee et al (2009) revealed that Panax ginseng 
can reduce IL-6 and COX-2 through the deactivation of MAPK pathways (ERK1/2) 
(234, 238). Choi et al (2011) also showed that ginsenoside Rh1 inactivated the MAPK 
pathway and decreased MCP-1 (235). 
 
Results from in vivo studies 
MAPK and NF-kB promote cytokine release and amplify inflammation. Joh et al (2011) 
found that ginsenoside Rb1 and its metabolite compound K could inhibit TNF-α, IL-1β, 
iNOS, and COX-2. The mechanism was revealed to be through the regulation of the 
NF-kB and MAPK pathways (245). 
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5.5.12 Discussion  
This review presents details of Panax ginseng’s effect on reducing inflammation and 
oxidative stress. The search identified diverse actions of Panax ginseng and 
ginsenosides and highlights key areas including modulation of inflammatory cells and 
mediators, reduction of oxidative stress, and regulation of their related pathways.  
   
TNF-α and NF-κB are intricately linked through bidirectional inducement (259). These 
factors play a significant role in the chronic inflammatory process seen in COPD. 
Cytokine inhibitors such as anti-TNF-α drugs are on the market and prescribed for 
chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease (57). 
For the treatment of COPD cytokine inhibitors are under investigation for use as drug 
therapy. The most promising targets are TNF-α inhibitors and IL-10 agonists (59). NF-
κB and MAPK are involved in the pathogenesis of COPD (260). From the studies 
included in this review, evidence suggests Panax ginseng can inhibit TNF-α and 
regulate several steps along the gene signalling and transcription pathway via inhibition 
of NF-κB and MAPK. Individual ginsenosides, Rb1, Rb2, Rc, Rg5 as well as whole 
Ginseng extracts can reduce TNF-α, IL- 4, 6, 8, 1β through deactivation of the NF-κB 
pathway and subsequent gene and/or protein transcription.  Panax ginseng also blocked 
other pathways including MAPK (245). The results show that Ginseng can reduce TNF-
α in experimental and clinical studies. This is significant as experimental research often 
does not hold up in the clinical setting. Compared to drug based cytokine inhibitors 
Panax ginseng may offer an advantage in that it is considered safe and well tolerated. 
Cytokine inhibitors impair defence mechanisms and often cause adverse effects such as 
hypersensitivity reactions, serious infections, and malignancies (59, 261).  
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Oxidative stress is increased in patients with COPD (262). Several antioxidants such as  
GSH and iNOS are under investigation for clinical use in COPD (59). Ginseng and 
ginsenosides may also be potent antioxidants with the ability to regulate 
oxidant/antioxidant imbalance and reduce cell apoptosis.  Ginsenoside Rg1 reduced 
ROS in vitro (232) and Kim et al reported a similar effect in a clinical trial (216). GSH 
which is an important antioxidant was reported to be increased by Ginseng in several 
studies. The specific cellular targets of Ginseng are still inconclusive however these 
important results indicate the need for further research.  
 
Panax ginseng regulates NF-κB, consequently regulating inflammation, oxidation and 
subsequent cell apoptosis and degradation of extracellular matrix. NF-κB promotes 
iNOS that produces nitric oxide and supports inflammation. Ginsenoside Rg1 increases 
and decreases nitric oxide (236, 241). Rg1 at 10 µg/mL induced vascular relaxation by 
increasing nitric oxide in one study and Rg1at 10 µM inhibited endothelial cell damage 
by reducing nitric oxide in another (236, 241). The variable outcomes may relate to 
differences in dosage of Rg1, or the chemical reagents used, or other unknown factors. 
At a low level nitric oxide is important for normal bodily functions however it is also a 
free radical. When secreted as an inflammatory response it can cause oxidative damage. 
Variable results in this example highlight the complexity of Panax ginseng’s effect and 
argue the need to undertake further studies to determine the precise mechanisms of 
action.  
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5.5.13 Limitations of the review  
Results were promising however, pathophysiological insight including specific cellular 
targets and explicit detail regarding Panax ginseng and ginsenosides function was 
limited. This detail would help to improve understanding in the future.  
 
5.5.14 Summary of findings 
Panax ginseng and ginsenosides exert complex actions. These actions are due to 
multiple ginsenoside compounds and multiple targets. The results from this review are 
diverse. Panax ginseng affects several processes including inflammation and oxidative 
stress by down regulating the activity of NF-kB and MAPK, reducing the activity and 
numbers of inflammatory cells including NK cells and lymphocytes, modulation of 
inflammatory mediators particularly TNF-α and IL-8, and reducing oxidative stress by 
reducing ROS and oxygen radical damage. The results showed the most beneficial 
effects through the inhibition of inflammation through TNF-α and NF-κB as well as 
improving antioxidant status.   
 
5.5.15 Conclusions and implications  
There is substantial evidence in the literature that Panax ginseng and ginsenosides are 
capable of reducing inflammation and oxidative stress. Much of the literature focuses on 
experimental studies however, there is also evidence from clinical trials. The results 
highlight the need for further investigation into Panax ginseng’s use in COPD in the 
view to develop new therapeutic treatments.   
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Chapter 6: A randomised controlled trial protocol on Panax ginseng for COPD 
 
6.1 Foreword 
The classical and modern literature reviews presented in Chapters 4 and 5 informed the 
design of the RCT protocol on Panax ginseng for COPD. The knowledge and insight 
generated from the reviews shaped a greater understanding on the topic and ensured the 
design and methodological undertakings would be to the highest quality. Previous 
shortfalls identified in the extant literature were addressed and new scope was created.   
 
6.2 Introduction  
Over the past two decades COPD has become one of the leading causes of death 
worldwide (14). The socio-economic impact of the disease is substantial, involving both 
direct costs to the individual and the healthcare system as well as indirect costs due to 
loss of productivity (4).  
 
Current conventional therapy for COPD offers only modest benefit and adverse events 
are common (1). Therefore, there is an unmet need to provide effective and safe 
medications that provide symptomatic relief and improve the quality of life (QoL) of 
sufferers.  
 
The RCT detailed in this chapter examines the efficacy and safety of a standardised 
Ginseng extract in the clinical management of patients with moderate COPD. The study 
is a multi-centre, randomised, placebo-controlled, double blind, and parallel clinical 
trial.  
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The trial will provide critical clinical data of the effect of Ginseng on QoL and 
pulmonary function. Findings from this study may lead to new therapeutic development 
for a range of chronic inflammatory diseases, particularly chronic respiratory diseases.  
 
The effect of Panax ginseng on COPD and related conditions has been evaluated in 
preclinical and clinical studies (Refer to Chapter 5). There is promising evidence of 
effect however previous clinical trials have been limited by methodological 
shortcomings including small sample sizes and unclear risk of bias (12, 201, 203).  
 
This chapter presents the design and methodology of the Ginseng for COPD clinical 
trial. The study is entitled ‘The effect of a standardised ginseng extract in patients with 
moderate COPD: a randomised, double blind, placebo controlled trial’, and the short 
title is ‘Ginseng extract and respiratory symptoms (GEARS)’. Recruitment began in 
October 2010 and will continue until December 2013. 
 
Study timeline: 
 Ethical approval, May 2010 
 Recruitment commenced, October 2010 
 Anticipated completion date, December 2013 
 Data analysis and dissemination of findings, June 2014 
 
The objective of the study is to evaluate the therapeutic value and safety profile of a 
standardised root extract of ‘Panax ginseng C.A Meyer’ for symptomatic relief, with a 
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focus on QoL improvements in individuals with moderate (Stage II) COPD. The full 
trial protocol has been published in an international peer-reviewed journal (11). 
 
6.3 Research funding 
The study is funded by a project grant from the National Health and Medical Research 
Council (NHMRC), project grant number 616609. The National Institute of 
Complementary Medicine (NICM) has also contributed to the funding.  
 
The Guangdong Provincial Academy of Chinese Medical Sciences and the Guangdong 
Provincial Hospital of Chinese Medicine, China, have provided additional funding 
through an international research grant.  
 
6.4 Ethical approval 
Ethics approval was granted from the Human Research Ethics Committees (HREC) of 
the participating clinical trial centres. Participating centres are the Austin Hospital, Box 
Hill Hospital, Northern Hospital and Frankston Hospital in Melbourne. Approval was 
granted in May 2010. The study was approved under the Streamlined Ethical Review 
Process (SERP). The SERP system was developed by the State government of Victoria, 
Australia to provide faster and more efficient ethical review for multi-site clinical trials 
(263). Austin Health was nominated as the reviewing HREC and individual site HRECs 
confirmed approval for conduct. The study also received full ethical approval from 
RMIT University’s HREC.  
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HREC reference numbers are: Austin Health HREC/10/Austin/8 (H2010/03892), 
Eastern Health E90/0910, Northern Hospital SSA/12/NH/12, Frankston Hospital 
SSA/12/PH72 and RMIT University E31/10. 
 
6.5 Trial registration 
The trial is registered with the Australian and New Zealand Clinical Trials Registry 
(ANZCTR Number: ACTRN12610000768099). Clinical trial notification has been filed 
with the Australian Government’s Therapeutic Goods Administration under the Clinical 
Trial Notification Scheme. 
 
6.6 Research team  
The research team consists of an international collaborative group with experts in 
Chinese medicine, respiratory medicine and clinical trials.  
 
6.7 Study justification 
There is an unmet need to optimise treatment of COPD, particularly for individuals with 
moderate COPD. Quality of life dramatically declines in sufferers and they often seek 
complementary and alternative therapies, including herbal medicine (7). Panax ginseng 
is an herbal medicine that may be effective for COPD. The evidence of Panax ginseng’s 
effectiveness in treating COPD symptoms is promising but not conclusive. A previous 
study suggested that Panax ginseng may be more effective than placebo for improving 
lung function and exercise capacity however the study was limited by methodological 
and design limitations (12).  
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6.8 Aims and hypothesis  
The specific aims are to evaluate the effectiveness of Panax ginseng for treating 
moderate COPD and to achieve symptomatic improvement, enhance QoL and 
determine the safety profile for this condition. 
 
It is hypothesised that Panax ginseng will alleviate some significant symptoms of 
COPD and improve QoL for individuals with moderate COPD. 
 
6.9 Research questions 
The research questions are: 
1. Does Panax ginseng produce beneficial effects/symptomatic relief in people 
with moderate COPD, in terms of improved QoL? 
2.  Does Panax ginseng produce beneficial effects in people with moderate 
COPD, in terms of improved respiratory function? 
3. Does Panax ginseng reduce the use of conventional symptom-relief 
medication in people with moderate COPD? 
4. With six months treatment and six months follow-up, what are the time 
courses of onset and persistence of any beneficial effects of Panax ginseng 
in people with moderate COPD? 
5. Does Panax ginseng have any adverse effects in people with moderate 
COPD, and if so, what is the nature of the adverse effect? 
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6.10 Trial design  
This study is a randomised, multi-centre, double blind, placebo-controlled, two-armed 
parallel clinical trial comparing a standardised Ginseng extract to placebo. The study 
will proportionately randomise 168 participants at a ratio of 1:1 into the Panax ginseng 
group or placebo group. The design of the study will integrate contemporary clinical 
research methodology in accord with principles set out in the Declaration of Helsinki 
and the Good Clinical Practice guidelines with the theory that guides the appropriate use 
of traditional Chinese medicine in clinical practice (264-266). 
 
6.10.1 Participants       
The trial centres will proportionately randomise volunteer participants from the local 
community in Melbourne, Australia.  
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6.10.2 Inclusion criteria  
Subjects must meet the following inclusion criteria to be eligible to participate. 
1. Both males and females aged 40 to 80 years (inclusive). 
2. Ex-smokers (ceased smoking at least three months prior trial entry), and agree to 
refrain from smoking throughout the trial.  
3. Satisfy the diagnostic criteria for moderate (stage II) COPD, defined by GOLD 
as post-bronchodilator spirometry, FEV1/FVC < 0.70 and FEV1 50%–80% 
predicted.  
4. Are clinically stable, that is, did not experience an acute infective exacerbation 
of COPD from at least 4 weeks prior to trial entry. 
5. Meet the Chinese medicine diagnostic criteria for Lung Qi deficiency or Lung 
and Spleen Qi deficiency. 
6. Give written informed consent to participate. 
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6.10.3 Exclusion criteria 
Subjects with any of the following exclusion criteria will not be eligible to participate.  
1. Current smokers.  
2. Those with a diagnosis of alpha–1 antitrypsin deficiency.  
3. A history of asthma or chronic systemic infections or inflammatory conditions in 
the last three months. 
4. Women who are pregnant or breast-feeding, or intending to become pregnant 
during the course of the study. 
5. Serious illnesses such as heart, liver or kidney disease. 
6. Individuals who are unable to adequately perform spirometry tests.  
7. Individuals taking long-term immunosuppressive agents or immune-stimulants. 
8. Individuals who have an allergic history to Ginseng products. 
9. Individuals currently using a Ginseng containing product or have used a Ginseng 
product within the last three months.  
10. Individuals currently using anticoagulants, anti-hyperglycaemics or monoamine 
oxidase inhibitor anti-depressants.  
11. Individuals who have undertaken pulmonary rehabilitation within three months 
of the commencement of the study, or intend to enter pulmonary rehabilitation 
during the study. 
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6.10.3.1 Chinese medicine diagnostic criteria 
Chinese medicine (CM) theory requires that, to be effective, its therapies must be 
individualised based on CM syndrome differentiation. Ginseng is prescribed for the 
CM syndromes of Lung Qi deficiency and Lung and Spleen Qi deficiency. It is likely 
that, in the absence of an acute exacerbation and exclusion of severe cases, under the 
CM syndrome framework, most individuals with moderate COPD would be classified 
as either Lung Qi deficiency or Lung and Spleen Qi deficiency.  
 
Participants must meet the CM syndrome criteria of Lung Qi deficiency or Lung and 
Spleen Qi deficiency. If they do not meet either of these they will not be eligible to 
participate. Table 44 presents the CM diagnositic criteria. 
 
Table 44: Chinese medicine diagnostic criteria of Lung and Spleen Qi deficiency 
Lung Qi deficiency Spleen Qi deficiency 
 Cough 
 Shortness of breath 
 Clear sputum 
 Wheezing 
 Catch a common cold easily 
 Difficult to recover from a common cold 
 Sweat easily 
 Tired or exhausted 
 Heavy limbs 
 Loss of appetite 
 Loose bowels 
 Headache or heavy head 
 Full in the stomach even without 
eating 
 
To determine the CM syndrome a qualified CM practitioner will examine the 
participant’s symptoms based on the CM Syndrome Differential Diagnosis Form and 
take a digital photo of the participants tongue. The tongue photo ensures a 
comprehensive evaluation of the individual in line with the traditional style of CM 
(Appendix 2).     
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6.11 Recruitment 
Departments of respiratory medicine at the participating hospitals will recruit 
participants. Methods of recruitment will include electronic and printed media 
promotion, advertising in clinic rooms, letters to general practice clinics and physician 
referrals [Table 45]. Examples of media promotion and advertising are displayed in 
Appendix 3. 
 
Interested individuals will telephone or email the trial co-ordinators at the 
corresponding hospitals for further information. Potential participants are sent a 
Participant Information and Consent Form (Appendix 4).  
 
Interested individuals will attend one of the hospitals for baseline assessment and 
preliminary screening for eligibility at visit 1. If the individual continues to stay stable 
in regards to their COPD during the 4 week run-in period they will be randomly 
assigned to one of the two treatment groups, Panax ginseng or placebo.  
 
Continued suitability requires that they do not experience an acute infective 
exacerbation of COPD during the run-in period and that their post-bronchodilator 
spirometry values stay within the moderate (Stage II) range. If an individual does not 
meet all of the inclusion criteria they will not be randomised and their participation in 
the trial will be discontinued. 
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Table 45: Media promotion and advertising  
 
Media type Source 
Newsletter  Australian Lung Foundation  
 Fifty Plus News   
 RMIT University updates (Email sent to RMIT staff) 
Web site  RMIT University www.rmit.edu.au/chinese-med/gears  
 Australian Lung Foundation (www.lungfoundation.com.au) 
 Trial spotting (www.trialspotting.com.au) 
 Google Adwords   
Newspaper  Local ‘Leader newspapers’  
 Herald Sun – Health noticeboard 
 The Senior 
 The Age 
Magazine  Nova Holistic Journal  
TV  Channel 7 News 
Radio  Eastern FM Radio 
 Plenty Valley FM Radio 
 Inner FM Radio 
 RPP FM 
 
6.11.1 Randomisation 
The study uses a simple randomisation ratio of 1:1. To minimise risk of imbalance 
between groups, two different sizes of block randomisation sequences will be used. The 
randomisation list is computer generated by an independent researcher and stratified by 
site. Treatment allocation numbers are entered into individually sealed opaque 
envelopes and provided to each site. At the time of randomisation, participants will 
draw an envelope. Each envelope contains a number that is concealed to the treatment 
allocation. A non-investigator independent at RMIT University holds the password 
protected list. In the event of an emergency medical situation, the participant’s 
randomisation code and group allocation can be identified. 
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6.11.2 Blinding  
This study is double blind in design. The randomisation sequence and allocation will be 
unknown to all study participants, research staff, investigators and pharmacists. The 
data will be analysed by blind assessors.  
 
At the final visit the credibility of participant blinding will be assessed by asking the 
question, ‘which treatment do you believe you have received, real, placebo or not sure?’  
 
6.12 Trial procedures 
Consenting eligible participants are enrolled for 52 weeks and will be required to attend 
6 visits in total. Figure 24 presents the participation flow chart.  
 
Trial phases:  
Phase 1: Four weeks run-in 
Phase 2: Twenty-four (24) weeks treatment  
Phase 3: Twenty-four (24) weeks follow-up 
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Figure 24: Participation flow chart 
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6.12.1 Initial assessment 
Individuals wishing to participate in the study will be assessed at one of the hospital 
trial sites. After signing the consent form, individuals will be assigned a participant 
number. 
 
Unique participant numbers combine the site initials, the site prefix number and a 
sequentially numbered suffix. For example, the first individual at the Austin Hospital 
will be assigned AH1001. Site initials and the prefix numbers are as follows: Austin 
Hospital (AH10xx); Box Hill Hospital (BH20xx); Northern Hospital (NH30xx); and 
Frankston Hospital (FH40xx). If an individual fails to be randomised the number will 
not be re-used.  
 
All trial information is recorded on the Case Record Form (CRF) (Appendix 5). The 
participant visit schedule is outlined in Table 46. 
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Table 46: Participant visit schedule 
Period Initial 
Assessment 
Randomisation Treatment Follow Up 
 
Visit 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
Week 
 
 
0 
 
4 
 
16 
 
28 
 
40 
 
52 
Procedures to be undertaken 
Informed consent ©      
Full medical assessment       
Current medication review       
Chinese medicine diagnosis       
Confirm eligibility © ©     
Smoking history and status © © © © © © 
Lung function testing 
(spirometry) © © © © © © 
Blood collection ©   ©   
Randomisation  ©     
Complete Case Record 
Form © © ©  ©        © © 
Symptom Assessment © © © © © © 
Dispense trial medication   © ©    
Dispense relief medication 
(if needed) © © © © ©  
Issue questionnaires 
(SGRQ, SF-36, CAT) © © © © © © 
Issue Questionnaire 
(Opinion of Chinese 
Medicine) 
     © 
Issue Participant Diary © © © © ©  
Review Participant Diary  © © © © © 
Current condition and 
medication review       
Individual conducting procedure: 
© - Trial co-ordinator  
 - Respiratory doctor 
 - Associate researcher  
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6.12.2 Screening  
Visit 1 (week 0) 
The initial assessment requires participants to perform a lung function test, have a 
sample of their blood taken and complete several questionnaires. These questionnaires 
are:  
 General information questionnaire  
 Screening questionnaire (Appendix 6) 
 St Georges Respiratory Questionnaire (SGRQ) (Appendix 7) 
 Short Form Health Survey (SF-36) (Appendix 8) 
 COPD Assessment Test (CAT) (Appendix 9) 
 Chinese medicine syndrome differential diagnosis form (Appendix 2) 
 
The study doctor will carry out a full medical assessment and review medications.  
Participants will be advised not to take certain COPD medications throughout the trial. 
These medications are presented in Table 47 and include short acting anti-cholinergics, 
long acting beta2-agonists, theophylline, inhaled corticosteroids (ICS) and combination 
ICS/beta2-agonists. Participants who are on any of these medications will be asked to 
discontinue use.  These medications are recommended for patients with more advanced 
COPD and with repeated exacerbations (1). To assess the potential safety and efficacy 
of Ginseng versus placebo it is necessary for participants to cease using ICS and certain 
long acting bronchodilator therapy. Cessation of medications will be done under the 
advice of a study doctor over a 24–48 hour period. Participants will be allowed to use 
Ventolin® as rescue medication throughout the trial. 
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Table 47: Medications not to be used throughout the trial 
Medication class Generic name Brand name  
Short acting anti-cholinergics Ipratropium  Atrovent 
Long acting β2-agonists Salmeterol 
Efermoterol 
Indacaterol 
Serevent 
Foradile/ Oxis 
Onbrez 
Methylxanthines Theophylline  Nuelin 
Inhaled corticosteroids (ICS) Budesonide 
Beclomethasone 
Fluticasone 
Ciclesonide 
Pulmicort 
Qvar 
Flixotide 
Alvesco 
Combination ICS/ β2-agonists  
 
Fluticasone/ Salmeterol 
Budesonide/Eformoterol 
Seretide  
Symbicort 
Oral corticosteroids  Prednisolone Panafocortelone/ Solone 
Monoamine oxidase inhibitors 
(anti-depressant) 
Phenelzine 
Tranylcypromine 
Nardil 
Parnate 
Anti-hyperglycaemic  Pioglitazone 
Glimepiride 
Rosiglitazone 
Glibenclamide 
Metformin 
Gliclazide 
Actos 
Amaryl 
Avandia 
Daonil, Glimel 
Diabex/Diaformin/ Glucophage 
Diamicron/ Minidiab 
Anti-coagulant Warfarin 
Phenindione 
Coumadin/ Marevan  
Dindevan 
Immunotherapy - - 
 
Participants will be dispensed Ventolin® to be used as ‘relief medication’ when needed. 
Participants will be given a diary to take home to complete details of their daily use of 
Ventolin® and/or any other concomitant medications (Appendix 10). After the initial 
assessment, the trial co-ordinator will inform the participants’ usual treating doctor of 
their participation in the study.  
 
6.12.3 Run-in period 
Participants will be required to undertake a four week run-in period prior to 
randomisation. This period will ensure participants are clinically stable in regards to 
their COPD and allow for baseline data gathering. If participants deteriorate during the 
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run-in period, that is, they have an exacerbation of COPD or there is a 4 point or more 
worsening of the SGRQ and/or deterioration in lung function (FEV1 greater than 12% or 
200 mL) they will be ineligible for randomisation. One further run-in period may be 
considered if a participants’ condition re-stabilises.  
 
6.12.4 Treatment phase 
Visit 2 (week 4) 
After the four week run-in period the participants will return for visit two. The trial co-
ordinator will confirm eligibility of the participant and they will be randomised. 
Participants will undergo lung function testing and complete the three questionnaires, 
SGRQ, SF-36, and the CAT.  
 
The participants will be dispensed their first pack of trial medication (sufficient for 12 
weeks) and the relief medication (if needed). The diaries from the run-in period will be 
collected.  Participants will be issued a new diary and they will be required to complete 
the diary every day after taking the trial medication and any other concomitant 
medications. Participants will be asked to return the completed diary and any leftover 
capsules at their next visit.  
 
Visit 3 (week 16) 
Similar to visit 2, at visit 3 the participants will undertake lung function testing and 
complete three questionnaires (SGRQ, SF-36 and the CAT). They will be given a new 
diary and dispensed the second pack of trial medication (sufficient for 12 weeks) and 
relief medication (if needed).  
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Visit 4 (week 28) 
Week 28 marks the end of the treatment phase. At visit 4 participants will undergo lung 
function testing and complete three questionnaires (SGRQ, SF-36 and the CAT). 
Additionally they will have a blood sample taken. They will not be dispensed any trial 
medication however they will receive a new diary to document concomitant medication 
use and dispensed relief medication (if needed).  
 
6.12.5 Follow-up phase 
Visit 5 (week 40) 
Participants will be required to undertake lung function testing and complete three 
questionnaires (SGRQ, SF-36 and the CAT). Participants will be given their final diary 
to document concomitant medication use and they will be dispensed relief medication 
(if needed).  
 
Visit 6 (week 52) 
The end of the follow-up phase and completion of the trial will be at week 52. At the 
final visit participants will be required to undertake lung function testing and complete 
three questionnaires (SGRQ, SF-36 and the CAT). They will also complete an 
additional questionnaire, ‘Participant opinion of Chinese medicine questionnaire’ 
(Appendix 11). 
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6.13 Treatment  
6.13.1 Intervention  
A standardised root extract of Panax ginseng will be used as the treatment. The extract, 
G115 and matching lactose-based placebo which is identical in appearance, taste and 
odour will be dispensed as 100 mg gel-filled capsules for oral intake [Table 48].  Two 
capsules will be taken daily, one with breakfast and one with dinner, for a total of 24 
weeks.  
 
Panax ginseng, G115 Ginsana™ is listed for use as an herbal medicine with the 
Therapeutic Goods Administration (TGA), Australian Register of Therapeutic Goods 
(ARTG), number 169069. 
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Table 48: Investigational product information, G115 and placebo 
Details Intervention Placebo 
Approved name Panax ginseng G115 extract  Placebo 
Trade name Ginsana™ G115  Not applicable  
Active 
compounds 
30–55% Panax ginseng extract 
(4% ginsenosides) 
Nil  
Excipients 2% silica colloidal anhydrous, 
43–68% lactose monohydrate, 
<2% mannitol 
Lactose monohydrate, silica 
colloidal anhydrous, lecithin, 
soya lecithin, wax mixture, 
rapeseed oil, ethyl vanillin, 
gelatine, glycerol 85%, iron 
oxide black, iron oxide red, 
dried substance from Anidrisorb 
85/70 (85% solution), soya-bean 
oil, soya oil 
Indications  No standard indications included 
on the TGA ARTG record 
Nil 
Usage Maintains stamina and 
endurance by improving the 
recovery rate after intense 
physical effort. A natural stress 
reliever of benefit during times 
of physical stress. Helps relieve 
nervous tension, anxiety and 
stress. Can increase the oxygen 
uptake capacity and reduce 
blood lactate levels. 
Nil 
Dosage regime 100 mg per capsule 100 mg per capsule 
Administration Oral, 100 mg (one capsule) 
twice daily 
Oral, 100 mg (one capsule) 
twice daily 
Known 
contraindications 
Hypersensitivity or allergy to 
any of the ingredients 
Hypersensitivity or allergy to 
any of the ingredients 
Known adverse 
effects 
Diarrhoea (from literature) Nil 
Concurrent drugs 
to be avoided 
Warfarin and monoamine 
oxidase inhibitors (from 
literature) 
Nil 
TGA ARTG: Therapeutic Goods Administration Australian Register of Therapeutic Goods 
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6.13.2 Dosage 
The dosage of G115 was determined by referencing previous clinical trials for the same 
indication (12, 203) and by recommendations from the manufacturer (267). Ginsana SA 
manufactures the standardised Panax ginseng extract, G115, and placebo in Switzerland 
(Appendix 12: Analytical reports of G115 and placebo). Each capsule contains 
approximately 4% (4 mg) ginsenosides, equivalent to dry root 212.5 mg. Table 49 
presents the specific ginsenoside content of G115 used in the clinical trial. The full 
method of extraction and the process of standardisation of Panax ginseng roots into 
G115 are not available outside of the company. However, the process follows Good 
Manufacturing Practice (GMP) [Table 50]. 
 
Table 49:  The ginsenoside content of G115 
Ginsenoside  % amount 
Rb1 0.91% 
Re 0.70% 
Rb2 0.65% 
Rc 0.60% 
Rg1 0.40% 
Rf 0.33% 
Rd 0.33% 
Rg2 0.08% 
Total ginsenosides 4.00% 
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Table 50: The process of standardising Panax ginseng into G115 
Step Process Method 
1 Cultivation 
Controlled cultivation and monitoring, 
including growing conditions and treatment 
after harvest. 
 
2 
Selection of raw material 
Roots aged 5–7 years are selected according 
to botanical and physical characteristics.  
The content of aflatoxins, heavy metals and 
pesticide residues are measured. 
3 Analysis 
A quali-quantitative determination of 
ginsenosides is measured using high 
performance liquid chromatography (HPLC). 
4 Extraction  
Hydro-alcoholic solvent: ethanol 96%: water 
(40:60 v/v). The ratio of the herb to extract is 
5:1. 
5 
Concentration  
 
After extraction a liquid extract is produced. It 
is concentrated and sterilised (UHT) and then 
spray-dried. 
 
The individual ginsenoside content is 
measured and checked for quality.  
6 
Standardisation 
 
Twenty-step standardisation process. 
Specific ginsenosides are not standardised 
however the total content of ginsenosides is 
adjusted to 4%. 
HPLC: high performance liquid chromatography,  UHT: ultra-heat treated 
 
6.13.3 Panax ginseng G115  
Routine quality control checks will be undertaken on the packaging and contents of the 
G115 batch to ensure stability and quality. G115 capsules and the placebo will be 
supplied in glass bottles containing 60 capsules per bottle and dispensed in two lots at 
visit 2 and at visit 3. Six bottles will be dispensed in total, three bottles each time.  
Figure 25 presents images of the study medication capsules and bottles.  
Figure 26 presents the study medication labels and Figure 27 shows the study 
medication being packaged and boxed for distribution to the trial sites. 
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Figure 25: Study medication capsules and bottle 
 
Figure 26: Study medication label 
 
Figure 27: Study medication packaged and boxed for distribution 
Source © Johannah Shergis 
KEEP OUT OF REACH OF CHILDREN 
 
Clinical Trial Medication 
Project Title:  GEARS 
Sponsor: RMIT University  
 
Ginseng or Placebo Capsules 100mg 
 
Instructions: Take one capsule in the morning with 
breakfast & one capsule with dinner (or as advised). 
 
Keep capsules dry, at room temperature 
 
Randomisation No: 001 
Bottle Number: 1/6 
Manufacturer: Ginsana SA Expiry: 12/2013  
Quantity: 60 capsules                       
 
From left, medications labelled and grouped and medications boxed for distribution.  
Source © Johannah Shergis 
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6.13.4 Other treatments  
Throughout the trial, participants will be supplied with a short acting beta2-agonist 
salbutamol, Ventolin®. This medication provides symptomatic relief and is used to 
provide rescue relief on an as needed basis. Ventolin® is a bronchodilator and rapidly 
opens the airways, giving relief from difficulty breathing. Table 51 presents the 
Ventolin® product information.  
 
Table 51: Ventolin® product information   
Items Details 
Active compound salbutamol sulfate 
Trade name Ventolin® 
Indication Relief of bronchospasm 
Dosage regime 1–2 inhalations every 4 hours if required (100 mcg per inhalation) 
Known 
contraindications 
Caution should be taken with patients with hypertension, 
hyperthyroidism, myocardial insufficiency, or diabetes mellitus. 
Known adverse 
effects 
Fine tremor, increase in cardiac output, tachycardia, increase in 
heart rate, headaches, nausea and palpitations. Potentially serious 
hypokalaemia may result from beta-2 agonist therapy. 
Concurrent drugs 
to be avoided 
Care is recommended if it is proposed to administer salbutamol in 
concomitant therapy with other sympathomimetic amines as 
excess sympathetic stimulation may occur. 
 
6.13.4.1 Dispensing medications 
The pharmacy departments of the participating hospitals will dispense medications. 
Participants are instructed to take one capsule twice daily, preferably with breakfast and 
dinner. The exact time of administration is not critical however participants are required 
to have a minimum of 4 hours between the two doses. The trial co-ordinators record 
compliance of medication dose on the ‘medication accountability form’ in the CRF. 
Participants will be given an information sheet detailing trial medication frequently 
asked questions (Appendix 13).  
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6.14 Outcomes  
6.14.1 Primary outcome measures 
The primary outcome measures are based on QoL improvement assessed using three 
validated questionnaires.  
1. St Georges Respiratory Questionnaire (SGRQ)  
2. Short Form Health Survey (SF-36) 
3. COPD Assessment Test (CAT) 
Participants will complete the three questionnaires at each visit, 6 times in total (Week 
0, 4, 16, 28, 40 and 52). 
 
6.14.1.1 St Georges Respiratory Questionnaire (SGRQ)  
This questionnaire was designed to measure health impairment in patients with COPD. 
It consists of two parts, part one covers the patients’ recollection of their symptoms and 
part two addresses the patients’ current state of health. The questions are weighted 
individually for scoring and higher scores indicate poorer QoL.  
 
The SGRQ is the standard COPD specific QoL questionnaire used in COPD trials. It 
has a higher discriminatory power in predicting lung function impairment (268). 
However, as it is disease specific it has limitations. 
 
6.14.1.2 Short Form Health Survey (SF-36)  
The SF-36 is used to assess more general QoL. It covers eight domains, broadly 
categorised as physical, emotional, general health and wellbeing. It also provides a 
summary of physical and mental health.  
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6.14.1.3 COPD Assessment Test (CAT)  
This questionnaire measures health status impairment in COPD. It consists of eight 
scaled questions and is a recommended tool to assess symptoms of COPD (1).  
 
6.14.2 Secondary outcome measures  
Secondary outcome measures include efficacy and safety components. 
1. Lung function using spirometry indices of FEV1 and FEV1/FVC ratio 
2. Use of relief medication short-acting bronchodilator (beta2-agonist salbutamol) 
3. Frequency, nature and severity of exacerbations 
4. Emergency department presentations and medical practitioner visits 
5. Full blood examination and blood biochemistry for liver and renal function 
6. Adverse events 
 
Relying on one outcome measure to demonstrate efficacy runs the risk of over 
interpreting the results of the study. Therefore, the secondary outcome measures were 
selected. Spirometry, is a standard measure of intervention efficacy for COPD (268). 
Measuring the amount of relief medication is an indirect measure of the efficacy of the 
intervention. It helps to validate the other outcome measures if they show a similar sort 
of response.  
 
Exacerbations and emergency visits are a major health burden in COPD and the 
evaluation of treatment effects will require this measure (1). Blood tests and monitoring 
adverse events are essential to assess safety.  
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Spirometry 
Spirometry will be conducted at all sites using the SpiroUSB™ and Spirometry PC 
software (CareFusion UK 232 Ltd) [Figure 28].  Participants will perform spirometry at 
each visit, 6 times in total (Week 0, 4, 16, 28, 40 and 52). 
 
The SpiroUSB™ spirometer is convenient to use and plugs into the USB port of a 
computer. This apparatus requires minimal maintenance and cleaning and is ideal for 
use in any setting (269). Standard operating procedures set out by the manufacturer will 
be followed at each site, including calibration. The predicted normal values will be 
referenced against NHANES III (270) as these values have been extensively used in 
clinical trials (271).  
 
Participants are advised not to take any inhaled respiratory medications for several 
hours prior to their spirometry testing, as this may alter the result. During testing, a 
participant places their mouth over the mouthpiece, takes a deep breath in, and then 
exhales forcefully and completely. Participants are required to complete three consistent 
blows and the ‘best blow’ is used. Two sets of blows are required, that is, pre-
bronchodilator and post-bronchodilator (10 to 15 minutes after 400 μg of inhaled 
Ventolin®, salbutamol). Results are recorded on the spirometry PC software where 
information is presented on the quality of blows, absolute values and flow-volume 
loops. A respiratory doctor will check the results at each visit. 
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Figure 28: SpiroUSB ™ user manual and spirometry equipment  
 
6.15 Adverse events  
Adverse events are documented in the CRF by the trial co-ordinators. Adverse event 
details will be scored by the trial co-ordinators using a three-point scale: 1 = mild, easily 
tolerated by patient, causing minimal discomfort; 2 = moderate, discomfort significant 
enough to interfere with daily activities; or 3 = severe incapacitating and/or requiring 
therapeutic intervention. Participants will be able to report adverse events anytime 
throughout the trial and will receive advice from the trial co-ordinators. However, they 
will be referred to their usual treating doctor for any treatment.  Serious adverse events 
(SAE) are defined as the potential to result in death, are life threatening, permanently 
incapacitating or resulting in hospitalisation. Serious adverse events will be reported to 
the HRECs, the manufacturer of the intervention and to the TGA.  
 
From left: SpiroUSB ™ user manual front cover and spirometry equipment including storage case, 
spirometry turbine, mouth piece and filter.  
Source © Johannah Shergis 
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Throughout the study period trial co-ordinators will contact the participant’s usual 
treating doctor to record relevant data on hospital presentations and exacerbations. 
 
6.15.1 Exacerbations 
Exacerbations of COPD have been defined by Anthonisen et al as at least a two day 
persistence of at least two major symptoms (such as worsening dyspnea and an increase 
in sputum purulence, volume, or both), or of any single major symptom plus more than 
one minor symptom (upper airway infection, unexplained fever, increased wheezing) 
(272). Change of medication may be necessary, including an increased dose and/or 
frequency of existing short-acting bronchodilator therapy, such as a beta2-agonist, and 
may include a dose of 30 to 40 mg prednisolone per day for 7 to 10 days. Evidence of 
bacterial infection such as increased sputum volume and purulence may indicate the 
need for antibiotics. 
 
If a participant experiences an exacerbation of COPD during the study they will be 
treated as deemed appropriate by their usual treating doctor. All relevant details will be 
recorded by the trial co-ordinators in the CRF. Following treatment for the exacerbation 
the participant will be expected to continue in the study. A review by the study doctor 
will be required if the participant requires the addition of new concomitant COPD 
medication that are listed as treatments not to be used throughout the study [Table 47]. 
They will also be reviewed if their use of the study medication is interrupted for more 
than three consecutive days. 
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6.16 Data collection and storage 
The research team will collect data and record results on the relevant questionnaires and 
the CRF. Source data will be entered onto Microsoft
®
 Excel spread sheets by staff 
blinded to group allocation. The data will then be prepared and entered into SPSS 
(IBM
®
 SPSS
®
 Statistics Version 20, 2010) for further analysis. For reporting purposes, 
de-identified and aggregated results will be used. 
 
Information collected for, and used in this study will be stored in secure facilities, in 
locked cabinets at the trial sites until the completion of the study.  After completion, all 
paper files will be stored in secure cabinets at RMIT University for 15 years. Electronic 
files will be held on RMIT University password protected computers for 15 years. All 
records will be disposed of after 15 years. The paper files will be shredded at a secure 
location, the electronic files will be erased permanently, and an appropriate IT expert 
will reformat the hard disk. 
 
6.17 Sample size calculation 
The sample size calculation has been determined on the basis of existing clinical data 
and power calculation. It is based on the effect size of QoL changes in COPD subjects, 
in an RCT of one of the most commonly used long-acting beta2-agonists  salmeterol 
(273). In the study, the mean score change on the SGRQ was significantly higher (p < 
0.05) in the treatment group (-6.8 ± 13.2) than in the placebo group (-1.4 ± 11.7). For 
the GEARS study, to achieve a similar difference between the Panax ginseng and 
placebo treatment groups with an 80% power and a two-tailed significance level of 5%, 
it is estimated that a sample size of 84 per group will be required, that is, 168 in total. 
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6.18 Withdrawal 
Participants may withdraw from the study for any reason, at any time, without 
repercussion. Investigators will only withdraw them if it is deemed medically unsafe for 
them to continue. Dropouts will not be replaced. 
 
6.18.1 Dropouts  
The research team will strive to minimise dropouts. Intention-to-treat analysis will be 
applied to minimise bias due to dropouts. Researchers will endeavour to limit false 
inclusions. Nevertheless, if they are included they will remain in the study and analysed 
in their original assigned groups irrespective of what occurred.  
 
6.18.2 Missing data 
An intention-to-treat analysis will be applied. Missing responses will be imputed using 
the last observation carried forward method. Missing data in the SGRQ and SF-36 will 
be dealt with using the standard method according to the developers’ instructions. 
 
6.19 Data analysis 
The trial data will be analysed by an independent biostatistician who will be blinded to 
the subject allocation. Data will be summarised as mean and standard deviations.  
 
Primary outcome measures, SGRQ, SF-36 and the CAT will be assessed at baseline, 
start of treatment, mid-treatment, end of treatment, mid follow-up and at the end of 
follow-up. Analysis of covariance with the baseline as covariate will be used to assess 
differences in treatment outcomes between the two groups at each of these time points. 
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To correct for inflated risk of Type 1 error, multiple comparison procedures suggested 
by Ludbrook et al will be used (274, 275). 
 
Comparability between baseline demographics in the two groups will be analysed using 
Chi-square or t-test and the number of adverse events will be analysed using Chi-
square. Baseline measures will be used as a covariate. Differences in outcome measures 
will be assessed between the two treatment groups using ANCOVA at four time points 
(mid-treatment, end of treatment, mid follow-up and at the end of follow-up). 
Probability value of less than 0.05 is considered statistically significant. 
 
The use of relief medication will be evaluated for its effect on the outcome measures as 
a covariate in the statistical analysis.  
 
A data safety and monitoring board has been established to assess the progress of the 
trial, particularly safety endpoints. 
 
6.20 Early termination of the trial 
The trial will be terminated if it becomes apparent that the treatment procedure is 
associated with any significant adverse events. Based on current literature, there is no 
evidence of significant adverse events associated with the use of Ginseng products 
(Refer to Chapter 3.7, Safety of Ginseng).  
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6.21 Reimbursements 
Participants will not be paid for any aspect of this research. The study medication, visits, 
and procedures will provided at no cost to the participant. Participants will be 
reimbursed for attending study visits. This includes parking, public transport and/or 
petrol costs.  
 
6.22 Reporting  
Reporting will be guided by the CONSORT statement (153) as well as its extension for 
herbal interventions (156). The results from the study will be presented at professional 
conferences and published in national and international peer-reviewed medical journals. 
 
A final report will be submitted to the funding bodies, the HRECs and the administering 
institution, RMIT University. 
 
6.23 Preliminary analysis of trial progress 
6.23.1 Recruitment  
The trial has been open for recruitment since October 2010. As of February 13, 2013 the 
following participants had been screened and recruited: 
 
Total screenings: 152 
Total randomisations: 45 
Total completions: 29 
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The screening to randomisation translation is approximately three to one. A brief review 
of the screen failures revealed the majority were unable to be randomised due to lung 
function being within the normal range, that is FEV1/FVC > 0.70.     
 
Enrolment has been steady, however, presupposed targets have not been met. Initially it 
was estimated six to seven participants would be randomised per month over 27 
months. Currently the average recruitment rate is 3 randomisations per month. 
 
Reasons for dilatory recruitment have not been fully defined. However, several reasons 
may have contributed. These are:  
 inclusion and exclusion criteria 
 availability of suitable participants 
 awareness of the study 
 
To remedy these inhibiting factors and expedite recruitment, discussions were 
undertaken within the research team. The main ideas to improve recruitment were to: 
 include new trial sites 
 obtain more referrals from general practitioner (GP) clinics 
 increase media presence 
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Changes have been implemented after discussions. Two new sites at the Northern 
Hospital and the Frankston Hospital will recruit participants. Melbourne and inter-state 
hospitals were examined for their suitability as new trial sites. These two sites have the 
best potential to meet trial requirements. They have large patient numbers and 
experienced research staff.  
 
Study doctors and local GP clinics have referred patients to the trial. Four patient lists 
have been supplied with over 400 names. Trial co-ordinators at the hospitals have 
followed up with these lists and it has translated into approximately 30 screenings. 
Additional GP clinics are being approached to refer patients and updated lists are being 
investigated.  
 
Advertising throughout 2010–2012 included an ad mixture of TV, newsletter, internet 
web sites, newspapers, and radio. The trial is ongoing, therefore the most effective 
recruitment strategy is unknown. Nevertheless, the majority of enquiries have come 
from the Channel 7 news story aired in June 2011. Table 52 presents the number of 
enquiries from different media. To increase media presence, newspaper and radio 
advertising is being implemented and several newspaper stories have been published in 
late 2012 and early 2013.   
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Table 52: Advertising enquiries from different media 
Media type Source Number of enquiries 
TV Channel 7 news 287 
Newsletters Australian Lung Foundation, Fifty Plus News 74 
Web sites RMIT University, Australian Lung Foundation, 
Trial spotting, Google Adwords   
32 
Newspapers Leader newspaper, the Herald Sun (health 
noticeboard), The Senior, The Age 
164 
Radio Eastern FM,  Plenty Valley FM and Inner FM  25 
 
6.23.2 Monitoring  
The hospital sites have been monitored throughout the trial. The trial co-ordinator at 
each site submits a fortnightly update including: 
 number of screening visits 
 number entered the  run-in phase 
 reasons for screen failures 
 number randomised 
 number of new enquiries 
 number of follow-up calls 
 number of return visits  
 other tasks, including advertising and community engagement 
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A communication strategy between the trial sites and administrating centre was 
discussed early. Regular telephone and email communication was part of the overall 
monitoring strategy and onsite visits were scheduled every two months. Four key areas 
were reviewed at the sites: 
 proper implementation of the protocol  
 review of standard operating procedures 
 adequate and accurate records 
 review of adverse events 
 
The funding bodies and the HRECs require annual reports. The funding bodies require 
information on the progress of the study, any changes to the research team or direction, 
and achievements related to the project. The HRECs require an annual report detailing 
the progress of the trial, any extensions required, any unanticipated issues, and 
assurance the study is being conducted in accordance with the protocol. Annual reports 
were submitted at the end of 2010, 2011 and 2012. A final report will be submitted at 
the end of 2013. 
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6.23.3 Serious adverse events  
As of February 13, 2013, seven serious adverse events had been reported.  All events 
required hospitalisation, however, no causal relationship between the events and the 
intervention were noted. Table 53 presents a summary of the serious adverse events.  
 
All events were reported to the relevant agencies, including the TGA, the HRECs, and 
the intervention manufacturer. In view of the nature of the events no further follow up 
was required. 
 
Table 53: Serious adverse event summary 
Event Length Reason for 
severity 
Outcome of 
event 
Causal 
relationship to 
intervention 
Brief description 
Dyspnea and 
left sided 
chest pain 
 
52 days hospitalisation  recovered no All tests were 
negative and there 
was no ischemia 
present.  
Perforated 
bowel 
3 days hospitalisation recovered no Perforated bowel 
post super-pubic 
catheter 
replacement. 
Pneumonia 
and 
exacerbation 
of COPD 
5 days hospitalisation recovered no Exacerbation of 
COPD and 
pneumonia. 
Acute 
respiratory 
infection 
2 days hospitalisation recovered no Acute infection of 
the lower 
respiratory tract and 
exacerbation of 
COPD. 
Mild stroke 3 days hospitalisation recovered no Tingling and 
weakness in the left 
arm. 
Creutzfeldt-
Jakob disease 
31 days fatal fatal no Deteriorating 
cognitive function, 
mobility and gait 
disturbance. 
Principal diagnosis 
on hospital report 
states Creutzfeldt-
Jakob disease.  
Pancreatitis 2 days hospitalisation recovered no Pancreatitis. 
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6.23.4 Ongoing monitoring and operation  
The trial has been conducted to the highest standards as per the protocol. Ongoing 
rigorous monitoring will ensure the protocol continues to be followed, and operation is 
successful. The key objectives for the coming year will require focused efforts on 
participant recruitment and completion of follow-up.    
 
6.24 Discussion 
Over the next decade, COPD will become the third most common cause of death 
worldwide (3). COPD is a disease of the elderly, and an ageing population is a 
significant factor in its increasing prevalence. Currently, conventional therapy for 
COPD is unsatisfactory. New therapies are being developed. However, there is a critical 
need to provide effective symptomatic relief and interventions that improve the QoL of 
sufferers (35).  
 
Ginseng may be beneficial for COPD sufferers in the mild to moderate stages, 
FEV1/FVC < 0.70 and FEV1 ≥ 50%. This group is often prescribed inhaled steroids 
without any evidence of benefit, but are at risk of long term side effects such as 
cataracts and osteoporosis (1). It is in this group of patients that the GEARS clinical 
trial may offer an alternative and safer treatment approach. The GEARS trial presented 
in this chapter examines the efficacy and safety of a standardised Ginseng extract for 
moderate COPD. The study employs rigorous RCT methodology with sufficient 
statistical power to detect any treatment effects.  
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This is the first trial of its kind in Australia with novelties in design and 
implementation. Novelties include WM diagnosis of COPD and a CM differential 
diagnosis as part of the inclusion criteria. Additionally QoL and lung function are being 
evaluated together which has not been examined in previous Ginseng studies and 
recruitment will be through multiple hospital sites. 
 
6.24.1 Challenges 
Researchers often face additional challenges when conducting herbal medicine studies 
(276). Researchers in the GEARS study addressed and overcame common challenges, 
discussed below. 
 
6.24.1.1 Managing bias and confounding 
The researchers have strived to minimise bias in the trial design. Selection bias has 
been minimised by generating the random sequence by computer and allocation 
concealment has been maintained using opaque sealed envelopes. Blinding of 
participants, personnel and outcome assessment is also ensured. The study will be 
analysed by intention-to-treat. Confounding factors are minimised by the selection 
criteria. Participants with moderate COPD are selected according to lung function as 
per the GOLD standard of classification. Other stages of COPD i.e., severe or very 
severe were not selected as they are often taking corticosteroids and the intervention 
Panax ginseng may not be suitable for these cases. Individuals with other severe 
medical disorders were excluded as these disorders may affect their QoL independent 
of COPD. Concomitant medications such as corticosteroids and some bronchodilators 
may confound results and were therefore not allowed during the study.  
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6.24.1.2 Quality interventions 
Ensuring quality herbal medicine interventions can be difficult due to the paucity of 
standardised herbal extracts. Additionally, many herbal studies use a combination of 
substances that are difficult to standardise. Conflicting findings in previous Ginseng 
clinical trials may be attributed to inconsistency in the quality of the Ginseng products 
investigated. In the GEARS study a quality certified internationally recognised 
standardised Panax ginseng extract (G115) is used.  
 
6.24.1.3 Placebo 
The placebo must match the intervention. The manufacturer of the trial intervention 
developed the placebo in the GEARS study. Encapsulating the herbs in gel not powder 
ensured better consistency between the capsules and maintained the integrity of 
blinding.  
 
6.24.2 Limitations 
This study employs several outcome measures to evaluate the diverse aspects of the 
disease. However there is a risk of data dredging with an emphasis on the most 
statistically impressive findings (277). To counter multiplicity issues the statistical 
analysis will be properly handled through pre-planned evaluation to limit bias of results.  
 
The CM syndrome differentiation is not as comprehensive as that in the clinical setting. 
The CM practitioner performing the diagnosis is not face to face with the participants 
and the diagnosis is based on a form and a photo of the tongue. Although the cameras 
used are of the highest quality, some textural components may be lost in the image.  
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6.24.3 Progress 
The GEARS clinical trial has been implemented for the last 2 years. Over this period 
the project has proceeded on schedule. The trial co-ordinators at each site have 
undertaken their day-to-day duties under the monitoring and guidance of the lead 
institution, RMIT University.  
 
There have been no major emerging issues and the project has been conducted in 
compliance with the protocol. The procedures and the direction of the project have 
remained on task. Recruitment has been laggard however new strategies have been 
implemented (Refer to Chapter 6.23.1 Recruitment). 
 
One protocol amendment was required soon after recruitment commenced. The initial 
protocol excluded individuals taking antidepressant medication. This exclusion was 
built into the protocol due to previous reports of interactions between Ginseng and 
phenelzine, a monoamine oxidase inhibitor antidepressant (98, 99). On review of 
participant recruitment, several individuals were taking antidepressant medications and 
were subsequently excluded. The research team considered this exclusion was 
unnecessarily restrictive. Several experts were consulted including an herbal 
pharmacologist, Ginseng experts and respiratory physicians to review the 
appropriateness of exclusion of antidepressant medication users. No reports or concerns 
were raised for potential interaction between Ginseng and other classes of 
antidepressants, for example selective serotonin reuptake inhibitors and tricyclic 
antidepressants. It was concluded that individuals taking monoamine oxidase inhibitor 
antidepressants would be excluded however, individuals taking any other class of 
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antidepressants would be eligible to participate. The HREC approved the protocol 
amendment in March 2011. 
 
6.25 Conclusions 
Upon successful completion, this trial will provide critical clinical data and build on 
previous RCTs and systematic reviews to answer the research questions in determining 
the efficacy and safety of Panax ginseng for moderate COPD. The study was designed 
by a multidisciplinary and international collaborative team and provides a novel 
approach in integrating rigorous RCT methodologies and theory that guides appropriate 
use of CM for translation into clinical practice. Findings from this study may lead to 
new therapeutic development for a range of chronic inflammatory diseases, particularly 
chronic respiratory diseases. 
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Chapter 7: General discussion and conclusions 
 
7.1 Overview 
COPD is one of the major health challenges in the developed and developing worlds 
(14). Despite a decline in cigarette smoking, the burden of COPD is likely to increase 
for some years (14). An ageing population means prevalence and health care costs will 
continue to rise.   
 
Treatment options for COPD are still relatively limited and patients continue to 
experience poor QoL. Therefore, there is an unmet need for new therapeutic treatments 
for patients with COPD.  
 
Panax ginseng is known as a “precious tonic”, with particular benefits for lung and 
digestive functions. It has been used over centuries for improving stamina and vitality. 
In addition, clinical observation indicates potential benefit for patients with COPD. 
 
Pre-clinical investigations showed Panax ginseng possesses a range of pharmacological 
actions such as anti-inflammatory and anti-oxidative stress (Refer to Chapter 5.5). 
Current clinical evidence is promising, however there is an overall paucity of high-level 
clinical evidence that supports the routine use of Panax ginseng for moderate COPD 
patients.  
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This research investigated the use Panax ginseng for COPD by: 
 Searching and analysing the classical Chinese literature to identify references to 
formulae and herbs used to treat conditions consistent with COPD. 
 Evaluating the systematic review literature for Panax ginseng.  
 Systematically reviewing the English and Chinese literature for Panax ginseng 
in RCTs. 
 Reviewing the literature specific to Panax ginseng’s potential pharmacological 
mechanisms relevant to COPD. 
 Designing and implementing an RCT to determine the efficacy and safety of 
Panax ginseng for COPD. 
 
The research presented in this thesis employs a “whole evidence” approach to 
systematically searching, reviewing and analysing traditional and modern literature to 
identify candidates for further therapeutic evaluation. Through this process, critical data 
will be gathered to determine the role of one of the most commonly used herbs, Panax 
ginseng, in the management of COPD.  
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7.2 Summary of the research 
7.2.1 Summary of classical literature on Chinese herbal medicine for COPD 
The classical literature was searched and analysed to reveal citations of Chinese herbal 
medicine (CHM) for COPD. The Zhong Yi Fang Ji Da Ci Dian (ZYFJDCD) 
compendium was searched and 1,557 citations were extracted. After data checking and 
exclusion of irrelevant entries and repetitions, 1,147 citations were analysed. Nine 
hundred and two (902) formulae and 426 different herbs were identified. The search 
terms ke chuan ‘cough and dyspnea’ and chuan zheng ‘dyspnea’ located the most 
citations, 566 and 413 respectively.  
 
When the formulae were ranked, 141 were broadly consistent with COPD. Twenty-five 
(25) citations had a global score of 4, that is ‘most likely COPD’ and the remainder 
were, ‘possibly COPD’ (n=735), ‘other diseases unlike COPD’ (n=311), ‘possible 
complications of COPD’ (n=27), and ‘not enough information to decide’ (n=49).  
 
The three most frequently cited formulae were Shen qi wan, Mai men dong tang and 
Xiao qing long tang. The frequently cited herbs were xing ren, ban xia, ren shen, kuan 
dong hua and sang gen bai pi. 
 
These results indicate that the use of formulae and herbs in the classical literature is 
similar to what is used in the modern setting. This research provides a novel approach 
and rationale for identifying formulae and herbs from classical literature. The method 
and results are in the process of being written up for submission to an international peer 
review journal (Refer to Publications, Manuscripts in preparation, number 1). 
237 
 
7.2.2 Summary of the overview of systematic reviews 
Search and evaluation of the extant systematic review literature on Panax ginseng was 
conducted. Two hundred and forty-five (245) articles were located and 13 systematic 
reviews were eligible. The systematic reviews showed promising results for several 
health conditions including disorders of glucose metabolism, angina pectoris, lung 
function, and erectile dysfunction. However the extant literature does not establish the 
efficacy of Panax ginseng for a particular health condition or indication. It does appear 
to have a sound safety profile and is rarely associated with adverse events or drug 
interactions. 
 
The overview of systematic reviews identified that Panax ginseng research is diverse 
yet often conducted using less than rigorous methods. Rigorous clinical trials focusing 
on specific conditions and indications are needed to further investigate Panax ginseng’s 
evidence of efficacy. 
 
7.2.3 Summary of the systematic review on Panax ginseng in RCTs 
Panax ginseng has been extensively researched in RCTs. The systematic review 
evaluated Panax ginseng for any type of health condition, aiming to summarise the 
current evidence, evaluate the methodological quality and risks of bias and identify 
promising areas for future research.  
 
Searches of English and Chinese databases revealed 1,778 potentially relevant studies, 
with 67 meeting the inclusion criteria. Thirteen (13) broad health areas were evaluated, 
these were psychomotor performance, physical performance, circulatory conditions, 
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glucose metabolism, respiratory conditions, erectile dysfunction, immunomodulation, 
quality of life and mood, anti-oxidant function, cancer, menopausal symptoms, dry 
mouth, and ulcerative colitis. Data synthesis was limited due to heterogeneity between 
studies and the planned met-analysis could not be performed.  
 
The systematic review is the most comprehensive and up-to-date. Panax ginseng 
appeared to have some positive therapeutic effects. However, caution needs to be taken 
when interpreting results due to poor methodological quality and risks of bias, 
particularly for random sequence generation and allocation concealment. The most 
promising evidence supports Panax ginseng for use in moderating the immune 
response, particularly cell-mediated immunity with implications for chronic respiratory 
diseases. Panax ginseng has a good safety profile with limited minor adverse events and 
no serious adverse events reported. Future clinical studies should focus on the most 
promising outcomes identified in this review. Quality methodology and standardised 
Ginseng products should be used and particular attention should be given to elucidating 
the mechanisms of action for specific conditions such as chronic respiratory diseases.   
 
This systematic review was published in an international peer review journal (11). The 
review of methodology was published separately (278).  
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7.2.4 Summary of Panax ginseng’s effect on reducing inflammation and oxidative 
stress and its prospective as a treatment for COPD  
Panax ginseng and its active constituents, ginsenosides, exert diverse actions. The 
experimental and clinical trial literature was analysed to explore Panax ginseng’s effect 
on reducing inflammation and oxidative stress with a focus on research relevant to 
COPD.  
  
The search identified 880 studies, 35 met the inclusion criteria. Fourteen (14) were in 
vitro, 10 in vivo and 11 were RCTs.  Panax ginseng was found to have several effects 
including modulation of inflammation and oxidative stress by down regulating the 
activity of NF-kB and MAPK, reducing the activity and numbers of inflammatory cells 
including NK cells and lymphocytes, modulating inflammatory mediators particularly 
TNF-α and IL-8, and reducing oxidative stress by down regulating ROS and oxygen 
radical damage. Panax ginseng showed its most beneficial effects by inhibiting 
inflammation through TNF-α and NF-κB as well as improving antioxidant status. These 
results highlight the need for further investigation into Panax ginseng’s use in COPD 
with the view to develop new therapeutic treatments.  
 
The research is in the process of being written up for submission to an international peer 
review journal (Refer to Publications, Manuscripts in preparation, number 2). 
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7.2.5 Summary of a clinical trial protocol on Panax ginseng for COPD  
There is an unmet need to optimise treatment for COPD, particularly for individuals 
with moderate COPD. The GEARS study is a randomised, multi-centre, double blind, 
placebo-controlled, two-armed parallel clinical trial comparing a standardised Panax 
ginseng extract to placebo. 
 
The literature reviews presented in Chapters 4 and 5 informed the design of the GEARS 
study, which addresses methodological issues identified and creates new scope. The 
study received ethical approval in May 2010 and recruitment commenced in October 
2010 (ANZCTR registration number: ACTRN12610000768099). Currently 152 
individuals have been screened for the study and 45 participants have been randomised. 
The anticipated completion date is in December 2013 with analysis and dissemination 
of findings by June 2014. 
 
This is the first trial of its kind in Australia. The study was designed by a 
multidisciplinary and international collaborative team and provides a novel approach by 
integrating rigorous RCT methodologies and theory that guides appropriate use of CM 
for translation into clinical practice. Findings from this study may lead to new 
therapeutic development for a range of chronic inflammatory diseases, particularly 
chronic respiratory diseases.  
 
The clinical trial protocol was published in an international peer reviewed journal 
(279).  
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7.3 Overall strengths of the research  
Structured research aids in informing choices and facilitating quality results. This 
research was informed by searching and evaluating the modern and classical literature 
and using the information gathered to help design a rigorous clinical trial. The specific 
approach was to evaluate the state of the current evidence including a search and 
analysis of the classical literature, an overview of systematic reviews, a systematic 
review, a review of the mechanisms of action of the test intervention (ginseng), and a 
clinical trial.    
 
This study identified gaps in the literature and weaknesses in the existing trials and 
facilitated the refinement of the methodology for the clinical trial. The clinical trial is of 
the highest standard with the intent to limit biased estimates of treatment effect. The 
trial evaluates 6 months of treatment and 6 months of follow-up. It is important to 
evaluate the time course of effects in a chronic disease like COPD. The outcomes were 
selected in accord with international recommendations and specifically address 
shortfalls in the design of previous studies (1, 12, 268).  
 
Herbal medicine RCTs can be challenging due to herbal compounds often lacking 
quality control standards and variable constituents (228). The GEARS trial used an 
internationally recognised and standardised Panax ginseng extract. The extract, G115 
has been used in over 24 RCTs and is considered the best quality standardised product 
for research and clinical use (90).  
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Reviewing the extant literature enhanced the design of the clinical trial and directly 
contributed to the evidence on Panax ginseng and the relevance of its use in COPD. The 
findings are reliable and conclusions valuable for both the research and clinical settings.    
 
7.4 Overall limitations of the research  
The reviews only included English and Chinese language studies. Studies in other 
languages are not included. To overcome this, planned future reviews of the Korean 
literature may help to make firm conclusions about Panax ginseng’s efficacy and safety 
in treating various health conditions.  
 
The methodological component of the systematic review may be limited by 
retrospectively analysing studies using new evaluation tools, such as the Cochrane risk 
of bias tool and the CONSORT statements. This is difficult to prevent and results were 
therefore interpreted with caution to overcome this limitation.   
 
Classic literature searches are productive if the disease has comparable classical terms. 
The terms used in this review were the best match, however citations may have been 
missed or incorrectly excluded due to terminology variations.   
 
When reviewing and discussing the potential mechanisms of action of Panax ginseng 
and the relevance to the treatment of COPD, the search may have missed some studies 
as the pathophysiology of COPD is yet to be fully elucidated. Results were promising 
but pathophysiological insight regarding the functions of Ginseng and ginsenosides is 
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not fully understood. Future studies will aid in improving understanding and 
overcoming the limitations of previous research. 
 
The GEARS clinical trial was not preceded by a pilot study. Although this was not 
essential it may have aided in polishing the protocol and testing feasibility. This may 
have highlighted potential issues and given a better understanding of the participant 
population and ability to achieve recruitment. In addition, the delivery of Panax ginseng 
alone and not in combination with other herbal medicines is not the typical style of 
herbal prescription in China.  The results from the clinical trial may have limited 
immediate applicability, however understanding the effect of a single herb is essential in 
developing effective formulations in future research.     
 
7.5 Implications for future research 
Future research will be enhanced by understanding the limitations and reflecting upon 
existing trials. The strategy for future studies should be focused on the most promising 
outcomes identified in the systematic review presented in Chapter 5. Rigorous 
methodology and standardised Ginseng preparations should be used and particular 
attention should be paid to designing adequately powered trials.  
 
The activity of Panax ginseng and ginsenosides is diverse. Evidence suggests Panax 
ginseng is capable of regulating inflammation and oxidative stress, however, the 
mechanisms of action have not been fully established. There is a need for further 
investigation into Panax ginseng’s use in COPD with the view to develop new 
therapeutic treatments.  
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Other areas of future research should include improving understanding of the best route 
of administration of Panax ginseng, establishing the most effective dose and selecting 
the relevant end points to establish efficacy.  
The clinical trial presented in Chapter 6 represents a quality RCT on herbal medicine. 
The study protocol has been published and other researchers may use this study as a key 
reference. Since publication, new trials have emerged that are similar in design to the 
GEARS study (280).  
 
7.6 Implications for clinical practice 
COPD is a significant health burden leading to reduced QoL. The findings of this study 
will contribute to the use of Panax ginseng for COPD in the clinical setting. The 
research will improve clinical practice, assist in the development of scientific 
investigation of CM, and facilitate evidence-based medicine to improve health 
outcomes. 
 
The results from the clinical trial, when available, will contribute towards the 
determination of the efficacy and safety of Panax ginseng that will inform future use of 
herbal medicine for COPD sufferers. Translation of results from this thesis into clinical 
practice is reliant on the dissemination of findings. Several publications have arisen and 
more are in the process of being finalised. This thesis is comprehensive, it includes 
reviews of both modern and classical literature that adds weight and verifies the use of 
Panax ginseng for COPD. This is further enhanced by the GEARS clinical trial that is 
methodologically rigorous.  
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7.7 Overall conclusions 
This thesis evaluates Panax ginseng and its potential efficacy and and safety for COPD. 
The systematic review was conducted under the Cochrane systematic review guidelines 
and the design of the clinical trial was conducted in accord with the principles set out in 
the Declaration of Helsinki and the Good Clinical Practice guidelines. The work 
emerged in a stepwise fashion, starting with the evaluation of the extant modern and 
classical literature. This evaluation informed the design of the clinical trial, addressing 
limitations in previous studies. Although there is extensive literature, methodological 
flaws often limit the generalisability and applicability of the results. Outcomes from this 
study highlight the importance of improving standards and reporting in future research 
on CM. The body of evidence would be improved by rigorous evaluation of existing 
evidence and quality clinical trials focusing on specific health conditions and 
indications. The clinical trial will provide critical clinical data and build on previous 
RCTs and systematic reviews. Although the RCT results are not yet available, the 
rigorous design foreshows successful completion and significant contributions to the 
development of an evidence base for Panax ginseng in treating COPD.  
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Appendices 
Appendix 1: Data extraction form for the systematic review 
Part A: Demographic characteristics of studies 
Item Details 
First author  
Year of publication  
Country where study was conducted  
Title  
Source of participants  
Trial design  
Condition treated  
Total number of participants  
Number of participants - Treatment group 
(Randomised/Analysed) 
 
Number of participants – Control group 
(Randomised/Analysed) 
 
Number of Male / Number of Female  
Age range and/or mean ± SD (years)  
Part B: Intervention and outcome characteristics of studies 
Study intervention        
Control intervention  
Administration type (e.g., capsules, power)  
Dosage  
Treatment duration and follow-up  
Outcomes  
Results, mean and standard deviation or number of events  
Adverse events  
Authors’ conclusions  
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Appendix 2: Chinese medicine syndrome differential diagnosis form 
Key:  0= None (does not have this symptom) 
1= Mild (symptom present once in a while but does not effect daily life) 
2= Moderate (symptom can cause an inconvenience to daily life) 
3= Severe (symptom effects the performance of daily duties) 
In the last one year; 
Severity 
(Trial coordinator 
to complete) 
Differentiation  
(Chinese medicine 
practitioner to complete) 
0 1 2 3 
1.  Have you had a cough?      
Lung Qi 
deficiency? 
(tick ) 
 
(   ) Yes 
 
(   ) No 
 
2.  Have you had wheezing?     
3.  Have you had shortness of breath at any time?     
4.  Have you had clear sputum?     
5.  Have you had white sputum?     
6.  
 
Did you catch a cold and/or was it difficult to recover from a 
cold? 
    
7.  Have you found that you sweat easily, even when you are not 
doing exercise? 
    
8.  Have you had headache or felt a heavy headed?     Spleen Qi 
deficiency? 
(tick ) 
 
(   ) Yes 
 
(   ) No 
 
9.  Have you felt tired or exhausted?     
10.  Have your limbs felt heavy?     
11.  Have you had a poor appetite?     
12.  Have you had loose bowel motions?     
13.  Have you felt full in the stomach even when you hadn’t just 
eaten? 
    
14.  Have you felt aversion to the cold?     Kidney Qi 
deficiency? 
(tick ) 
 
(   ) Yes 
 
(   ) No 
 
15.  Have your limbs felt cold?     
16.  Have you felt weak, especially in the lower back area, or the 
knees? 
    
17.  Have you frequently (>2 times) woken in the night to go to the 
toilet? 
    
18.  Have you felt short of breath after slight exercise?     
Tongue 
Provide details if the subject has taken food/drink within 2 hours prior to examination:  
(Trial coordinator to complete)_____________________________________________________________ 
 
Tongue observation: (Chinese medicine practitioner to complete).  
Colour:__________Coating:___________Shape:___________Texture:___________Other:_________  
 
 
 
 
 
 
Chinese Medicine Syndrome Differentiation: Tick () 
 
(1)  Lung Qi Deficiency  (2)  Lung & Spleen Qi Deficiency  
(3)  Other (specify)_______________________________________________________ 
Diagnosis completed By: __________________________________ 
Signature: ______________________________________________ 
Date: __________________________________________________ 
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Appendix 3: Media promotion and advertising for the GEARS clinical trial 
Appendix 3.1: ‘The Senior’ Newspaper 
 
 
 
 
 
 
 
 
Appendix 3.2: ‘Nova Holistic’ Magazine 
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Appendix 3.3: ‘Diamond Valley and Heidelberg Leader’ Newspaper 
 
 
Appendix 3.4: ‘Channel 7 News’ 
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Appendix 3.5: ‘The Age’ Newspaper Advertising  
 
 
 
 
 
Appendix 3.6: ‘Whittlesea Leader’ Newspaper Advertising 
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Appendix 4: Participant information and consent form 
 
                                                                                           
PARTICIPANT INFORMATION AND CONSENT FORM (PICF) 
 
Version: 6.0 dated 29.09.2010 
 
 Participant number:________ 
 
                  
Short Title (Acronym): Ginseng Extract And Respiratory Symptoms 
(GEARS) 
 
 
PROJECT TITLE: The effect of a standardised ginseng extract in patients with moderate 
chronic obstructive pulmonary disease (COPD): a randomised, double blind, placebo controlled 
trial 
 
PRINCIPAL INVESTIGATORS:     
Dr. Christopher Worsnop (Respiratory and Sleep Physician, Austin Health) 
A/Prof. Frank Thien (Head, Respiratory Medicine, Box Hill Hospital) 
A/Prof. David Langton (Director, Thoracic and Sleep Medicine, Frankston Hospital) 
 
OTHER PROJECT CHIEF INVESTIGATORS: 
Professor Charlie Xue (Director, TCM Research Program, RMIT University) 
Dr Tony Zhang (Research Fellow, TCM Research Program, RMIT University) 
 
 
This Participant Information and Consent Form is 11 pages long. Please make sure you have 
all the pages. 
 
1. Introduction 
You are invited to take part in this research project. This is because you have Chronic 
Obstructive Pulmonary Disease, including Chronic Bronchitis and Emphysema. The research 
project is testing a new compound for Chronic Obstructive Pulmonary Disease. The new 
compound is a standardised Ginseng extract, called Ginseng G115 and comparing it to a 
placebo (a look alike inactive medication). 
 
This Participant Information and Consent Form (PICF) tells you about the research project. It 
explains the tests and treatments involved. Knowing what is involved will help you decide if you 
want to take part in the research. Please read this information carefully. Before deciding 
whether or not to take part, you might want to talk about it with a relative or friend. If you have 
questions about anything that you don’t understand or want to know more about, please ask 
the study doctor or research staff. Participation in this research is voluntary. If you don’t wish to 
take part, you don’t have to. You are also free to leave the study at any time. If you decide you 
want to take part in the research project, you will be asked to sign the consent section. By 
signing it you are telling us that you: 
 
 Understand what you have read; 
 Consent to take part in the research project; 
 Consent to have the tests and treatments that are described; and 
 Consent to the use of your personal and health information as described. 
You will be given a copy of this Participant Information and Consent Form to keep. 
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2. What is the purpose of this research? 
 
The aim of this project is to investigate the effectiveness and safety of a standardised Ginseng 
extract, with the focus being on quality of life improvements in adults with moderate Chronic 
Obstructive Pulmonary Disease.  
 
There are an increasing number of Chronic Obstructive Pulmonary Disease sufferers in 
Australia. Current treatments aim to relieve and control symptoms and to reduce complications. 
However, many people still have reduced quality of life. There has been a lot of interest in 
complementary / alternative medicine (CAM) especially herbal medicine for managing Chronic 
Obstructive Pulmonary Disease. Despite a long history of use and much research into herbal 
medicines, there is not much research into how effective they are in many conditions, including 
the use of Ginseng for people with Chronic Obstructive Pulmonary Disease. This research will 
test whether the standardised Ginseng extract compared to a placebo improves lung function, 
reduces the use of usual medications, as well as improves the quality of life in people with 
moderate Chronic Obstructive Pulmonary Disease. Many clinical studies looking at the safety of 
Ginseng have shown that, if taken at the recommended dosage, Ginseng is safe and does not 
have any significant side effects. Ginseng has been listed with the Therapeutic Goods 
Administration (TGA) for public use in Australia since 2002 as a medicine/herbal product (Aust 
L14987), for maintaining stamina and endurance by improving the recovery rate after intense 
physical effort. It helps to relieve nervous fatigue, tension, anxiety, stress and can increase the 
oxygen uptake capacity. It also improves vitality and general quality of life. However, it is 
considered an experimental treatment, and it is not an approved treatment for Chronic 
Obstructive Pulmonary Disease.  
 
If you take part in this research you will be one of the 168 participants. 84 people are expected 
to participate at Austin Health and 84 people are expected to participate at the Box Hill Hospital. 
You will have a 50/50 chance of being randomly assigned to either the active Ginseng group or 
the placebo (non-active study medication) group. This design allows us to compare the 
therapeutic effects of the active treatment with the placebo treatment and make sure changes 
are not just happening by chance. If the results of this study show that Ginseng is effective in the 
treatment of moderate Chronic Obstructive Pulmonary Disease, then we will be happy to provide 
the same dose and duration of real treatment (24 weeks) free of charge to those in the placebo 
group, at the completion of the study including data analysis for all participants (i.e., from the 
beginning of 2013 based on current study plan). 
 
During the 24-week treatment phase of your participation in the study, you will either receive 
Ginseng 100mg capsule or identical placebo capsule, twice daily for 24 weeks, followed by 24 
weeks of follow-up, without study medication. 
 
This study is being conducted by the Traditional & Complementary Medicine Research Program 
at RMIT University’s Health Innovations Research Institute, the Respiratory and Sleep Medicine 
Department of Austin Health and the Respiratory Medicine Department of the Box Hill Hospital. 
This research is funded by a Project Grant from the Australian Government’s National Health 
and Medical Research Council (NHMRC) and a Development Grant from the Australian 
National Institute of Complementary Medicine  (NICM). The results of this research will be 
used by the student researcher Johannah Shergis for her Doctor of Philosophy (PhD) degree. 
No member of the research team will obtain any financial benefit from their involvement in this 
project (other than their ordinary wages).  
 
3. What does participation in this research involve? 
 
If the study is suitable for you, you will be asked to attend one of the two study sites/hospitals, 6 
times in total over 52 weeks. 
 
Visit 1-Initial assessment: (this will take approximately 1.5 hours) It will involve discussion 
about the study and signing of the consent form. You will be asked to complete a screening 
questionnaire and a respiratory doctor will carry out a medical assessment, and if needed your 
271 
 
current Chronic Obstructive Pulmonary Disease medicines. You may need to withdraw from 
medications for Chronic Obstructive Pulmonary Disease. This is to avoid a mix-up of 
effects/results between the old medicine and the study medicine. You will also take a lung 
function test. This is to measure your lung function before participation and help to differentiate 
between various disease processes. It requires you to be in a seated position, and you blow into 
a tube as instructed by an experienced researcher. This will occur before and then 10 minutes 
after inhalation of Ventolin
®
. We will also collect 10mL (about a teaspoon) of blood from a vein 
in your arm.  
 
Consenting participants will complete 3 questionnaires (this will take approximately 20-30 
minutes in total) as the baseline data before completion of the visit. These are: 
 SGRQ: St Georges Respiratory Questionnaire 
 SF-36: Quality of Life Questionnaire  
 CAT: Chronic Obstructive Pulmonary Disease Assessment Test 
 
The trial coordinator will complete a Chinese Medicine Syndrome Differential Diagnosis Form 
with you (this will take approximately 5 minutes). They will also take a digital photo of your 
tongue. In Chinese medicine, important health information can be obtained from reviewing the 
tongue including colour, coating, shape and texture by an experienced practitioner to confirm 
the diagnosis.  To ensure your privacy, the photo will be restricted to the tongue only and no 
other part of your face or body will be included in this image. A representative from the research 
team will be available to answer any questions. 
 
Between Visits 1 and 2, a four-week run-in period will occur, you only have to complete the 
participant diary. You will not commence the Ginseng or placebo treatment until visit number 2. 
You will be contacted by the research team in this time to confirm eligibility after reviewing your 
blood test results and schedule your second visit. 
During the study, you will be given Ventolin® Inhaler, to use as “relief medication”, when 
needed. This is a short acting bronchodilator to rapidly open up the airways for the relief of 
breathlessness.  
 
You will also be given a participant diary to note down daily relief medication usage during the 
next four weeks. A member from the research team will explain the questionnaires and 
participant diary fully. 
 
Visit 2 - Randomisation: this visit will be scheduled 4 weeks after the first visit and will take 
approximately 1.5 hours. Participants are to return the participant diary for relief medication use 
and discussion will occur as to any questions or concerns prior to treatment allocation. You will 
be again asked to perform a lung function test (by blowing into a tube). You will be randomly 
allocated to receive either the active Ginseng treatment or the placebo treatment, which is an 
inactive look alike medication. You have a 50 / 50 chance of being entered into the active 
Ginseng group. Once randomisation occurs, you will need to complete 3 questionnaires 
(SGRQ, SF-36, CAT) this will take approximately 20-30 minutes in total, during the visit.  A 
participant diary will be given to you to take home for completion. The first pack of trial 
medication (12 weeks) will be supplied. You will be asked to take one capsule (100mg) each 
time, twice a day (after meal in the morning and evening OR with 4 hours between the two daily 
dosages) for 12 weeks. You should not take more than two capsules each day. In a situation 
that you forgot to take it in the morning, mid-day is alright as long as you have 4 hours between 
the two doses. Please record your medication usage in the participant diary.  
 
Visits 3 & 4 - Treatment Period: during the 24-week treatment period, you will be asked to 
attend 2 visits, at week 16 and week 28. They will last approximately 1.5 hours and involve 
symptom assessment, completion of questionnaires (this will take approximately 20-30 minutes 
in total), collection and distribution of the participant diary as well as lung function tests. You will 
receive your next pack of trial medication. At the end of the treatment phase (Visit 4), another 
10mL (about a teaspoonful) of blood will be taken from your arm. 
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Visits 5 & 6 - Follow-Up Period: during the 24-week follow-up period, you will be asked to 
attend 2 visits, at week 40 and week 52. They will last approximately 1.5 hours and involve 
symptom assessment, completion of questionnaires (this will take approximately 20-30 minutes 
in total), collection and distribution of participant diary as well as lung function tests. Visit 6 will 
mark your completion of the trial.  
At your final visit, the study doctor will discuss your current condition. They will then provide you 
with details about the treatment options and refer any comments/concerns onto your local 
doctor.  
 
You will not have to pay for any aspect of this research including consultation, tests and 
medication. The study medication, visits, and procedures will all be covered by the research 
grants that we received. Other health care not related to this Chronic Obstructive Pulmonary 
Disease study will be your own responsibility and/or that of your insurance company. 
 
You will not be paid for your participation in this research. You will be reimbursed for parking 
and/or public transport costs you incur from attending study visits (on production of a receipt).  
 
4. What will happen to my test samples? 
 
Blood samples will be taken on two occasions, at the first visit (initial visit) and visit 4. These 
samples will be assessed for α1-antitrypsin level (an enzyme deficiency that causes 
emphysema, at the initial assessment), full blood count and blood biochemistry for liver and 
kidney function (at the initial assessment and week 28). The samples will be labelled with your 
trial participant ID and date of collection, there will be no other identifiable information. The 
samples will be safely stored at the pathology laboratories at the two hospitals, and used only 
for this trial. These samples are taken so we are able to monitor any changes in blood counts 
and chemistry throughout the treatment phase. This will contribute to assessing any 
inflammation and safety of the trial medication. Once the research is completed the samples will 
be destroyed. 
 
5. What are the possible benefits? 
 
We cannot guarantee or promise that you will receive any benefits from this research. Results 
arising from the current study may help other people with moderate Chronic Obstructive 
Pulmonary Disease in the future. 
 
6. What are the possible risks? 
 
Medical treatments often cause side effects. You may have none, some or all of the effects 
listed below, and they may be mild, moderate or severe. If you have any of these side effects, or 
are worried about them, talk with your doctor. Your doctor will also be looking out for side 
effects. 
 
Many side effects go away shortly after treatment ends. However, sometimes side effects can 
be severe, long lasting or permanent. If a severe side effect or reaction occurs, your doctor may 
need to stop your treatment with the study medication. Tell your doctor if you have any 
problems. Your doctor will discuss the best way of managing any side effects with you. There 
may be unknown or unforseen side effects from this study medication.  
 
In a medical emergency, call 000, or go to the emergency department 
 
Description of known possible side effects are listed below  
 
Study Medication 
Ginseng G115 
Rarely some people are allergic to Ginseng, if you experience hives, difficulty breathing, 
itching, and/or swollen face/tongue call for medical assistance immediately. There are no 
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specific warnings for Ginseng G115, however rare occurrences of minor gastrointestinal 
discomfort such as diarrhoea may occur. 
 
Study Relief medication 
Ventolin®  
Ventolin® is available by prescription and over the counter, it will be given to you to use when 
needed.  
It can produce some side effects: 
COMMON 
 Headache 
 Shaky or tense feeling 
 Tachycardia – fast heart beat  
UNCOMMON 
 Mouth or throat irritation 
 Muscle cramps 
 ‘Warm’ feeling 
 Decrease in potassium in the blood  
 
What other possible risks are there? 
 
Lung Function Test  
During the lung function tests (by blowing into a tube), you may feel some shortness of breath, 
chest tightness, coughing and/or faintness. If any of these symptoms occur you will receive 
medical treatment immediately.  
 
Blood Sample Taking  
Having blood taken may cause some discomfort or bruising. Sometimes, the blood vessel may 
swell, or blood may clot in the blood vessel, or the spot from which blood is taken could become 
inflamed. Rarely, there could be a minor infection or bleeding. If this happens, it can easily be 
treated. 
  
Conception, Pregnancy and Breast-feeding 
The effects of Ginseng G115 on the unborn child and on the newborn baby are not known. 
Because of this, it is important that the study participants are not pregnant or breastfeeding and 
do not become pregnant during the course of the research project. You must not participate in 
the research if you are pregnant or trying to become pregnant, or breast-feeding.  
 
Both male and female participants are strongly advised to use effective contraception during the 
course of the research. You should discuss methods of effective contraception with your doctor.  
 
For female participants: If you do become pregnant whilst participating in the study, you 
should advise your treating doctor immediately. Your doctor will withdraw you from the study 
and advise on further medical attention should this be necessary. You must not continue in the 
research if you become pregnant.  
 
For male participants: You should advise your treating doctor if you father a child while 
participating in the research project. Your doctor will advise on medical attention for your partner 
should this be necessary. 
 
Could my Chronic Obstructive Pulmonary Disease get worse during the study?  
You will be asked to stop taking your relief medication (ventolin/salbutamol) for a certain period 
of time prior to a breathing test.  In addition, there are certain medications that you will not be 
able to use throughout the study. Talk to your study doctor about these medications. If you stop 
your regular medication to be in the study, your Chronic Obstructive Pulmonary Disease 
symptoms might come back or get worse.  Notify the study doctor or staff if this occurs. 
 
During the study, your Chronic Obstructive Pulmonary Disease symptoms may get worse, stay 
the same, or get better.  If you feel that your Chronic Obstructive Pulmonary Disease is getting 
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worse, use the relief medication given to you. If your Chronic Obstructive Pulmonary Disease 
does not get better after using the relief medication, call the study doctor at the phone number 
listed on this form. Please follow your study doctor’s instructions.  
 
If you become upset or distressed as a result of your participation in this research, the 
researcher is able to arrange for counselling or other appropriate support. Any counselling or 
support will be provided by staff who are not members of the research team. 
 
There may be side effects that the researchers do not expect or do not know about and that may 
be serious. Tell your doctor immediately about any new or unusual symptoms that you get.   
 
7. What if new information arises during this research project? 
 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you will be told about this new information and 
your doctor will discuss whether this new information affects you. 
 
8. Can I have other treatments during this research project? 
 
While you are participating in this research project, you may not be able to take some or all of 
the medications or treatments that you have been taking for your Chronic Obstructive 
Pulmonary Disease or for other reasons.  It is important to tell your doctor and the research staff 
about any treatments or medications you may be receiving, including over the counter 
medications, vitamins or herbal remedies, acupuncture or other alternative treatments. You 
should also tell your doctor and the research staff about any changes to these during your 
participation in the research.  Also ask your doctor to explain to you which treatments or 
medications may need to be stopped for the time that you are in the trial.  
If your Chronic Obstructive Pulmonary Disease symptoms get worse during the trial you may 
have to take new medications prescribed by your local doctor, if this happens you may have to 
be withdrawn from the study.  
 
9. Are there alternatives to participation? 
 
Participation in this research is not your only option. Your other options may include continuation 
of previous care, speaking with your doctor about new and/or different treatments or seeking out 
other clinical trials for Chronic Obstructive Pulmonary Disease. Discuss these options with your 
doctor before deciding whether or not to take part in this research project. 
 
10. Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you don’t have 
to. If you decide to take part and later change your mind, you are free to withdraw from the 
project at any stage. Your decision whether to take part or not take part, or to take part and then 
withdraw, will not affect your routine treatment, your relationship with those treating you or your 
relationship with Austin Health or Box Hill Hospital or Northern Hospital or Frankston Hospital  
and/or RMIT University.  
 
11. What if I withdraw from this research project? 
 
If you decide to withdraw from the project, please notify a member of the research team before 
you withdraw. This notice will allow the research team to further discuss any health risks or 
special requirements linked to withdrawing.  
 
If you decide to leave the project, the researchers would like to keep the personal and health 
information about you that have been collected. This is to help them make sure that the results 
of the research can be measured properly. If you do not want them to do this, you must tell them 
before you join the research project. 
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12. Could this research project be stopped unexpectedly? 
 
This research project may be stopped for a variety of reasons. These may include reasons such 
as: 
 Unacceptable side effects; 
 The study medication being shown not to be effective; 
 The study medication being shown to work and not need further testing. 
The research team and study doctor may remove you from further participation in this study if: 
 Staying in the study would be unsafe or harmful; 
 You need treatment not allowed in this study; 
 You fail to follow instructions; 
 You resume smoking; 
 You become pregnant. 
 
13. What will happen when my participation in this research project ends? 
 
After the research project ends including both the treatment and follow-up period (in total 52-
weeks) as well as the time required for data analysis, those individuals who received the 
placebo treatment will be offered the real Ginseng treatment free of charge for a period of 24 
weeks (equivalent to that in the trial). You are advised to inform your medical doctor about 
Ginseng usage after your participation in this study. You should also seek advice from your 
medical doctor about the use of other medications including Ventolin®.  
 
The Ginseng study medication is currently listed in the Australian Register of Therapeutic Goods 
and it is a practitioner only product. There are other Ginseng products available in Australia, but 
we are not sure about their equivalence.   
 
14. How will I be informed of the results of the research project? 
 
After completion of the trial by all participants, the results will be compiled and a detailed 
research report will then be prepared. These results will be published in Australian and/or 
international peer-reviewed medical journals. A summary report of the study will also be 
provided to you. 
 
15. What else do I need to know? 
 
What will happen to information about me? 
- All case record forms (CRF) and participant diaries will be stored at RMIT University, 
Bundoora Victoria, for 15 years after completion of the trial. This is in line with Australian 
Government’s Therapeutic Goods Administration (TGA) guidelines. 
- Data will be stored in locked cabinets and all electronic files will be stored in a password-
protected computer. Access will only be authorised personnel involved in the research.  
- This data will not be reused or extended for use in any other research projects. 
 
Any information obtained in connection with this research project that can identify you will 
remain confidential and will only be used for the purpose of this research project. It will only be 
disclosed with your permission, except as required by law.  
Your health records and any information obtained during the study are subject to inspection (for 
the purpose of verifying the procedures and the data) by the relevant authorities, or as required 
by law. By signing the consent section, you authorise release of, or access to, this confidential 
information to the relevant study personnel and regulatory authorities as noted above. 
 
In any publication and/or presentation, information will be provided in such a way that you 
cannot be identified. Data will be presented as group data and aggregates, not data relating to 
specific individuals.  
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It is desirable that your local doctor be advised of your decision to participate in this research 
project. By signing the consent section, you agree to your local doctor being notified of your 
decision to participate in this research project. Information about your participation in this 
research may be recorded in your health records. 
 
How can I access my information? 
 
In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you 
have the right to access the information collected and stored by the researchers about you. You 
also have the right to request that any information with which you disagree be corrected. Please 
contact one of the researchers named at the end of this document if you would like to access 
your information.  
 
What happens if I am injured as a result of participating in this research project? 
 
If you suffer an injury as a result of participation in this research project, hospital care and 
treatment will be provided by the public health service at no extra cost to you if you elect to be 
treated as a public patient. 
 
Is this research project approved? 
 
The ethical aspects of this research project have been approved by the Human Research Ethics 
Committees of Austin Health.  
 
This project will be carried out according to the National Statement on Ethical Conduct in Human 
Research (2007) produced by the National Health and Medical Research Council of Australia. 
This statement has been developed to protect the interests of people who agree to participate in 
human research studies. 
 
Is this treatment the same or similar to the standard treatment for moderate Chronic 
Obstructive Pulmonary Disease? 
 
This study uses a new medication for moderate Chronic Obstructive Pulmonary Disease. 
Standard treatment may involve several different and/or a combination of medications 
depending on what works best for each individual. Relief medication Ventolin® will be provided 
to all participants for use when needed, this is in line with current standard treatment.  
 
Who can I contact? 
 
The person you may need to contact will depend on the nature of your query. Therefore, please 
note the following: 
 
For further information and appointments: 
 
If you want any further information concerning this project or if you have any medical problems 
which may be related to your involvement in the project (for example, any side effects), you can 
contact the Trial Doctor at Austin Health, Northern Hospital, Dr Christopher Worsnop or at Box 
Hill Hospital, Prof. Frank Thien or at Frankston Hospital, Prof. David Langton. 
If you need urgent medical treatment, please contact your GP or dial 000 as appropriate. 
 
For complaints: 
 
If you wish to contact someone, independent of the study, about ethical issues 
or your rights or to make a complaint, you may contact (Name of site representative, 
Position, Contact Number). 
 
Thank you, we appreciate you taking the time to read this information. 
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CONSENT FORM 
 
PROJECT TITLE: The effect of a standardised ginseng extract in patients with  
Moderate Chronic Obstructive Pulmonary Disease: a randomised, double blind, placebo 
controlled trial 
 
I have read, or have had read to me in a language that I understand, participant information  
version 6.0 dated 29.09.2010 and I understand the purposes, procedures and risks of this 
research project as described within it. 
 
I give permission for my doctors, other health professionals, hospitals or laboratories outside this 
hospital to release information to RMIT University concerning my disease and treatment that is 
needed for this project. I understand that such information will remain confidential. 
 
I understand that relevant sections of any of my medical records and data collected during the 
study may be looked at by responsible individuals from the Traditional & Complementary 
Medicine Research Program at RMIT University, Austin Health or Box Hill Hospital or Northern 
Hospital or Frankston Hospital, from regulatory authorities or from the approving Ethics 
Committee.  I give permission for these individuals to have access to my records. 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
 
I freely agree to participate in this research project as described. 
 
I consent to the storage and use of blood samples taken from me for use in this specific 
research project, as described in Section 4 of this document. 
 
I agree to my GP being informed of my participation in the study.  
 
I understand that I will be given a signed copy of this document to keep. 
 
 
 
Participants name (printed)……………………………………………………………. 
 
Signature______________________________________ Date____/____/____                                                                                        
 
 
Name of witness to participants signature (printed)…………………………………. 
 
Signature______________________________________ Date____/____/____                                                                                        
 
Declaration by researcher*: I have given a verbal explanation of the research project, its 
procedures and risks and I believe that the participant has understood the explanation. 
 
Researcher’s name (printed)…………………………………………………..………. 
 
Signature______________________________________  Date____/____/____                                                                                        
 
*A member of the research team must provide the explanation and provision of information 
concerning the research project.  
Note: All parties signing the Consent Form must date their own signature. 
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Appendix 5: Case Record Form 
 
Visit 1 (Week 0): Initial Assessment 
 
Date of visit: _ _ / _ _ / _ _ _ _ 
 
Has the participant completed the General Information Questionnaire?   Yes   No  
Has the participant completed the Screening Questionnaire?                   Yes   No  
 
 
 
SMOKING STATUS 
  
Is the participant an ex-smoker?   Yes   No       Last day of smoking: _ _ / _ _ / _ _ _ 
_ 
 
Number of years smoking;……..years, cigarettes/ day________ 
 
 
SPIROMETRY    
 
 
 
Taken By: ________________________________ 
 
Please attach a printed copy of all results to the CRF. 
 
BLOOD COLLECTION 
 
 
Taken By: ________________________________  
           
 
Please attach a printed copy of all results to the CRF. 
 
QUESTIONNAIRES 
 
Has the participant completed the SGRQ? Yes   No  
Has the participant completed the SF-36? Yes   No  
Has the participant completed the CAT? Yes   No  
Have you completed the Chinese medicine differential 
diagnosis form with the participant? Yes   No  
Have you taken a digital photo of their tongue? Yes   No  
 
 
  
INFORMED CONSENT 
 
Has the patient freely given written informed consent?    Yes   No  
 
Date of Consent: _ _ / _ _ / _ _ _ _ Time of Consent: __________ 
 
 
DEMOGRAPHICS 
 
 
Date of Birth: _ _ / _ _ / _ _ _ _ 
 
 
Age (yrs):  
 
Gender: Female  Male  
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VITAL SIGNS 
 
Pulse Rate:  
Bpm 
Blood Pressure (seated):  /  mmHg 
 
Height (cm): .      Weight (Kg): .   
 
 
 
 
MEDICAL HISTORY (to be completed by the trial doctor) 
 
Medical Condition 
 
Current 
(Yes / No) 
 
Year of 
Onset 
 
Treatment/ Outcome/ Comment 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
  
 
Medical History taken by: ___________________________ 
 
Signature: ___________________________ Date: _ _ / _ _ / _ _ _ _ 
 
278 
 
 
MEDICATION USAGE 
 
Is the participant currently on any medications? Yes*   No  * If yes, what are these 
medications? 
Please also record any continuing medications on the ‘Concomitant Medication Form’ 
 
1._____________________________________ 
 
6. 
___________________________________ 
 
2. 
_______________________________________ 
 
7. 
__________________________________ 
 
 
3. 
_______________________________________ 
 
8. 
___________________________________ 
 
 
4. 
_______________________________________ 
9. 
___________________________________ 
 
 
 
 
5. 
_______________________________________ 
10. 
_________________________________  
  
Are any of these medications ‘NOT TO BE USED throughout the trial? Yes*   No  
(As per section 6.6 the study protocol – See below) 
Treatments for COPD not to be used throughout the trial: 
 Short acting anticholinergics 
 Combinations of β2-agonists and inhaled 
corticosteroids 
 Long-acting β2-agonists as monotherapy 
 Short acting β2-agonists (other than Ventolin®)  
 Theophylline (any formulation) 
Treatments for other conditions not to be used 
throughout the trial: 
 Corticosteroids 
 Immunotherapy 
 Monoamine Oxidase Inhibitor anti-depressants 
 Anti-coagulants 
 Anti-hyperglycaemics 
*If yes, does the participant agree to discontinue these medications throughout the trial? Yes   
No*  
If yes, what medication were stopped and what was the stop date 
________________________________________________________________ 
 
 
* If no, please provide a reason 
________________________________________________________________ 
 
 
 
 
Medication review conducted by: ___________________________ 
 
Signature: ___________________________ Date: _ _ / _ _ / _ _ _ _ 
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INCLUSION CRITERIA Yes  (tick )   No* 
1 Has the participant willingly given written informed consent?           
2 Is the participant between 40 to 80 years inclusive?           
3 Is the participant an ex smoker, ceased smoking at least 3 months ago 
and agree to refrain from smoking throughout the trial? 
          
4 Are the participant’s spirometry values within moderate (stage II) 
range?  
That is; FEV1/FVC ratio < 0.7 (post-broncho) and FEV1 between 50% to 80% (post-
broncho) 
FEV1/FVC: ____________ FEV1: ____________ 
          
5 Is the participant clinically stable?  
Did not experience an acute infective exacerbation of COPD from at least 4 week prior 
to trial entry. 
          
6 Meet the Chinese medicine diagnostic criteria for Lung Qi deficiency or 
Lung and Spleen Qi deficiency? 
          
             *If any inclusion criteria are ticked NO then the participant is not eligible for the study. 
EXCLUSION CRITERIA  Yes*(tick )   No 
1 Does the participant have a history of asthma or chronic systematic 
infections or inflammatory conditions in the last 3 months? 
 
          
2 Is the participant pregnant, breast-feeding or intending to become 
pregnant during the course of the study? 
 
          
3 Does the participant have a serious illness such as e.g. severe heart 
disease, liver or kidney disease? 
 
          
4 Is the participant unable to perform spirometry?           
5 Is the participant taking long-term immunosuppressive agents or 
immuno- stimulants? 
 
          
6 Has the participant used ginseng-containing products in the last 3 
months? 
          
7 Does the participant have an allergic history to ginseng products?           
8 Is the participant currently using monoamine oxidase inhibitor 
antidepressants, anticoagulants and/or anti-hyperglycemic 
medications? 
 
          
9 Is the participant a Current smoker?           
10 Has the participant undertaken pulmonary rehabilitation within the last 
3 months, or intend to enter pulmonary rehabilitation during the study? 
          
           * If any exclusion criteria are ticked YES then the participant is not eligible for the study.      
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MEDICATIONS 
 
 
Have you dispensed relief medication, Ventolin? 
(If yes, Please complete Medication Accountability Form) Yes   No  
 
 
PARTICIPANT DIARY 
 
 
Have you issued a participant diary? Yes   No  
 
 
 
POST VISIT FOLLOW UP 
 
 
 
BIOCHEMISTRY/ HAEMATOLOGY  
 
 
Have the biochemistry/ haematology reports been reviewed? Yes     No    
Are any of the findings clinically significant? Yes*   No    
* If yes please comment 
______________________________________________________________________ 
 
 
 
Name of reviewer: ________________________________ 
 
Signature: ___________________________ Date: _ _ / _ _ / _ _ _ _ 
 
 
LOCAL DOCTOR FOLLOW UP 
 
Have you contacted the participants ‘usual’ treating doctor to 
inform them of their patients interest in participating in the 
study? 
 
Yes   No    
 
CHINESE MEDCINE DIAGNOSIS 
 
Have you emailed the Chinese medicine syndrome 
differential diagnosis form and digital tongue photo to the 
Chinese medicine practitioner? 
Yes   No    
  
 
 
 
Clinical trial coordinator signature: __________________      Date:  __ __/__ __ /__ __  
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Visit 2 (Week 4): Randomisation/ Start of Treatment 
 
Date of visit: _ _ / _ _ / _ _ _ _ 
 
PLEASE CONDUCT SPIROMETRY AND COMPLETE SGRQ TO DETERMINE 
ELIGIBILITY PRIOR TO RANDOMISATION 
 
EXCLUSION CRITERIA  Yes*(tick )   No 
1 Was there deterioration in the participant’s spirometry values and they 
are no longer within the moderate (stage II) range?  
That is; FEV1/FVC ratio < 0.7 (post-broncho) and FEV1 between 50% to 80% (post-
broncho) 
          
2 Has the participant been diagnosed as Alpha1-antitrypsin deficient?           
3 Did the participant experience an acute infective exacerbation of 
COPD since baseline, visit 1? 
          
* If any of the exclusion criteria are ticked YES then the participant is not eligible for randomisation. 
 
 
RANDOMISATION 
 
Does the participant continue to meet the eligibly 
criteria?  
Yes   No    
 
If Yes, select randomisation envelope. If No, participant should be withdrawn from the study. 
 
Randomisation Number:  
 
 
 
 
 
 
 
SMOKING STATUS 
 
Has the participant smoked since the last visit? 
Note: As per section 8 of the study protocol, subjects who resume 
smoking during the trial period need to be reviewed by the Principal 
Investigator to determine ongoing eligibility. 
Yes    No   
 
SPIROMETRY    
 
 
Taken By: ________________________________ 
 
Please attach a printed copy of all results to the CRF. 
 
QUESTIONNAIRES 
 
Has the participant completed the SGRQ? Yes    No   
Has the participant completed the SF-36? Yes    No   
Has the participant completed the CAT? Yes    No   
 
 
ttach randomisation sticker 
here 
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PARTICIPANT DIARY 
 
Have you collected the participant diary? Yes    No   
Have you issued a participant diary? Yes    No   
 
 
DATA COLLECTION 
 
Have any adverse events occurred since the last visit?  
(If yes, please record on Adverse Event Record Form) 
 
Yes   No  
Have any exacerbations occurred since the last visit? 
(If yes, please record on Exacerbations Form) 
 
Yes   No  
Have any other medical services relating to COPD been accessed 
since the last visit? 
(If yes, please record on Medical Service Utilisation Form) 
 
Yes   No  
Have any concomitant medications (other than Ventolin) been taken 
since the last visit?  
(If yes, please record on Concomitant Medication Form) 
 
Yes   No  
 
MEDICATIONS 
 
Have you dispensed the trial medication? 
(If yes, Please complete Medication Accountability Form) 
 
Yes   No  
Have you dispensed relief medication, Ventolin? 
(If yes, Please complete Medication Accountability Form) 
 
Yes   No  
 
LOCAL DOCTOR FOLLOW UP 
 
Have you contacted the participants ‘usual’ treating doctor to collect 
data on number of consultations? Yes   No    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical trial coordinator signature: __________________      Date:  __ __/__ __ /__ __  
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Visit 3 (Week 16): Mid Treatment 
 
Date of visit: _ _ / _ _ / _ _ _ _ 
 
 
SMOKING STATUS 
 
Has the participant smoked since the last visit? 
Note: As per section 8 of the study protocol, subjects who resume 
smoking during the trial period need to be reviewed by the Principal 
Investigator to determine ongoing eligibility. 
Yes   No  
 
SPIROMETRY 
 
Taken By: ________________________________ 
 
 Please attach a printed copy of all results to the CRF. 
 
QUESTIONNAIRES 
 
 
Has the participant completed the SGRQ? 
Yes   No  
Has the participant completed the SF-36? 
Yes   No  
Has the participant completed the CAT? 
Yes   No  
 
PARTICIPANT DIARY 
 
 
Have you collected the participant diary? Yes   No  
Have you issued a participant diary? Yes   No  
 
DATA COLLECTION 
 
Have any adverse events occurred since the last visit?  
(If yes, please record on Adverse Event Record Form) 
 
Yes   No  
Have any exacerbations occurred since the last visit? 
(If yes, please record on Exacerbations Form) 
 
Yes   No  
Have any other medical services relating to COPD been accessed 
since the last visit? 
(If yes, please record on Medical Service Utilisation Form) 
 
Yes   No  
Have any concomitant medications (other than Ventolin) been taken 
since the last visit?  
(If yes, please record on Concomitant Medication Form) 
 
Yes   No  
 
MEDICATIONS 
 
 
Have you dispensed the trial medication? 
(If Yes, Please complete Medication Accountability Form) 
 
Yes   No  
 
Have you dispensed relief medication, Ventolin? 
(If yes, Please complete Medication Accountability Form) 
 
Yes   No  
 
LOCAL DOCTOR FOLLOW UP 
 
Have you contacted the participants ‘usual’ treating doctor to collect 
data on number of consultations? Yes   No  
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Visit 4 (Week 28): End of Treatment 
 
Date of visit: _ _ / _ _ / _ _ _ _ 
 
 
SMOKING STATUS 
 
Has the participant smoked since the last visit? 
Note: As per section 8 of the study protocol, subjects who resume 
smoking during the trial period need to be reviewed by the Principal 
Investigator to determine ongoing eligibility. 
Yes    No  
 
SPIROMETRY 
 
Taken By: ________________________________ 
 
Please attach a printed copy of all results to the CRF. 
 
BLOOD COLLECTION 
 
Taken By: _________________         
                     
Please attach a printed copy of all results to the CRF. 
 
QUESTIONNAIRES 
 
 
Has the participant completed the SGRQ? 
Yes   No  
Has the participant completed the SF-36? 
Yes   No  
Has the participant completed the CAT? 
Yes   No  
 
PARTICIPANT DIARY 
 
 
Have you collected the participant diary? Yes   No  
Have you issued a participant diary? Yes   No  
 
DATA COLLECTION 
 
Have any adverse events occurred since the last visit?  
(If yes, please record on Adverse Event Record Form) 
 
Yes   No  
Have any exacerbations occurred since the last visit? 
(If yes, please record on Exacerbations Form) 
 
Yes   No  
Have any other medical services relating to COPD been accessed since 
the last visit? 
(If yes, please record on Medical Service Utilisation Form) 
 
Yes   No  
Have any concomitant medications (other than Ventolin) been taken 
since the last visit?  
(If yes, please record on Concomitant Medication Form) 
 
Yes   No  
 
MEDICATIONS 
 
 
Have you dispensed relief medication, Ventolin? 
(If yes, Please complete Medication Accountability Form) 
 
Yes   No  
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POST VISIT FOLLOW UP 
 
 
 
BIOCHEMISTRY/ HAEMATOLOGY  
 
 
Have the biochemistry/ haematology reports been 
reviewed? 
Yes    No    
 
Are any of the findings clinically significant? 
 
(If yes, Please complete Adverse Event Record Form) 
Yes*   No    
 
Name of reviewer: ________________________________ 
 
Signature: ___________________________ Date: _ _ / _ _ / _ _ _ _ 
 
 
LOCAL DOCTOR FOLLOW UP 
 
Have you contacted the participants ‘usual’ treating 
doctor to collect data on number of consultations? Yes   No    
 
 
 
Clinical trial coordinator signature: __________________      Date:  __ __/__ __ /__ __  
 
 
286 
 
Visit 5 (Week 40): Mid Follow Up 
 
Date of visit: _ _ / _ _ / _ _ _ _ 
 
 
SMOKING STATUS 
 
Has the participant smoked since the last visit? 
Note: As per section 8 of the study protocol, subjects who resume 
smoking during the trial period need to be reviewed by the Principal 
Investigator to determine ongoing eligibility. 
Yes   No  
 
SPIROMETRY 
 
Taken By: ________________________________ 
 
 Please attach a printed copy of all results to the CRF. 
 
QUESTIONNAIRES 
 
 
Has the participant completed the SGRQ? 
Yes   No  
Has the participant completed the SF-36? 
Yes   No  
Has the participant completed the CAT? 
Yes   No  
 
PARTICIPANT DIARY 
 
 
Have you collected the participant diary? Yes   No  
Have you issued a participant diary? Yes   No  
 
DATA COLLECTION 
 
Have any adverse events occurred since the last visit?  
(If yes, please record on Adverse Event Record Form) 
 
Yes   No  
Have any exacerbations occurred since the last visit? 
(If yes, please record on Exacerbations Form) 
 
Yes   No  
Have any other medical services relating to COPD been 
accessed since the last visit? 
(If yes, please record on Medical Service Utilisation Form) 
 
Yes   No  
Have any concomitant medications (other than Ventolin) been 
taken since the last visit?  
(If yes, please record on Concomitant Medication Form) 
 
Yes   No  
 
MEDICATIONS 
 
Have you dispensed relief medication, Ventolin? 
(If yes, Please complete Medication Accountability Form) 
 
Yes   No  
 
LOCAL DOCTOR FOLLOW UP 
 
Have you contacted the participants ‘usual’ treating doctor to 
collect data on number of consultations? Yes   No  
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Visit 6 (Week 52): Completion of Trial 
 
Date of visit: _ _ / _ _ / _ _ _ _ 
 
 
SMOKING STATUS 
 
Has the participant smoked since the last visit? 
Note: As per section 8 of the study protocol, subjects who resume 
smoking during the trial period need to be reviewed by the Principal 
Investigator to determine ongoing eligibility. 
Yes   No  
 
SPIROMETRY 
 
Taken By: ________________________________ 
 
Please attach a printed copy of all results to the CRF. 
 
QUESTIONNAIRES 
 
 
Has the participant completed the SGRQ? 
Yes   No  
Has the participant completed the SF-36? 
Yes   No  
Has the participant completed the CAT? 
Yes   No  
Has the participant completed the Opinion of 
Chinese Medicine Questionnaire? Yes   No  
 
PARTICIPANT DIARY 
 
 
Have you collected the participant diary? Yes   No  
 
DATA COLLECTION 
 
Have any adverse events occurred since the last visit?  
(If yes, please record on Adverse Event Record Form) 
 
Yes   No  
Have any exacerbations occurred since the last visit? 
(If yes, please record on Exacerbations Form) 
 
Yes   No  
Have any other medical services relating to COPD been 
accessed since the last visit? 
(If yes, please record on Medical Service Utilisation Form) 
 
Yes   No  
Have any concomitant medications (other than Ventolin) been 
taken since the last visit?  
(If yes, please record on Concomitant Medication Form) 
 
Yes   No  
 
LOCAL DOCTOR FOLLOW UP 
 
Have you contacted the participants ‘usual’ treating doctor to 
collect data on number of consultations? Yes   No  
Have you informed the participants ‘usual’ treating doctor of their 
completion of participation in the trial? Yes   No  
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MEDICATION ACCOUNTABILITY 
 
Trial Medication Ginseng/Placebo 100mg capsules 
 
Date of 
Dispensing 
Randomisation 
& Bottle 
Number 
No. of 
capsules 
dispensed 
Dispenser’s 
initials 
Date 
Returned 
No. of 
capsules 
returned 
Receiver’s 
initials 
Comment 
        
   
   
  
 
      
   
   
 
Relief Medication Ventolin 100mcg MDI 
 
Date of 
Dispensing 
Visit 
Number 
No. of 
inhalers 
dispensed 
Dispenser’s 
initials 
Date 
Returned 
No. of 
inhalers 
returned 
Receiver’s 
initials 
Comment 
 
 
 
        
 
ADVERSE EVENTS RECORD FORM 
 
Event  
 
Start 
(Date/Time) 
Stop 
(Date/Time) 
Intensity 
(1-3) 
Relationship to 
treatment 
(1,2,3 or 4) 
Serious 
adverse 
event* 
Yes/No 
 
 
     
 
 
     
 
Intensity: 
1 = mild (easily tolerated by patient, causing minimal discomfort) 
2 = moderate (discomfort significant enough to interfere with daily activities) 
3 = severe (incapacitating and/or requiring therapeutic intervention) 
 
Relationship to treatment: 
1 = unrelated   2 = possibly   3 = probably   4 = definitely 
  
* Serious adverse event (SAE): defined as potential to be fatal, life threatening, 
permanent incapacitating or resulting in hospitalisation. 
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RECORD OF MEDICAL SERVICE UTILISATION  
RELATING TO  
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
 
 
Actions Date Out of 
pocket 
expenses 
($) 
Remarks 
Visits to Medical Doctor 
and/or Specialists 
 
   
   
 
Hospitalisation 
 
 
   
   
 
 
Emergency Department 
Presentations 
 
 
   
Medications /  
Other (please specify) 
 
   
   
 
EXACERBATIONS FORM 
 
Event  
 
Start 
(Date/Time) 
Stop 
(Date/Time) 
Intensity 
(1-3) 
Medication 
use  
(Specify) 
Remarks  
 
 
 
 
                            
 
 
 
 
CONCOMITANT MEDICATION FORM 
 
Name of 
Medication 
Start 
(Date) 
Stop 
(Date) 
Dose Frequency Remarks / 
Continuing 
 
 
  
  
 
 
 
  
  
 
 
                                                     
290 
 
   COMPLETION/TERMINATION FORM 
 
                              
Completion of Study: Please mark the primary reason why the participant has 
finished with their participation in the study. Reasons ‘other than’ Completed 
Study require explanation next to the response. 
 COMPLETED STUDY (52 weeks) 
 AE/SAE (complete AE & SAE form, if applicable)  
 Lost to follow-up 
 Non-compliant participant 
 Concomitant medication 
 Medical contraindication 
 Withdrawal of consent 
 Death (complete SAE form)  
 Other  
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Appendix 6: Screening questionnaire 
 
 
1. What is your smoking status? 
 
 Current           Former              Never 
 
If current smoker, how many cigarettes per day? _____/day, and for how many years? _____years 
 
If former smoker, when did you stop smoking? Approximate date_____/_____/_____ 
 
How many cigarettes per day and for how many years did you smoke? ____per day for ___years 
 
2.One of the conditions to participate in the current trial is agree to refrain from smoking throughout 
the trial. Please confirm you agree to do so for the whole duration of the trial (52 weeks)?  
 
 No             Yes     
 
3. Your participation is voluntary and you are free to withdraw from the study at any time. However, 
to get meaningful results from this study, it is desirable that you stay in the trial until it is fully 
completed, except for situations that you are advised by the research team and/or your medical 
doctor to discontinue participation. Do you agree with this statement?  
 
 No                            Yes   
 
4. Have you been diagnosed with Chronic Obstructive Pulmonary Disease (COPD), including chronic 
bronchitis and emphysema, by a medical practitioner?   
 
 No    Not sure Yes, and the year of diagnosis was _______       
 
5. Do you or any of your family members suffer from Chronic Obstructive Pulmonary Disease (COPD) 
or other respiratory disease?  
 
 No    Not sure  Yes   
 
If yes, please tick () relevant box(es) 
 
Family 
Member 
Chronic 
Obstructive 
Pulmonary 
Disease  
Including: Chronic 
Bronchitis & /or 
Emphysema 
Asthma Bronchiectasi
s 
Alpha-1 antitrypsin 
deficiency 
Other 
respiratory 
disease 
Yourself       
Father      
Mother      
Brother      
Sister      
Other:      
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6. Do you have any of the following symptoms? If yes, please also indicate the severity of the 
symptoms. (Please tick ) 
Symptoms Severity  
0= no symptoms  1= mild  2= moderate  3= severe   
0 1 2 3 
Breathlessness 
 
 
   
Cough 
 
 
 
   
Sputum / Phlegm 
 
 
   
Chest Tightness 
 
 
   
Wheezing 
 
 
   
Rapid or laboured Respiration 
 
 
   
 
 
7. Do the symptoms above interfere with your daily life? 
 
 Never 
 
 Rarely (1-2 day per week)  Sometimes (3-4 days per week) 
 Often (5-7 days per week)  Always   (Everyday) 
 
8. Have you had a surgical treatment for Chronic Obstructive Pulmonary Disease (COPD)? 
 
 No 
 
 Yes,    Please specify 
_______________________________________________________ 
 
9. Have you been hospitalised due to an exacerbation of Chronic Obstructive Pulmonary Disease 
(COPD), in the last 3 months? 
 
 No  Yes,    Please specify when and for how long____________________________________ 
 
10. Have you used antibiotics for a Chronic Obstructive Pulmonary Disease (COPD) exacerbation, in 
the last 3 months?  
 
 No  Yes,    Please specify when and name 
__________________________________________ 
 
11. Have you been taking long acting β2-agonists (eg. Seretide/Serevent/Foradile/Oxis/Symbicort) 
and/or Anticholinergics (eg. Atrovent/Spiriva) and /or Methylxanthines (eg.Nuelin) within the last 3 
months? 
 
 No   Yes,    Please specify when and name 
__________________________________________ 
 
12. Have you been treated with inhaled corticosteroids (eg. Qvar(beclomethasone)/ Pulmicort/ 
Symbicort(budesonide)/Flixotide/Seretide(fluticasone)/Alvesco(ciclesonide)) / oral corticosteroids 
(eg. Panafocortelone/Prednisolone/Solone(prednisolone)) / cortisone injections for Chronic 
Obstructive Pulmonary Disease (COPD) or other conditions within the last 3 months? 
 
 No  
 
 Yes,    Please specify___________________________________________________ 
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13. Have you used long-term oxygen therapy for your Chronic Obstructive Pulmonary Disease 
(COPD)?          
 
 No 
 
 Yes,    Please specify ________________________________________________ 
 
 
17. 14. Have you used a non-invasive ventilator (CPAP/BiPAP) for supporting your breathing in the past 
one year? 
 
 No  Yes,    Please specify________________________________________________ 
 
15. Do you have any other diseases including infectious disease (eg. HIV, Hep B, Hep C)? 
 
 No 
 
 Yes,    Please specify________________________________________________ 
 
16. Are you currently taking any of the following medications? 
 
a) Anti-depressant (e.g.Aropax, Aurorix, 
Avanza, Cipramil, Deptran, Endep, Lexapro, 
Lovan, Luvox, Pristiq, Prozac, Sinequan, 
Tofranil, Tolvon, Zoloft) 
 
 No    Yes,  Please specify_______________ 
 
b) Anti-coagulant (stops blood clotting) (e.g. 
Warfarin, Coumadin, Dindevan) 
 
 No    Yes,  Please specify_______________ 
 
c) Anti-hyperglycaemic (lowers blood sugar) 
(e.g. Actos, Amaryl, Avandia, Daonil, Diabex, 
Diaformin, Diamicron, Glimel, Glucophage, 
Minidiab) 
 No    Yes,  Please specify_______________ 
 
18.  
17. Have you been treated with Chinese Herbal Medicine in the last year? 
If so, for what condition? 
 
 No  Yes,    Please specify________________________________________________ 
19. 18. Have you used any ginseng containing product in the last 3 months? 
 
 No  
 
 Yes,    Please specify________________________________________________ 
 
19. Do you have any allergies (including allergy to ginseng products)? 
 
 No                                     Yes,    Please specify________________________________________________ 
 
20. If you are female, please answer the following questions: 
 
a. Are you currently pregnant or planning to get pregnant in 
the next 12 months? 
 
 No                           Yes 
b. Are you currently breast-feeding? 
 
 No                           Yes 
 
20.  
21.  
22.  
23.  
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21. Please list any regular medicines you use for Chronic Obstructive Pulmonary Disease (COPD) 
and/or any medicines you use for other diseases/symptoms. 
24.  
Name of 
Medication 
Medical condition Dosage Frequency  
(times/day or 
week) 
How long have 
you been taking 
it? 
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Appendix 7: St. George’s Respiratory Questionnaire 
 
Before completing the rest of the questionnaire: 
 
Please tick one box which best describes your present health: 
 
 
 
Very good 
 
 
 
Good 
 
 
 
Fair 
 
 
 
Poor 
 
 
 
Very 
poor 
 
 
 
PART 1 
 
These questions are about how much chest trouble you have had over the last 4 weeks. 
 
Please tick () one box for each question: 
 
 most days  
a week 
several 
days  
a week 
a few days  
a month 
only with 
chest 
infections 
not  
at  
all 
1. Over the last 4 weeks, I have coughed:      
 
2. Over the last 4 weeks, I have brought up  
phlegm (sputum):      
 
3. Over the last 4 weeks, I have had shortness 
of breath:       
 
4. Over the last 4 weeks, I have had attacks  
of wheezing:       
 
5. During the last 4 weeks, how many severe or very  
unpleasant attacks of chest trouble have you had? 
Please tick () one: 
 more than 3 attacks 
 3 attacks 
 2 attacks 
 1 attack  
 no attacks 
 
6. How long did the worst attack of chest trouble last? 
(Go to question 7 if you had no severe attacks) 
Please tick () one: 
 a week or more  
 3 or more days  
 1 or 2 days  
 less than a day  
 
7. Over the last 4 weeks, in an average week, how many good days 
(with little chest trouble) have you had? 
Please tick () one: 
 No good days 
 1 or 2 good days 
 3 or 4 good days 
 nearly every day is good 
 every day is good 
 
8. If you have a wheeze, is it worse in the morning? 
Please tick () one: 
 No  
 Yes  
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PART 2 
 
Section 1 
How would you describe your chest condition? 
Please tick () one: 
 The most important problem I have  
 Causes me quite a lot of problems  
 Causes me a few problems  
 Causes no problem  
 
If you have ever had paid employment. 
Please tick () one: 
 My chest trouble made me stop work altogether  
 My chest trouble interferes with my work or made me change my work  
 My chest trouble does not affect my work  
 
Section 2 
These questions are about what activities usually make you feel breathless these days. 
For each activity, please tick () 
one box as it applies to you these days: 
 True False 
 Sitting or lying still   
 Getting washed or dressed   
 Walking around the home   
 Walking outside on level ground   
 Walking up one flight of stairs   
 Walking up hills   
 Playing sports or active games   
 
 
Section 3 
 
Some more questions about your cough and breathlessness these days. 
 
For each situation, please tick () 
one box as it applies to you these days: 
 True False 
 My cough hurts   
 My cough makes me tired   
 I am breathless when I talk   
 I am breathless when I bend over   
 My cough or breathing disturbs my sleep   
 I get exhausted easily   
 
Section 4 
 
These are questions about other effects that your chest trouble may have on you these days. 
 
For each situation, please tick () 
one box as it applies to you these days: 
 True False 
 My cough or breathing is embarrassing in public   
 My chest trouble is a bother to my family, friends or neighbours   
 I get afraid or panic when I cannot get my breath   
 I feel that I am not in control of my chest problem   
 I do not expect my chest to get any better   
 I have become frail or an invalid because of my chest   
 Exercise is not safe for me   
 Everything seems too much of an effort   
 
Section 5 
 
These are questions about your medication. If you are receiving no medication go straight to  
Section 6. 
For each situation please tick () 
one box as it applies to you these days: 
 True False 
 My medication does not help me very much   
 I get embarrassed using my medication in public   
 I have unpleasant side effects from my medication   
 My medication interferes with my life a lot   
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Section 6 
 
These are questions about how your activities might be affected by your breathing. 
 
For each situation, please tick () the correct box that applies to you because of your breathing: 
 True False 
 I take a long time to get washed or dressed   
 I cannot take a bath or shower, or I take a long time   
 I walk slower than other people, or I stop for rests   
 Jobs such as housework take a long time, or I have to stop for rests   
 If I walk up one flight of stairs, I have to go slowly or stop   
 If I hurry or walk fast, I have to stop or slow down   
 My breathing makes it difficult to do things such as walk up hills, carry things 
 up stairs, light gardening (e.g. weeding), dance, play bowls or play golf   
 My breathing makes it difficult to do things such as carry heavy loads, dig the 
 garden, jog or walk fast (8 km/hr), play tennis or swim laps   
 My breathing makes it difficult to do things such as very heavy manual work, 
 run, cycle, swim fast or play competitive sports   
 
Section 7 
 
We would like to know how your chest trouble usually affects your daily life. 
 
For each situation, please tick () the correct box that applies to you because of your chest trouble: 
 True False 
 I cannot play sports or active games   
 I cannot go out for entertainment or recreation   
 I cannot go out of the house to do the shopping   
 I cannot do housework   
 I cannot move far from my bed or chair   
 
 
 
 
Here is a list of other activities that your chest trouble may prevent you doing. (You do not have to tick these, they are just 
to remind you of ways in which your breathlessness may affect you): 
 
Going for walks or walking the dog 
Doing things at home or in the garden 
Sexual intercourse 
Going out to church or place of entertainment 
Going out in bad weather or into smoky rooms 
Visiting family or friends or playing with children 
 
 
Please write in any other important activities that your chest trouble may stop you doing: 
  
  
  
Now, would you tick the box (one only) which you think best describes how your chest trouble affects you: 
 It does not stop me doing anything I would like to do  
 It stops me doing one or two things I would like to do  
 It stops me doing most of the things I would like to do  
 It stops me doing everything I would like to do  
 
Thank you for filling in this questionnaire. Before you finish would you please check to see that you have answered all the 
questions. 
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Appendix 8: Short Form Health Survey (SF-36) 
In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
   1    2    3    4    5 
 
 
 
2. Compared to one year ago, how would you rate your health in general now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
     
   1    2    3    4    5 
 
3 The following questions are about activities you might do during a typical day.  
Does your health now limit you in these activities?  If so, how much?  
 
 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
    
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports...............................  1 ...............  2 ...............  3 
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf ......................................  1 ...............  2 ...............  3 
 c Lifting or carrying groceries ..............................................................  1 ...............  2 ...............  3 
 d Climbing several flights of stairs .......................................................  1 ...............  2 ...............  3 
 e Climbing one flight of stairs ..............................................................  1 ...............  2 ...............  3 
 f Bending, kneeling, or stooping .........................................................  1 ...............  2 ...............  3 
 g Walking more than a kilometre .........................................................  1 ...............  2 ...............  3 
 h Walking several hundred metres ......................................................  1 ...............  2 ...............  3 
 i Walking one hundred metres............................................................  1 ...............  2 ...............  3 
 j Bathing or dressing yourself .............................................................  1 ...............  2 ...............  3 
299 
 
4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your physical 
health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities.......................................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 b Accomplished less than you  
  would like ..............................................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 c Were limited in the kind of  
  work or other activities ..........................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 d Had difficulty performing the 
  work or other activities (for  
  example, it took extra effort) .................  1 ...............  2 ...............  3 ...............  4 ...............  5 
5. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities.......................................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 b Accomplished less than you  
  would like ..............................................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 c Did work or other activities 
  less carefully than usual .......................  1 ...............  2 ...............  3 ...............  4 ...............  5 
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbours, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
   1    2    3    4    5 
7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
      
   1    2    3    4    5    6 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
   1    2    3    4    5 
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9. These questions are about how you feel and how things have been with you during 
the past 4 weeks.  For each question, please give the one answer that comes closest 
to the way you have been feeling.  How much of the time during the past 4 weeks… 
 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
   1    2    3    4    5 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
      
 a I seem to get sick a little 
easier than other people .......................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 b I am as healthy as  
anybody I know.....................................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 c I expect my health to  
get worse ..............................................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 d My health is excellent ...........................  1 ...............  2 ...............  3 ...............  4 ...............  5 
 
 
 
 
 
 
  
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Did you feel full of life? .........................  1 ...............  2 ...............  3 ...............  4 ..............  5 
 b Have you been very nervous? ..............  1 ...............  2 ...............  3 ...............  4 ..............  5 
 c Have you felt so down in the  
dumps that nothing could  
cheer you up? .......................................  1 ...............  2 ...............  3 ...............  4 ..............  5 
 d Have you felt calm and   
peaceful? ..............................................  1 ...............  2 ...............  3 ...............  4 ..............  5 
 e Did you have a lot of energy? ...............  1 ...............  2 ...............  3 ...............  4 ..............  5 
 f Have you felt downhearted   
and depressed? ....................................  1 ...............  2 ...............  3 ...............  4 ..............  5 
 g Did you feel worn out? ..........................  1 ...............  2 ...............  3 ...............  4 ..............  5 
 h Have you been happy? .........................  1 ...............  2 ...............  3 ...............  4 ..............  5 
 i Did you feel tired? .................................  1 ...............  2 ...............  3 ...............  4 ..............  5 
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Appendix 9: COPD Assessment Test 
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Appendix 10: Participant dairy 
Trial Medication  
(Please indicate with a tick (), every time you take this medication). 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
/     / /     / /     / /     / /     / /     / /     / 
AM PM AM PM AM PM AM PM AM PM AM PM AM PM 
              
 
Relief Medication - Ventolin® 
 
 
(Please indicate the NUMBER OF PUFFS of the relief medication you used during the past 24 
hours).      
 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
/     / /     / /     / /     / /     / /     / /     / 
 
 
      
 
 
Other Medications 
 
 
NOTE: You are required to cease any existing COPD medication prior to the commencement of the 
trial, standardised relief medication will be provided to you (Ventolin®). 
 
If you use any medications other than those provided by the research team, please fill in the details 
below:  
 
Medication Name: 
 
Date Taken: 
/   / /   / /   / /   / /   / /   / /   / 
Dose: 
 
 
      
Frequency: 
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Appendix 11: Participant opinion of Chinese medicine questionnaire 
1. At this point, how logical does the treatment offered to you seem? 
 
1 2 3 4 5 6 7 8 9 
Not at all    Somewhat 
logical 
   Very 
logical 
 
2. At this point, how useful do you think the treatment will be in reducing your Chronic 
Obstructive Pulmonary Disease symptoms?  
 
1 2 3 4 5 6 7 8 9 
Not 
useful 
   Somewhat 
useful 
   Very 
useful 
 
3. How confident would you be in recommending this treatment to a friend who experiences 
similar problems? 
 
1 2 3 4 5 6 7 8 9 
Not at all 
confident 
   Somewhat 
confident 
   Very 
much 
confident 
 
4. By the end of the treatment period, how much improvement in your Chronic 
Obstructive Pulmonary Disease symptoms do you think will occur?  
 
1 2 3 4 5 6 7 8 9 
None at 
all  
   Some    Total 
Improveme
nt 
 
5. At this point, how much do you really feel that treatment will help you to reduce your 
Chronic Obstructive Pulmonary Disease symptoms? 
 
1 2 3 4 5 6 7 8 9 
Not at all 
useful 
   Somewhat 
useful 
   Very 
useful 
 
6. By the end of the treatment period, how much improvement in your Chronic 
Obstructive Pulmonary Disease symptoms do you really feel will occur? 
 
1 2 3 4 5 6 7 8 9 
Not at all     Somewhat     Very 
much 
 
Reference 
G.J. Devilly, T.D. Borkovec. Psychometric properties of the credibility/expectancy questionnaire. J. Behav. Ther. & Exp. Psychiat. 
31 (2000) 73-86. 
 
Additional Question: 
 
For assessing the effectiveness of the blinding process in this study, please indicate the 
treatment that you believe you have received (please): 
 
□ Real treatment 
 
□ Placebo treatment 
 
□ Not sure 
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Appendix 12: Analytical reports 
Appendix 12.1: Analytical report of G115 
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Appendix 12.2: Analytical report of placebo 
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Appendix 13: Trail medication frequently asked questions 
For how many weeks will I have to take the trial medication? 
You will be asked to take the trial medication for 24 weeks in total, between your 2
nd
 and 7
th
 months of 
participation. 
 
Does the trial medication need to be taken every day?  
Yes, twice a day.  
 
How many capsules per day? 
2, one each time. 
 
Does the trial medication have to be taken at a particular time? 
Preferably the capsules should be taken in the morning with breakfast and in the evening with dinner.  
 
Can I take 2 capsules at once as I am very forgetful in the afternoons? 
No, you need to wait at least 4 hours between each capsule. 
 
Should I take the trial medication before or after a meal? 
There is no specific rule as long as you take 2 capsules per day. 
 
What happens if I forget to take a capsule at breakfast? 
This is not a problem. The capsules can be taken anytime throughout the day as long a minimum of 4 
hours is left between doses. For example you could take a capsule at lunchtime and then at dinner. 
 
What happens if I only take one capsule for the day? Should I take a double dose the next day? 
No, you should not take a double dosage. The next day just take 2 capsules as you normally would. 
 
Should I chew the capsules or just swallow them? 
You should not chew the capsules. They should be swallowed with a small amount of liquid (non 
alcoholic). 
 
Will all the trial medications be given to me at the first visit? 
No, you will be given the medications in 2 lots. The first lot will be given at visit 2 and the second at visit 
3. 
 
Will the trial medications be in one bottle? 
No, you will be given 3 bottles of trial medication each time. There are 60 capsules per bottle and one 
bottle will last 4 weeks.  
 
Sometimes I am forgetful and need to keep my medications in the kitchen for my morning dose and 
in the bedroom for my night time dose, can I open two bottles and leave them in different locations? 
Yes, as long as it helps you to remember to take your medications. 
 
I have other medications that I take, is it ok to take the trial medications at the same time? 
Yes, you can take the trial medication with other medications. However if you start any new medication/s 
you must seek advice from the research team as soon as possible. 
 
Should I keep the trial medications in the fridge? 
It is not necessary to keep them in the fridge. They should be kept at room temperature, with the lid on. 
 
What happens if the trial medications make me feel sick? 
If you feel unwell, you should contact your local doctor and notify the research team. 
 
What happens if I misplace my trial medications? 
Contact the research team immediately. 
 
 
